<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 - Kreuzberger, N - 2021 | Cochrane Library</title> <meta content="SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 - Kreuzberger, N - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013825.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 - Kreuzberger, N - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013825.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013825.pub2" name="dc.identifier" scheme="DOI"/> <meta content="SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19" name="citation_title"/> <meta content="Nina Kreuzberger&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Caroline Hirsch&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Khai Li Chai" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Eve Tomlinson" name="citation_author"/> <meta content="University of Bristol" name="citation_author_institution"/> <meta content="Zahra Khosravi" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Maria Popp" name="citation_author"/> <meta content="University Hospital Wuerzburg" name="citation_author_institution"/> <meta content="Miriam Neidhardt" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Vanessa Piechotta" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Susanne Salomon" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Sarah J Valk" name="citation_author"/> <meta content="Sanquin/Leiden University Medical Center" name="citation_author_institution"/> <meta content="Ina Monsef" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Christoph Schmaderer" name="citation_author"/> <meta content="Technical University of Munich, School of Medicine, Klinikum rechts der Isar" name="citation_author_institution"/> <meta content="Erica M Wood" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Cynthia So-Osman" name="citation_author"/> <meta content="Erasmus Medical Centre" name="citation_author_institution"/> <meta content="David J Roberts" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Zoe McQuilten" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Lise J Estcourt" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Nicole Skoetz" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="nicole.skoetz@uk-koeln.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD013825.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/09/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013825.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013825.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013825.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal [therapeutic use]; Cause of Death; *COVID-19; Randomized Controlled Trials as Topic; *SARS-CoV-2" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013825.pub2&amp;doi=10.1002/14651858.CD013825.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="xNbeAU8n";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013825\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013825\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ko","th","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013825.pub2",title:"SARS\\u2010CoV\\u20102\\u2010neutralising monoclonal antibodies for treatment of COVID\\u201019",firstPublishedDate:"Sep 2, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013825.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013825.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013825.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013825.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013825.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013825.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013825.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013825.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013825.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013825.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>23954 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013825.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-sec-0160"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-sec-0149"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/appendices#CD013825-sec-0165"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/table_n/CD013825StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/table_n/CD013825StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="* contributed equally"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0004">Nina Kreuzberger</a><sup>a</sup></li> <li class="author custom-tooltip" title="* contributed equally"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0005">Caroline Hirsch</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0006">Khai Li Chai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0007">Eve Tomlinson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0008">Zahra Khosravi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0009">Maria Popp</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0010">Miriam Neidhardt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0011">Vanessa Piechotta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0012">Susanne Salomon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0013">Sarah J Valk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0014">Ina Monsef</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0015">Christoph Schmaderer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0016">Erica M Wood</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0017">Cynthia So-Osman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0018">David J Roberts</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0019">Zoe McQuilten</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0020">Lise J Estcourt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information#CD013825-cr-0021"><i class="icon corresponding-author fa fa-envelope"></i>Nicole Skoetz</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information/en#CD013825-sec-0178">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 September 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013825.pub2">https://doi.org/10.1002/14651858.CD013825.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013825-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013825-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013825-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013825-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013825-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013825-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013825-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD013825-abs-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013825-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013825-abs-0001" lang="en"> <section id="CD013825-sec-0001"> <h3 class="title" id="CD013825-sec-0001">Background</h3> <p>Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived from the B cells of an infected host. They are being investigated as a potential therapy for coronavirus disease 2019 (COVID‐19). </p> </section> <section id="CD013825-sec-0002"> <h3 class="title" id="CD013825-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of SARS‐CoV‐2‐neutralising mAbs for treating patients with COVID‐19, compared to an active comparator, placebo, or no intervention. To maintain the currency of the evidence, we will use a living systematic review approach. </p> <p>A secondary objective is to track newly developed SARS‐CoV‐2‐targeting mAbs from first tests in humans onwards.  </p> </section> <section id="CD013825-sec-0003"> <h3 class="title" id="CD013825-sec-0003">Search methods</h3> <p>We searched MEDLINE, Embase, the Cochrane COVID‐19 Study Register, and three other databases on 17 June 2021. We also checked references, searched citations, and contacted study authors to identify additional studies. Between submission and publication, we conducted a shortened randomised controlled trial (RCT)‐only search on 30 July 2021. </p> </section> <section id="CD013825-sec-0004"> <h3 class="title" id="CD013825-sec-0004">Selection criteria</h3> <p>We included studies that evaluated SARS‐CoV‐2‐neutralising mAbs, alone or combined, compared to an active comparator, placebo, or no intervention, to treat people with COVID‐19. We excluded studies on prophylactic use of SARS‐CoV‐2‐neutralising mAbs. </p> </section> <section id="CD013825-sec-0005"> <h3 class="title" id="CD013825-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed search results, extracted data, and assessed risk of bias using the Cochrane risk of bias tool (RoB2). Prioritised outcomes were all‐cause mortality by days 30 and 60, clinical progression, quality of life, admission to hospital, adverse events (AEs), and serious adverse events (SAEs). We rated the certainty of evidence using GRADE. </p> </section> <section id="CD013825-sec-0006"> <h3 class="title" id="CD013825-sec-0006">Main results</h3> <p>We identified six RCTs that provided results from 17,495 participants with planned completion dates between July 2021 and December 2031. Target sample sizes varied from 1020 to 10,000 participants. Average age was 42 to 53 years across four studies of non‐hospitalised participants, and 61 years in two studies of hospitalised participants. </p> <p><b>Non‐hospitalised individuals with COVID‐19</b> </p> <p>Four studies evaluated single agents bamlanivimab (N = 465), sotrovimab (N = 868), regdanvimab (N = 307), and combinations of bamlanivimab/etesevimab (N = 1035), and casirivimab/imdevimab (N = 799). We did not identify data for mortality at 60 days or quality of life. Our certainty of the evidence is low for all outcomes due to too few events (very serious imprecision).  </p> <p><i>Bamlanivimab compared to placebo</i> </p> <p>No deaths occurred in the study by day 29. There were nine people admitted to hospital by day 29 out of 156 in the placebo group compared with one out of 101 in the group treated with 0.7 g bamlanivimab (risk ratio (RR) 0.17, 95% confidence interval (CI) 0.02 to 1.33), 2 from 107 in the group treated with 2.8 g (RR 0.32, 95% CI 0.07 to 1.47) and 2 from 101 in the group treated with 7.0 g (RR 0.34, 95% CI 0.08 to 1.56). Treatment with 0.7 g, 2.8 g and 7.0 g bamlanivimab may have similar rates of AEs as placebo (RR 0.99, 95% CI 0.66 to 1.50; RR 0.90, 95% CI 0.59 to 1.38; RR 0.81, 95% CI 0.52 to 1.27). The effect on SAEs is uncertain. Clinical progression/improvement of symptoms or development of severe symptoms were not reported. </p> <p><i>Bamlanivimab/etesevimab compared to placebo</i> </p> <p>There were 10 deaths in the placebo group and none in bamlanivimab/etesevimab group by day 30 (RR 0.05, 95% CI 0.00 to 0.81). Bamlanivimab/etesevimab may decrease hospital admission by day 29 (RR 0.30, 95% CI 0.16 to 0.59), may result in a slight increase in any grade AEs (RR 1.15, 95% CI 0.83 to 1.59) and may increase SAEs (RR 1.40, 95% CI 0.45 to 4.37). Clinical progression/improvement of symptoms or development of severe symptoms were not reported. </p> <p><i>Casirivimab/imdevimab compared to placebo</i> </p> <p>Casirivimab/imdevimab may reduce hospital admissions or death (2.4 g: RR 0.43, 95% CI 0.08 to 2.19; 8.0 g: RR 0.21, 95% CI 0.02 to 1.79). We are uncertain of the effect on grades 3‐4 AEs (2.4 g: RR 0.76, 95% CI 0.17 to 3.37; 8.0 g: RR 0.50, 95% CI 0.09 to 2.73) and SAEs (2.4 g: RR 0.68, 95% CI 0.19 to 2.37; 8.0 g: RR 0.34, 95% CI 0.07 to 1.65). Mortality by day 30 and clinical progression/improvement of symptoms or development of severe symptoms were not reported. </p> <p><i>Sotrovimab compared to placebo</i> </p> <p>We are uncertain whether sotrovimab has an effect on mortality (RR 0.33, 95% CI 0.01 to 8.18) and invasive mechanical ventilation (IMV) requirement or death (RR 0.14, 95% CI 0.01 to 2.76). Treatment with sotrovimab may reduce the number of participants with oxygen requirement (RR 0.11, 95 % CI 0.02 to 0.45), hospital admission or death by day 30 (RR 0.14, 95% CI 0.04 to 0.48), grades 3‐4 AEs (RR 0.26, 95% CI 0.12 to 0.60), SAEs (RR 0.27, 95% CI 0.12 to 0.63) and may have little or no effect on any grade AEs (RR 0.87, 95% CI 0.66 to 1.16).  </p> <p><i>Regdanvimab compared to placebo</i> </p> <p>Treatment with either dose (40 or 80 mg/kg) compared with placebo may decrease hospital admissions or death (RR 0.45, 95% CI 0.14 to 1.42; RR 0.56, 95% CI 0.19 to 1.60, 206 participants), but may increase grades 3‐4 AEs (RR 2.62, 95% CI 0.52 to 13.12; RR 2.00, 95% CI 0.37 to 10.70). 80 mg/kg may reduce any grade AEs (RR 0.79, 95% CI 0.52 to 1.22) but 40 mg/kg may have little to no effect (RR 0.96, 95% CI 0.64 to 1.43). There were too few events to allow meaningful judgment for the outcomes mortality by 30 days, IMV requirement, and SAEs.  </p> <p><b>Hospitalised individuals with COVID‐19</b> </p> <p>Two studies evaluating bamlanivimab as a single agent (N = 314) and casirivimab/imdevimab as a combination therapy (N = 9785) were included.   </p> <p><i>Bamlanivimab compared to placebo</i> </p> <p> We are uncertain whether bamlanivimab has an effect on mortality by day 30 (RR 1.39, 95% CI 0.40 to 4.83) and SAEs by day 28 (RR 0.93, 95% CI 0.27 to 3.14). Bamlanivimab may have little to no effect on time to hospital discharge (HR 0.97, 95% CI 0.78 to 1.20) and mortality by day 90 (HR 1.09, 95% CI 0.49 to 2.43). The effect of bamlanivimab on the development of severe symptoms at day 5 (RR 1.17, 95% CI 0.75 to 1.85) is uncertain. Bamlanivimab may increase grades 3‐4 AEs at day 28 (RR 1.27, 95% CI 0.81 to 1.98). We assessed the evidence as low certainty for all outcomes due to serious imprecision, and very low certainty for severe symptoms because of additional concerns about indirectness. </p> <p><i>Casirivimab/imdevimab with usual care compared to usual care alone</i> </p> <p>Treatment with casirivimab/imdevimab compared to usual care probably has little or no effect on mortality by day 30 (RR 0.94, 95% CI 0.87 to 1.02), IMV requirement or death (RR 0.96, 95% CI 0.90 to 1.04), nor alive at hospital discharge by day 30 (RR 1.01, 95% CI 0.98 to 1.04). We assessed the evidence as moderate certainty due to study limitations (lack of blinding). AEs and SAEs were not reported.  </p> </section> <section id="CD013825-sec-0007"> <h3 class="title" id="CD013825-sec-0007">Authors' conclusions</h3> <p>The evidence for each comparison is based on single studies. None of these measured quality of life. Our certainty in the evidence for all non‐hospitalised individuals is low, and for hospitalised individuals is very low to moderate. We consider the current evidence insufficient to draw meaningful conclusions regarding treatment with SARS‐CoV‐2‐neutralising mAbs. </p> <p>Further studies and long‐term data from the existing studies are needed to confirm or refute these initial findings, and to understand how the emergence of SARS‐CoV‐2 variants may impact the effectiveness of SARS‐CoV‐2‐neutralising mAbs. Publication of the 36 ongoing studies may resolve uncertainties about the effectiveness and safety of SARS‐CoV‐2‐neutralising mAbs for the treatment of COVID‐19 and possible subgroup differences.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013825-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013825-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD013825-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD013825-abs-0021">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013825-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013825-abs-0018">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013825-abs-0014">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013825-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013825-abs-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013825-abs-0019">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013825-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD013825-abs-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013825-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013825-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013825-abs-0002" lang="en"> <h3>Are laboratory‐made, COVID‐19‐specific monoclonal antibodies an effective treatment for COVID‐19? </h3> <p><b>Key messages</b> </p> <p>‐ We do not know whether antibodies (the body’s natural defence against disease) made in a laboratory and all the same as one another (monoclonal) and designed to target COVID‐19, are an effective treatment for COVID‐19 because we assessed only six studies exploring different treatments in different types of patients. </p> <p>‐ We identified 36 ongoing studies that will provide more evidence when completed.</p> <p>‐ We will update this review regularly as more evidence becomes available.</p> <p><b>What are ‘monoclonal’ antibodies?</b> </p> <p>Antibodies are made by the body as a defence against disease. However, they can also be produced in a laboratory from cells taken from people who have recovered from a disease.  </p> <p>Antibodies that are designed to target only one specific protein – in this case, a protein on the virus that causes COVID‐19 – are ‘monoclonal’. They attach to the COVID‐19 virus and stop it from entering and replicating in human cells, which helps to fight the infection. Monoclonal antibodies have been used successfully to treat other viruses. They are thought to cause fewer unwanted effects than convalescent plasma, which contains a variety of different antibodies. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know if COVID‐19 specific monoclonal antibodies are an effective treatment for COVID‐19. We looked at whether they:  </p> <p>‐ reduced the number of deaths from any cause; </p> <p>‐ improved symptoms or made them worse; </p> <p>‐ increased admissions to hospital; and</p> <p>‐ caused any serious or other unwanted effects.</p> <p><b>What did we do?</b> </p> <p>We searched for studies that investigated one or more monoclonal antibodies to treat people with confirmed COVID‐19 compared with placebo (sham treatment), another treatment or no treatment. Studies could take place anywhere globally and include participants of any age, gender or ethnicity, with mild, moderate or severe COVID‐19.  </p> <p>We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and size. </p> <p><b>What did we find?</b> </p> <p>We found six active studies including a total of 17,495 people. Four studies investigated non‐hospitalised people with no symptoms or mild COVID‐19. Two studies investigated hospitalised people with moderate to severe COVID‐19. Studies took place across the world. Three studies were funded by pharmaceutical companies. The monoclonal antibodies they studied were bamlanivimab, etesevimab, casirivimab and imdevimab, sotrovimab, regdanvimab. We did not identify data for mortality at 60 days and quality of life. </p> <p><b><i>Non‐hospitalised people, with no symptoms or mild COVID‐19 (four studies)</i> </b> </p> <p>One study investigated different doses of bamlanivimab (465 people), compared to placebo.</p> <p>We don’t know whether bamlanivimab:</p> <p>‐ increases or reduces the number of deaths because no participants died within 30 days of treatment; </p> <p>‐ causes more or fewer serious unwanted effects because there were few events.</p> <p>Bamlanivimab may reduce the number of admissions to hospital within 30 days of treatment compared to placebo. </p> <p>‐ May cause slightly fewer unwanted effects than placebo. </p> <p>‐ We did not find data for improved symptoms or worsened symptoms.</p> <p>One study investigated a combination of bamlanivimab and etesevimab (1035 people), compared to placebo. </p> <p>‐ Bamlanivimab and etesevimab may reduce the number of deaths and admissions to hospital.</p> <p>‐ May cause slightly more unwanted effects.</p> <p>‐ May cause more serious unwanted effects.</p> <p>For treatment with bamlanivimab alone or in combination with etesevimab we did not find data for improved symptoms or worsened symptoms. </p> <p>One study (phase 1/2 with 799 people) investigated different doses of casirivimab combined with imdevimab, compared to placebo. </p> <p>‐ Casirivimab combined with imdevimab may reduce the number of hospital admissions or death. </p> <p>‐ We don't know whether casirivimab and imdevimab causes more unwanted (grades 3 and 4) and serious unwanted effects than placebo because there were too few deaths to allow us to make a judgment.  </p> <p>‐  We did not find data for the number of people who died at day 30 and development of severe symptoms. </p> <p>‐ We did not include results from phase 3 (5607 people) of this study, because of high risk of bias, as it was not clear which participants were included in the analysis. </p> <p>One study (583 people) investigated sotrovimab, compared to placebo.</p> <p>We don't know whether sotrovimab: </p> <p>‐ increases or reduces the number of deaths and people requiring invasive mechanical ventilation or dying, because there were too few deaths to allow us to make a judgment. </p> <p>‐ Sotrovimab may reduce the number of people requiring oxygen, unwanted (grades 3 to 4) and serious unwanted effects; </p> <p>‐ may have little or no effect on unwanted effects (all grades). </p> <p>Another study (327 people) investigated different doses of regdanvimab (40 mg/kg and 80 mg/kg), compared to placebo. </p> <p>‐ Regdanvimab at either dose may reduce the number of admissions to hospital or death.</p> <p>‐ May increase unwanted events (grades 3 to 4).</p> <p>‐ Regdanvimab at a dose of 80 mg/kg may reduce unwanted effects (all grades) and 40 mg/kg may have little to no effect. </p> <p>‐ We don't know whether regdanvimab increases or decreases the number of deaths, requirement for invasive mechanical ventilation, and serious unwanted effects,  because there were too few events to allow us to make a judgment. </p> <p><b><i>Hospitalised people with moderate to severe COVID‐19 (2 studies)</i> </b> </p> <p>One study (314 people) investigated bamlanivimab compared to placebo.</p> <p>‐ We don’t know whether bamlanivimab increases or decreases the number of deaths due to any cause up to 30 or 90 days after treatment because there were too few deaths to allow us to make a judgment (6 deaths with bamlanivimab and 4 deaths with placebo in 314 people).  </p> <p>‐ Bamlanivimab may slightly increase the development of severe COVID‐19 symptoms five days after treatment and the number of people with unwanted effects. </p> <p>‐ Bamlanivimab may have little to no effect on time until discharge from hospital.</p> <p>‐ We don’t know whether bamlanivimab causes serious unwanted effects by day 30 because the study was small and reported few serious unwanted effects.  </p> <p>Another study (9785 people) investigated casirivimab combined with imdevimab, compared to standard of care. </p> <p>‐ Casirivimab combined with imdevimab has probably little to no effect on the number of deaths, requirement for invasive mechanical ventilation or death, and hospital discharge alive.  </p> <p>‐  We did not find data for unwanted and serious unwanted effects.</p> <p><b>What are the limitations of the evidence? </b> </p> <p>Our confidence in the evidence is low because we found only six studies, and they did not report everything we were interested in, such as the number of deaths within 60 days and quality of life. We found 36 ongoing studies. When they are published, we will add their results to our review. These results are likely to change our conclusions and will also help us understand how new variants affect how well monoclonal antibodies work.  </p> <p><b>How up to date is this evidence? </b> </p> <p>The evidence is up to date to 17 June 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013825-sec-0160" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013825-sec-0160"></div> <h3 class="title" id="CD013825-sec-0161">Implications for practice</h3> <section id="CD013825-sec-0161"> <p>The evidence for each comparison results from one study only, and we rated certainty in the evidence as low due to very serious imprecision for all comparisons except casirivimab/imdevimab versus usual care in hospitalised individuals (moderate certainty evidence). Therefore, the identified evidence is mostly insufficient to draw meaningful conclusions regarding treatment with any specific monoclonal antibody (mAb), and the disease stage in which mAbs should be used. </p> <p>For non‐hospitalised participants (asymptomatic or mild disease), we are uncertain about the effectiveness and safety of bamlanivimab, the combination of bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab, and regdanvimab compared to placebo. Information on patient‐relevant outcomes such as mortality, quality of life, and serious adverse events is either inconclusive or entirely lacking, although bamlanivimab alone and in combination with etesevimab, as well as casirivimab/imdevimab, sotrovimab, and regdanvimab may reduce the occurrence of hospital admission or death. Data on adverse events (AEs) vary for the substances, doses and even type of AE (all grades, grades 3‐4, serious adverse events). For all comparisons, the 95% confidence interval includes both benefit and harm and our certainty in the evidence is low. We acknowledge that the true effect may substantially vary from the reported effects. </p> <p>For hospitalised participants (moderate‐to‐severe disease), bamlanivimab may have little to no effect on efficacy outcomes when compared to placebo, but it may increase the occurrence of severe symptoms and grade 3 to 4 adverse events. Casirivimab/imdevimab has probably no effect on mortality, progression to invasive mechanical ventilation (IMV), and hospital discharge alive by day 30. Unfortunately, we are lacking important information on AE and SAE for this comparison. Subgroup analyses within the studies suggest that it could be worth examining the subgroup of participants who have not developed antibodies at baseline.  </p> </section> <h3 class="title" id="CD013825-sec-0162">Implications for research</h3> <section id="CD013825-sec-0162"> <p>We did not conduct meta‐analyses because studies were heterogeneous with regard to different mAbs used for treatment, setting, and inconsistently reported outcomes. Moreover, only one of the included studies reported all‐cause mortality exceeding 60 days, and none reported quality of life. WHO Progression Scale outcomes are reported on various versions of the scale, at different time points and as different effect measures. This highlights the urgent need for adequately‐powered randomised controlled trials (RCTs) with comparable study arms, as well as the assessment and reporting of clinically relevant outcomes such as quality of life and long‐term adverse events. </p> <p>Future research will need to consider whether the emergence of SARS‐CoV‐2 variants impacts the effectiveness of SARS‐CoV‐2‐neutralising mAbs. <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> explored resistance to four variants for bamlanivimab and etesevimab, and further research will be required as variants emerge. </p> <p>We identified 36 ongoing RCTs. Publication of these ongoing studies may resolve some uncertainties and allow a better judgment regarding the effectiveness and safety of SARS‐CoV‐2‐neutralising mAbs for the treatment of COVID‐19. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013825-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013825-sec-0008"></div> <div class="table" id="CD013825-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Bamlanivimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>Bamlanivimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> non‐hospitalised individuals with COVID‐19  <b>Setting:</b> outpatient<b> Intervention:</b> bamlanivimab<b> Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b> </b> </p> <p><b>Anticipated absolute effects* (95% CI)</b> </p> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty in the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with SARS‐CoV‐2‐specific mAb<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Not estimable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101 bamlanivimab/156 placebo</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No events observed. We are uncertain whether 0.7 g bamlanivimab has any impact on mortality at up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 2.8 g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Not estimable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107 bamlanivimab/156 placebo</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No events observed. We are uncertain whether 2.8 g bamlanivimab has any impact on mortality at up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 7.0 g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Not estimable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101 bamlanivimab/156 placebo</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No events observed. We are uncertain whether 7.0 g bamlanivimab has any impact on mortality at up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression/improvement of symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Admission to hospital by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>58 per 1000<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000 </b> </p> <p>(1 to 77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.17</b> </p> <p>(0.02 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g may decrease hospital admission at day 30.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 2.8 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>58 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18 per 1000 </b> </p> <p>(4 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.32</b> </p> <p>(0.07 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g may decrease hospital admission at day 30.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 7.0 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>58 per 1000<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20 per 1000 </b> </p> <p>(5 to 90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.34 </b> </p> <p>(0.08 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g may decrease hospital admission at day 30.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: all grades</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>269 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>267 per 1000 </b> </p> <p><b>(178 to 404)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b> </p> <p>(0.66 to 1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g may have little to no effect on all‐grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 2.8 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>269 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>242 per 1000</b> </p> <p>(159 to 372)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.90</b> </p> <p>(0.59 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263 </p> <p>(1RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 2.8 g may have little to no effect on all‐grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 7.0 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>269 per 1000<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>218 per 1000 </b> </p> <p>(140 to 342)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.81</b> </p> <p>(0.52 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 7.0 g may have little to no effect on all‐grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3 per 1000</b> </p> <p>(0 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.51</b> </p> <p>(0.02 to 12.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257 </p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>b</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced serious adverse events to determine whether bamlanivimab 0.7 g made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 2.8 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 1000<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3 per 1000</b> </p> <p>(0 to 76)<br/><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.48 </b> </p> <p>(0.02 to 11.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced serious adverse events to determine whether bamlanivimab 2.8 g made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 7.0 g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3 per 1000</b> </p> <p>(0 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.51</b> </p> <p>(0.02 to 12.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced serious adverse events to determine whether bamlanivimab 7.0 g made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk on the comparison group and the <b>relative effect</b> of the intervention (and its 95% confidence interval). </p> <p> </p> <p><b>CI:</b> confidence interval; <b>mAb:</b> monoclonal antibody; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty: </b>our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision, no events observed, effect not estimable<br/><sup>b</sup>Downgraded two levels for very serious imprecision, because of small sample size, low number of events and/or wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013825-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Bamlanivimab/etesevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bamlanivimab/etesevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) <b>Setting</b> : outpatients <b>Intervention</b> : bamlanivimab/etesevimab <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with bamlanivimab/ etesevimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b><br/>(0 to 15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.05</p> <p>(0.00 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1035<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab/etesevimab may reduce all‐cause mortality by day 30.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60 ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Admission to hospital or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>21 per 1000</b><br/>(11 to 41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.30</b><br/>(0.16 to 0.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1035<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab/ etesevimab may decrease the risk hospital admission by day 30.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: all grades</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>116 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>133 per 1000</b><br/>(96 to 184) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.15</b><br/>(0.83 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1035<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab/ etesevimab may have little to no effect on the risk of all grade adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>14 per 1000</b><br/>(4 to 42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.40</b><br/>(0.45 to 4.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1035<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab/ etesevimab may increase the risk of serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_422966277463976837" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_422966277463976837</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels for very serious imprecision due to low number of events and low sample size<br/><sup>b</sup> Downgraded two levels for very serious imprecision, because of small sample size </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013825-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Casirivimab/imdevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Casirivimab/imdevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population</b> : non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) <b>Setting</b> : outpatients <b>Intervention</b> : casirivimab/imdevimab <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants </b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with casirivimab/imdevimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one study which was excluded from analysis reported results on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression: requirement of IMV (WHO 7, 8 or 9), 1.2g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one study which was excluded from analysis reported results on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Admission to hospital or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1.2g</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.4g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9 per 1000</b><br/>(2 to 47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.43</b><br/>(0.08 to 2.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>446<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Casirivimab/imdevimab at 2.4 g or 8.0 g may reduce the occurrence of hospital admissions or death at day 30. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8.0g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b><br/>(0 to 39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.21</b><br/>(0.02 to 1.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>450<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Adverse events: grade 3‐4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1.2g</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one study which was excluded from analysis reported results on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.4g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>15 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12 per 1000</b><br/>(3 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.76</b> </p> <p>(0.17 to 3.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>a </sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>There were too few who experienced am event to determine whether any dose of casirivimab/imdevimab made a difference </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8.0g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>15 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b><br/>(1 to 42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.50</b><br/>(0.09 to 2.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>522<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: all grades</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one study which was excluded from analysis reported results on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1.2g</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one study which was excluded from analysis reported results on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.4g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16 per 1000</b><br/>(4 to 54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.68</b><br/>(0.19 to 2.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>There were too few who experienced am event to determine whether any dose of casirivimab/imdevimab made a difference. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8.0g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b><br/>(2 to 38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.34</b><br/>(0.07 to 1.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>522<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels due to very serious imprecision; low sample size and low number of events  </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013825-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sotrovimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sotrovimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) <b>Setting</b> : outpatients <b>Intervention</b> : sotrovimab <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants** <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with sotrovimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b> </p> <p>(0 to 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.33</b><br/>(0.01 to 8.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced mortality to determine whether sotrovimab made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression: oxygen requirement (≥ 5 WHO scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>65 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>7 per 1000</b> </p> <p>(1 to 29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.11</b><br/>(0.02 to 0.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab may reduce the number of participants with any oxygen requirement.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression: IMV or death (≥ 7 WHO scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b> </p> <p>(0 to 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.14</b><br/>(0.01 to 2.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced an event to determine whether sotrovimab made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Admission to hospital or death by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>72 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b> </p> <p>(3 to 35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.14</b><br/>(0.04 to 0.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab may reduce the occurrence of hospital admissions or death.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: all grades</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>194 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>169 per 1000</b> </p> <p>(128 to 225)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.87</b><br/>(0.66 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>868</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab may have little to no effect on the occurrence of all grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: grades 3 and 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 per 1000</b> </p> <p>(7 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.26</b><br/>(0.12 to 0.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>868</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab may reduce the occurrence of grade 3‐4 adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 per 1000</b> </p> <p>(7 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.27</b><br/>(0.12 to 0.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>868</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab may reduce the occurrence of serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/>  </p> <p>**This study included a total of 868 participants. All were 868 participants randmoised were included in the safety set, but only 583 participants were analysed in the efficacy set. </p> <p> <br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty: </b>our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels for very serious imprecision, because of low sample size, very low number of events and very wide confidence interval </p> <p><sup>b</sup> Downgraded two levels for very serious imprecision, because of low sample size and/or low number of events </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013825-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Regdanvimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Regdanvimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population</b> : non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) <b>Setting</b> : outpatient <b>Intervention</b> : regdanvimab <b>Comparison</b>: placebo    </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI)<b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI) </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies) </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE) </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with regdanvimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Regdanvimab 40mg/kg</p> <p>CT‐P59 80 mg/kg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b><br/>(0 to 0)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No events observed. We are uncertain whether CT‐P59 has any impact on mortality at up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Clinical progression: development of severe symptoms (≥ 7 WHO scale, IMV)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b><br/>(0 to 0)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No events observed. We are uncertain whether 40 mg/kg regdanvimab has any impact on IMV requirement or death. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b><br/>(0 to 0)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.00</b><br/>(0.12 to 72.80)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103<br/>(1 study)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced IMV or death to determine whether CT‐P59, 80 mg/kg made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Admission to hospital or death by day 30 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>87 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39 per 1000</b><br/>(12 to 124) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.45</b><br/>(0.14 to 1.42)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204<br/>(1 RCT)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Regdanvimab, 40 mg/kg or 80 mg/kg may decrease hospital admission or death by day 30. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>87 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>49 per 1000</b><br/>(17 to 140) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.56</b><br/>(0.19 to 1.60)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206<br/>(1 RCT)  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events: all grades</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>309 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>297 per 1000</b><br/>(198 to 442) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.96</b><br/>(0.64 to 1.43)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>215<br/>(1 RCT)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regdanvimab 40 mg/kg may have little to no effect on all grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>309 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>244 per 1000</b><br/>(161 to 377) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.79</b><br/>(0.52 to 1.22)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220<br/>(1 RCT)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regdanvimab 80 mg/kg may reduce the occurrence of all grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events: grades 3 and 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>48 per 1000</b><br/>(9 to 239)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.62</b><br/>(0.52 to 13.12)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>215<br/>(1 RCT)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Regdanvimab 40 mg/kg or 80 mg/kg may increase the occurrence of grade 3 adverse events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>36 per 1000</b><br/>(7 to 195)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.00</b><br/>(0.37 to 10.70)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220<br/>(1 RCT)  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> <p>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>b</sup>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether regdanvimab, 40 mg/kg or 80 mg/kg has an effect on serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty: </b>our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels for very serious imprecision, because no events were observed, the sample size small and the effect not estimable </p> <p><sup>b</sup> Downgraded two levels for very serious imprecision, because few event(s) were observed and/or  the sample size was small. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013825-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Bamlanivimab compared to placebo in hospitalised individuals with COVID‐19 (moderate to severe disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bamlanivimab compared to placebo in hospitalised individuals with COVID‐19 (moderate to severe disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : hospitalised individuals with COVID‐19 (moderate to severe disease) <b>Setting</b> : inpatient <b>Intervention</b> : bamlanivimab <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty in the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with bamlanivimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>37 per 1000</b><br/>(11 to 128) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.39</b><br/>(0.40 to 4.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether bamlanivimab has an effect on mortality at 28 days.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 90</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>73 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> <p>(36 to 168) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HR 1.09</b> </p> <p>(0.49 to 2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab may have little to no effect on mortality by day 90.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7)<br/>assessed with: 7‐point scale, lower better </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>180 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>211 per 1000</b><br/>(135 to 333) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.17</b><br/>(0.75 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>311<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab may slightly increase the development of severe symptoms (assessed by the need for NIV, IMV, ECMO, or renal replacement therapy) at day 5. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to hospital discharge up to 26.10.2020, absolute effects for day 10</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>762 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>752 per 1000</b><br/>(664 to 816) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HR 0.97</b><br/>(0.76 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab may have little to no impact on hospital discharge until data cut off (26 October 2020). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: grades 3 and 4 by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>179 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>227 per 1000</b><br/>(145 to 354) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.27</b><br/>(0.81 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab may slightly increase the risk of grade 3 and 4 adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>31 per 1000</b><br/>(9 to 104) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.93</b><br/>(0.27 to 3.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether bamlanivimab has an effect the occurrence of serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR:</b> hazard Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_422871223304980961" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_422871223304980961</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels for very serious imprecision, because of wide confidence interval, low sample size and/or low number of events, imbalances in baseline characteristics. </p> <p><sup>a</sup> Downgraded one level for serious indirectness, because the time frame of 5 days was short for assessing clinical status. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013825-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Casirivimab/imdevimab compared to usual care alone in hospitalised individuals with COVID‐19 (moderate to severe disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Casirivimab/imdevimab compared to usual care in hospitalised individuals with COVID‐19 (moderate to severe disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : hospitalised individuals with COVID‐19 (moderate to severe disease) <b>Setting</b> : inpatient <b>Intervention</b> : casirivimab/imdevimab <b>Comparison</b>: usual care alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty in the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with usual care alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p>Risk with c<b>asirivimab/imdevimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>236 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>221 per 1000</b><br/>(205 to 241) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.94</b><br/>(0.87 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9785<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casirivimab/imdevimab 8.0 g has probably little to no effect on mortality by day 30 in the overall cohort of hospitalised participants. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression: need for IMV or death (WHO ≥ 7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>248 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>238 per 1000</b><br/>(223 to 258) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.96</b><br/>(0.90 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9198<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casirivimab/imdevimab 8.0 g has probably little to no effect on IMV requirement or death by day 30 in the overall cohort of hospitalised participants. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospital discharge alive by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>690 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>697 per 1000</b><br/>(676 to 718) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b><br/>(0.98 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9785<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casirivimab/imdevimab 8.0 g has probably little to no effect on discharge from hospital alive by day 30 in the overall cohort of hospitalised participants. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: grades 3 and 4 by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious risk of bias, the study was not blinded. Currently, there is no clearly defined standard of care for COVID‐19, therefore, a lack of blinding can have resulted in differential treatments/timings of treatment between arms. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013825-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013825-sec-0009"></div> <section id="CD013825-sec-0010"> <h3 class="title" id="CD013825-sec-0010">Description of the condition</h3> <p>The clinical syndrome novel coronavirus disease 2019 (COVID‐19) is a rapidly spreading infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; <a href="./references#CD013825-bbs2-0265" title="World Health Organization. Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 6 November 2020).">WHO 2020a</a>). Declared a pandemic on 11 March 2020, COVID‐19 is unprecedented in comparison to previous coronavirus outbreaks, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), with 813 and 858 deaths, respectively (<a href="./references#CD013825-bbs2-0263" title="World Health Organization. Cumulative number of reported probable cases of SARS. www.who.int/csr/sars/country/2003_07_11/en (accessed 13 April 2020).">WHO 2007</a>; <a href="./references#CD013825-bbs2-0264" title="World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). www.who.int/emergencies/mers-cov/en (accessed 13 April 2020).">WHO 2019</a>). Despite intensive international efforts to contain its spread, it has resulted in more than 198 million confirmed cases and more than 4.2 million deaths worldwide up to 3 August 2021 (<a href="./references#CD013825-bbs2-0266" title="World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. covid19.who.int (accessed 11 June 2020).">WHO 2020b</a>), impacting severely on healthcare facilities, healthcare workers, and medical equipment resources. </p> <p>Since 23 March 2020, weekly hospitalisation rates in the USA fluctuated between 3 and 17.2 per 100,000 population, with a recent peak increase at the end of December 2020 (<a href="./references#CD013825-bbs2-0182" title="Centers for Disease Control and Prevention. COVIDView - a weekly surveillance summary of U.S. COVID-19 activity (Key updates for week 43). www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html (accessed 12 January 2020).">CDC 2020</a>). Risk for severe disease, hospitalisation and mortality is higher for individuals aged 65 years or older, smokers and individuals with certain underlying medical conditions, such as cancer, chronic kidney disease, chronic obstructive pulmonary disease (COPD), heart conditions, immunocompromised state, obesity, sickle cell disease or type 2 diabetes mellitus (<a href="./references#CD013825-bbs2-0209" title="HuangC , WangY , LiX , RenL , ZhaoJ , HuY , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020;395(10223):497-506.">Huang 2020</a>; <a href="./references#CD013825-bbs2-0219" title="LiangW , GuanW , ChenR , WangW , LiJ , XuK , et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology2020;21(3):335-7.">Liang 2020</a>; <a href="./references#CD013825-bbs2-0265" title="World Health Organization. Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 6 November 2020).">WHO 2020a</a>; <a href="./references#CD013825-bbs2-0275" title="WilliamsonE , WalkerAJ , BhaskaranKJ , BaconS , BatesC , MortonCE , et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature2020;584:430-6. [DOI: 10.1038/s41586-020-2521-4]">Williamson 2020</a>). COVID‐19 case fatality ratios varied widely between countries and reporting periods, from 0.0% to more than 25% (<a href="./references#CD013825-bbs2-0211" title="Johns Hopkins University &amp; Medicine. Mortality analysis. coronavirus.jhu.edu/data/mortality (accessed 11 March 2021).">Johns Hopkins 2021</a>). However, these numbers may be misleading as they tend to overestimate the infection fatality ratio (the probability of dying for an infected individual) due to varying testing frequency, lag in reporting dates, and variations in case definitions, especially at the beginning of a pandemic where the main focus lies on severe cases (<a href="./references#CD013825-bbs2-0267" title="World Health Organization. Estimating mortality from COVID-19 - scientific brief. www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1 (accessed 2 November 2020).">WHO 2020c</a>). A recent estimate of the infection fatality ratio of SARS‐CoV‐2 based on seroprevalence data from the general population of a country ranged between 0.00% and 1.54% for 51 different locations (corrected median: 0.23%; <a href="./references#CD013825-bbs2-0210" title="IoannidisJP . Infection fatality rate of COVID-19 inferred from seroprevalence data. Bulletin of the World Health Organization2021;99(1):19–33F. [DOI: 10.2471/BLT.20.265892]">Ioannidis 2020</a>). </p> <p>The median incubation time is estimated to be between five and six days, and 97.5% of symptomatic cases develop symptoms within 11.5 days of exposure (<a href="./references#CD013825-bbs2-0215" title="LauerSA , GrantzKH , BiQ , JonesFK , ZhengQ , MeredithHR , et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine2020;172(9):577–82. [DOI: 10.7326/M20-0504]">Lauer 2020</a>). Signs and symptoms can include sore throat, cough, fever, headache, fatigue, and myalgia (muscle pain) or arthralgia (joint pain) (<a href="./references#CD013825-bbs2-0253" title="StruyfT , DeeksJJ , DinnesJ , TakwoingiY , DavenportC , LeeflangMM , et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013665. [DOI: 10.1002/14651858.CD013665]">Struyf 2020</a>). Other symptoms include shortness of breath, chills, nausea or vomiting, diarrhoea, nasal congestion, haemoptysis (coughing up blood), and conjunctival congestion (<a href="./references#CD013825-bbs2-0265" title="World Health Organization. Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 6 November 2020).">WHO 2020a</a>). The proportion of infected people with mild disease is around 80% (<a href="./references#CD013825-bbs2-0276" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>). Of those, 20% may remain completely asymptomatic (<a href="./references#CD013825-bbs2-0178" title="Buitrago-GarciaD , Egli-GanyD , CounotteMJ , HossmannS , ImeriH , Ipekci AzizM , et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLOS Medicine2020;17(9):e1003346.">Buitrago‐Garcia 2020</a>), 14% are affected by severe disease, and 5% experience critical disease with intensive care unit (ICU) admittance due to respiratory failure, septic shock, or multiple organ dysfunction (<a href="./references#CD013825-bbs2-0276" title="WuZ , McGooganJM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>). Due to the extent of the pandemic and a current lack of potent medication and vaccines, targeted immunotherapies such as monoclonal antibodies (mAbs) raise hopes for combating the disease. </p> </section> <section id="CD013825-sec-0011"> <h3 class="title" id="CD013825-sec-0011">Description of the intervention</h3> <p>Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived from natural B cells of hosts who have experienced or been injected with the antigen of interest, to substitute antibodies that are able to mimic a person's own immune attack (<a href="./references#CD013825-bbs2-0176" title="BayerV . An overview of monoclonal antibodies. Immunotherapy in Oncology2019;35(5):150927. [DOI: 10.1016/j.soncn.2019.08.006]">Bayer 2019</a>). While traditional serum therapy uses antibodies derived from more than one type of white cell (polyclonal), mAbs target only a single, predetermined epitope, thereby generally showing fewer adverse events, such as serum sickness and anaphylaxis (<a href="./references#CD013825-bbs2-0227" title="MarstonHD , PaulesCI , FauciAS . Monoclonal antibodies for emerging infectious diseases - borrowing from history. New England Journal of Medicine2018;378(16):1469-72. [DOI: 10.1056/NEJMp1802256]">Marston 2018</a>). More than 75 mAbs have already been licensed by the US Food and Drug Administration (FDA) for a spectrum of medical conditions, especially in oncology and immunology (<a href="./references#CD013825-bbs2-0212" title="KaplonH , MuralidharanM , SchneiderZ , ReichertJM . Antibodies to watch in 2020. mAbs2019;12(1):e1703531. [DOI: 10.1080/19420862.2019.1703531]">Kaplon 2020</a>; <a href="./references#CD013825-bbs2-0222" title="LuR , HwangY , LiuI , LeeC , TsaiH , LiH , et al. Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science2020;27(1):1. [DOI: 10.1186/s12929-019-0592-z]">Lu 2020b</a>). </p> <p>The main principle of the production of monoclonal antibodies follows this sequence:</p> <p> <ul id="CD013825-list-0001"> <li> <p>isolation and identification of antibodies against the desired antigen;</p> </li> <li> <p>selection of the best candidate antibodies;</p> </li> <li> <p>mass production of these antibodies;</p> </li> <li> <p>and consequently, testing of these antibodies.</p> </li> </ul> </p> <p>The first step, the method to create, isolate and identify potential antibodies, has evolved markedly over time. The first mAb, a mouse IgG2a antibody, was licensed in 1986 to prevent kidney transplant rejection by targeting CD3 on T‐lymphocytes. Early mAbs were generated using a hybridoma technique, which involves the extraction of B‐lymphocytes from the spleen of an immunised animal (e.g. a mouse), fusion with immortal myeloma cells and in vitro culturing of the cells (‐omab; <a href="./references#CD013825-bbs2-0176" title="BayerV . An overview of monoclonal antibodies. Immunotherapy in Oncology2019;35(5):150927. [DOI: 10.1016/j.soncn.2019.08.006]">Bayer 2019</a>; <a href="./references#CD013825-bbs2-0220" title="LiuJK . The history of monoclonal antibody development - progress, remaining challenges and future innovations. Annals of Medicine and Surgery2014;3(4):113-6. [DOI: 10.1016/j.amsu.2014.09.001]">Liu 2014</a>). Antii‐mouse antibody reactions in patients, and advances in genetic engineering led to the development of chimeric mAbs. These use the same hybridoma technique but replace the constant region of the mouse antibodies with equivalent proteins from human antibodies (~ 65% human, identified by ending ‐ximab; <a href="./references#CD013825-bbs2-0176" title="BayerV . An overview of monoclonal antibodies. Immunotherapy in Oncology2019;35(5):150927. [DOI: 10.1016/j.soncn.2019.08.006]">Bayer 2019</a>). In humanised mAbs, all regions except the complementary‐determining regions (CDRs) that create contact with the antigen, are replaced with its human equivalents (~ 95% human, identified by the ending ‐zumab; <a href="./references#CD013825-bbs2-0176" title="BayerV . An overview of monoclonal antibodies. Immunotherapy in Oncology2019;35(5):150927. [DOI: 10.1016/j.soncn.2019.08.006]">Bayer 2019</a>). Both latter strategies sometimes result in low antibody specificity. The most recent generation which aims at resolving this issue, called fully humanised or human mAbs (identified by the ending ‐umab), can be generated by two routes. The first route follows the hybridoma technique, but uses genetically‐altered mice that carry human antibody genes (<a href="./references#CD013825-bbs2-0176" title="BayerV . An overview of monoclonal antibodies. Immunotherapy in Oncology2019;35(5):150927. [DOI: 10.1016/j.soncn.2019.08.006]">Bayer 2019</a>). The second route, called phage display, involves the isolation of B‐lymphocytes from human blood, obtaining the genetic information of the CDRs by polymerase chain reaction (PCR), and inserting it into bacteriophages that are used to infect <i>Escherichia coli</i> . The <i>E coli</i> generate a cell library that can be more easily screened for ideal candidate antibodies (<a href="./references#CD013825-bbs2-0220" title="LiuJK . The history of monoclonal antibody development - progress, remaining challenges and future innovations. Annals of Medicine and Surgery2014;3(4):113-6. [DOI: 10.1016/j.amsu.2014.09.001]">Liu 2014</a>). </p> <p>Ideally, mAbs intended for clinical practice should be easily mass‐produced, show high potency (high antigen binding activity), be stable (prolonged shelf‐life), have a long half‐life, and should not elicit a strong immune response (<a href="./references#CD013825-bbs2-0225" title="MarovichM , MascolaJR , CohenMS . Monoclonal antibodies for prevention and treatment of COVID-19. JAMA2020;324(2):131-2.">Marovich 2020</a>). Immunogenicity varies by drug dosage, route of administration, possible contamination, structural features, and humanness of the mAbs, as well as by patient characteristics, such as age, genetic background, and related diseases (<a href="./references#CD013825-bbs2-0222" title="LuR , HwangY , LiuI , LeeC , TsaiH , LiH , et al. Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science2020;27(1):1. [DOI: 10.1186/s12929-019-0592-z]">Lu 2020b</a>). The strategy to target a single epitope can, depending on the specific target, be utilised both for halting disease progression and as temporary prophylaxis for groups with increased antigen exposure, such as  healthcare workers, or those at increased risk of severe disease and mortality (<a href="./references#CD013825-bbs2-0227" title="MarstonHD , PaulesCI , FauciAS . Monoclonal antibodies for emerging infectious diseases - borrowing from history. New England Journal of Medicine2018;378(16):1469-72. [DOI: 10.1056/NEJMp1802256]">Marston 2018</a>). This may also interrupt the chain of infections. A mixture of mAbs, 'mAbs cocktails', may be more efficient for some antigens, so that they do not escape or mutate. </p> <p>Although the majority of mAbs are licensed and used to treat chronic diseases, mAbs have also been used to treat infectious diseases, such as Zaire Ebola virus (<a href="./references#CD013825-bbs2-0173" title="ReichertJ . FDA approves inmazeb for ebola virus infection. www.antibodysociety.org/tag/approved-antibodies (accessed 5 November 2020).">Antibody Society 2020</a>), respiratory syncytial virus, anthrax and <i>Clostridioides difficile</i>, which highlights the great potential of mAbs for the treatment of COVID‐19 (<a href="./references#CD013825-bbs2-0225" title="MarovichM , MascolaJR , CohenMS . Monoclonal antibodies for prevention and treatment of COVID-19. JAMA2020;324(2):131-2.">Marovich 2020</a>). </p> </section> <section id="CD013825-sec-0012"> <h3 class="title" id="CD013825-sec-0012">How the intervention might work</h3> <p>SARS‐CoV‐2 stems from the coronavirus family, characterised by a positive‐sense, single‐stranded RNA (ribonucleic acid; <a href="./references#CD013825-bbs2-0221" title="LuR , ZhaoX , LiJ , NiuP , YangB , WuH , et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet2020;395(10224):565-74.">Lu 2020a</a>). The spike proteins on its envelope, which give the virus its name, play a critical role in enabling it to enter a host cell by two mechanisms (<a href="./references#CD013825-bbs2-0206" title="HoffmannM , Kleine-WeberH , SchroederS , KrügerN , HerrlerT , ErichsenS , et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell2020;181(2):271-280.e8. [DOI: 10.1016/j.cell.2020.02.052]">Hoffmann 2020</a>; <a href="./references#CD013825-bbs2-0238" title="OuX , LiuY , LeiX , LiP , MiD , RenL , et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Communications2020;11(1):1620. [DOI: 10.1038/s41467-020-15562-9]">Ou 2020</a>). The human angiotensin‐converting enzyme 2 (ACE2) receptor on the spike protein binds to ACE2 proteins that are found throughout the body, but with higher expression in respiratory epithelial cells, type I and II alveolar cells in the lungs, oral cavity, kidneys, testes and intestines (<a href="./references#CD013825-bbs2-0256" title="TolouianR , VahedSZ , GhiyasvandS , TolouianA , ArdalanM . COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. Journal of Renal Injury Prevention2020;9(2):e19. [DOI: 10.34172/jrip.2020.19]">Tolouian 2020</a>). This activates the S proteins' fusion machinery, which inserts into the cellular plasma membrane, brings the viral membrane into proximity and fuses them to create a portal to deposit the virus RNA genome into the host cell, where it starts replicating (<a href="./references#CD013825-bbs2-0200" title='GlaunsingerB . Lecture 2: "Coronavirus biology", from the course "COVID-19, SARS-CoV-2 and the pandemic" [video]. biology.mit.edu/undergraduate/current-students/subject-offerings/covid-19-sars-cov-2-and-the-pandemic/ (accessed 4 November 2020).'>Glaunsinger 2020</a>; <a href="./references#CD013825-bbs2-0256" title="TolouianR , VahedSZ , GhiyasvandS , TolouianA , ArdalanM . COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. Journal of Renal Injury Prevention2020;9(2):e19. [DOI: 10.34172/jrip.2020.19]">Tolouian 2020</a>). </p> <p>Although the exact cellular mechanisms are yet to be uncovered, it is hypothesized that the ACE2 protein plays additional roles in COVID‐19 disease severity, especially lung injury. Excessive Inflammation (the so‐called 'cytokine storm' seen in some cases), especially interleukin 1 and 6 (IL‐1, IL‐6), activates the kallikrein‐kinin system, which in several steps produces des‐Arg<sup>9</sup>‐BK (DABK). DABK is a ligand that binds to the bradykinin 1 receptor (B1R), responsible for controlling vascular permeability. Usually, ACE2 proteins play the role of guardians of B1R activity by counteracting DABK. Due to internalisation of ACE2 by SARS‐CoV‐2, they are unable to fulfill their role. In addition, inflammation increases the expression of B1Rs. Both overstimulation and overexpression of B1Rs may lead to increased plasma leakage, which in turn activates more plasma kallikrein–kinin, creating a loop to facilitate local angioedema in the lung, and is potentially responsible for acute respiratory distress syndrome (ARDS) (<a href="./references#CD013825-bbs2-0257" title="Van de VeerdonkF , NeteaMG , Van DeurenM , Van der MeerJW , De MastQ , BruggemannR , et al. Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach. Preprints.org2020. [DOI: 10.20944/preprints202004.0023.v1]">Van de Veerdonk 2020a</a>; <a href="./references#CD013825-bbs2-0258" title="Van de VeerdonkFL , NeteaMG , Van DeurenM , Van der MeerJW , De MastQ , BrüggemannRJ , et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife2020;9:e57555. [DOI: 10.7554/eLife.57555]">Van de Veerdonk 2020b</a>; <a href="./references#CD013825-bbs2-0179" title="BuszkoM , Park J-H, VerthelyiD , SenR , YoungHA , RosenbergAS . The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nature Immunology2020;21(10):1146-51. [DOI: 10.1038/s41590-020-0779-1]">Buszko 2020</a>). </p> <p>Due to the importance of this pathway in viral replication and symptom severity, the focus of current research on SARS‐CoV‐2‐neutralising monoclonal antibodies is on blocking the binding of SARS‐CoV‐2 to the ACE2 receptor on human cells by targeting the receptor‐binding domain on the spike protein of the virus (<a href="./references#CD013825-bbs2-0225" title="MarovichM , MascolaJR , CohenMS . Monoclonal antibodies for prevention and treatment of COVID-19. JAMA2020;324(2):131-2.">Marovich 2020</a>). The first COVID‐19‐specific mAb, bamlanivimab, has been tested in humans since June 2020 (<a href="./references#CD013825-bbs2-0194" title="Eli Lilly and Company. Lilly begins world's first study of a potential COVID-19 antibody treatment in humans [press release]. investor.lilly.com/news-releases/news-release-details/lilly-begins-worlds-first-study-potential-covid-19-antibody (accessed 5 November 2020).">Eli Lilly and Co 2020</a>; <a href="./references#CD013825-bbs2-0235" title="NCT04427501. A randomized, double-blind, placebo-controlled, phase 2/3 study to evaluate the efficacy and safety of LY3819253 and LY3832479 in participants with mild to moderate COVID-19 illness. clinicaltrials.gov/ct2/show/NCT04427501 (first received 11 June 2020).">NCT04427501</a>). Interim results show a possible lower symptom burden and fewer hospitalisations, with a favourable safety profile in the mAbs group as compared with placebo (<a href="./references#CD013825-bbs2-0183" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]">Chen 2020</a>). </p> <p>Studies have examined the effect of previously established immune‐modulatory mAbs, such as: IL‐6 and IL‐1 receptor antagonists (tocilizumab, sarilumab; canakinumab, RPH‐104; <a href="./references#CD013825-bbs2-0180" title="CatanzaroM , FagianiF , RacchiM , CorsiniE , GovoniS , LanniC . Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduction and Targeted Therapy2020;5(1):84. [DOI: 10.1038/s41392-020-0191-1]">Catanzaro 2020</a>), and kallikrein‐targeting mAbs (e.g. lanadelumab), in controlling the cytokine storm. In this review, we focus on SARS‐CoV‐2‐neutralising mAbs only. As of 10 November 2020, at least 120 SARS‐COV‐2‐neutralising mAbs targeting the spike protein are in discovery, development or testing phases, and 16 are in clinical trial phases (<a href="./references#CD013825-bbs2-0185" title="Chinese Antibody Society. chineseantibody.org (accessed 9 November 2020).">Chinese Antibody Society 2020</a>; <a href="./references#CD013825-bbs2-0277" title="YangL , LiuW , YuX , WuM , ReichertJM , HoM . COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antibody Therapeutics2020;3(3):205-12. [DOI: 10.1093/abt/tbaa020]">Yang 2020</a>). Many questions, besides their potential clinical effectiveness and most favourable timing of administration, remain to be addressed. For example: their adverse events, the duration of protection, and possible mutations of the virus that lead to antibody resistance (for example, cluster 5 linked to mink farming, with previously unseen mutations; <a href="./references#CD013825-bbs2-0268" title="World Health Organization. SARS-CoV-2 mink-associated variant strain – Denmark. www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en (accessed 9 November 2020).">WHO 2020d</a>). Changes to the virus may mean the viruses are no longer neutralised or cleared by the mAb, and may instead lead to increased severity of the infection, termed 'antibody‐dependent enhancement (ADE)' (<a href="./references#CD013825-bbs2-0216" title="LeeWS , WheatleyAK , KentSJ , DeKoskyBJ . Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nature Microbiology2020;5:1185–91. [DOI: 10.1038/s41564-020-00789-5]">Lee 2020</a>). </p> </section> <section id="CD013825-sec-0013"> <h3 class="title" id="CD013825-sec-0013">Why it is important to do this review</h3> <p>The drastically increasing numbers of COVID‐19 cases worldwide and the enduring scarcity of treatment options threatens to burden health systems and increase mortality. Many ongoing studies are investigating pharmacological treatment options, but up to now only a few options have shown an effect. With the exception of corticosteroids in people on ventilation (<a href="./references#CD013825-bbs2-0214" title="LamontagneF , AgoritsasT , MacdonaldH , Leo Y-S, DiazJ , AgarwalA , et al. A living WHO guideline on drugs for COVID-19. BMJ2020;370:m3379. [DOI: 10.1136/bmj.m3379]">Lamontagne 2020</a>; <a href="./references#CD013825-bbs2-0269" title="World Health Organization. Corticosteroids for COVID-19 - living guidance 2 September 2020. www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 (accessed 5 November 2020).">WHO 2020e</a>) and remdesivir (<a href="./references#CD013825-bbs2-0177" title="BeigelJH , TomashekKM , DoddLE , MehtaAK , ZingmanBS , KalilAC , et al. Remdesivir for the treatment of COVID-19 — final report. New England Journal of Medicine2020;383:1813-26. [DOI: 10.1056/NEJMoa2007764]">Beigel 2020</a>; <a href="./references#CD013825-bbs2-0236" title="National Institutes of Health. COVID-19 treatment guidelines - therapeutic management of patients with COVID-19 (version last updated on 9 October 2020). www.covid19treatmentguidelines.nih.gov/therapeutic-management (accessed 6 November 2020).">NIH 2020</a>), supportive care remains the only current treatment option, in addition to oxygen therapy in mild cases and invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) in severe cases (<a href="./references#CD013825-bbs2-0236" title="National Institutes of Health. COVID-19 treatment guidelines - therapeutic management of patients with COVID-19 (version last updated on 9 October 2020). www.covid19treatmentguidelines.nih.gov/therapeutic-management (accessed 6 November 2020).">NIH 2020</a>). Multiple vaccines against SARS‐CoV‐2 have been approved in several countries. For example: BNT162b2 by Pfizer‐BioNTech, mRNA‐1273 by Moderna and Janssen, COVID‐19 Vaccine by Johnson&amp;Johnson (<a href="./references#CD013825-bbs2-0196" title="US Food and Drug Administration. COVID-19 vaccines. www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines (accessed 12 January 2021).">FDA 2021a</a>), AZD1222 by<i> </i>AstraZeneca (<a href="./references#CD013825-bbs2-0175" title="AstraZeneca. AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK. www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html (accessed 12 January 2021).">AstraZeneca 2020</a>), CoronaVac by Sinovac (<a href="./references#CD013825-bbs2-0271" title="World Health Organisation. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations.">WHO 2021a</a>). However, their distribution takes time and not everyone may be willing to be vaccinated. In addition, vaccines may not work equally well for everyone. Immunocompromised individuals, for example, may show a lower immune response to the vaccine (<a href="./references#CD013825-bbs2-0232" title="Monin-AldamaL , LaingAG , Muñoz-RuizM , McKenzieDR , delMolino del BarrioI , AlaguthuraiT , et al. Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines. medRxiv [Preprint]2021. [DOI: 10.1101/2021.03.17.21253131]">Monin‐Aldama 2021</a>) and once infected, may be unable to clear the virus, which can lead to long bouts of illness and forms a source for the emergence of new variants (<a href="./references#CD013825-bbs2-0186" title="ChoiB , ChoudharyMC , ReganJ , SparksJA , PaderaRF , QiuX , et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. New England Journal of Medicine2020;383:2291-3. [DOI: 10.1056/NEJMc2031364]">Choi 2020</a>; <a href="./references#CD013825-bbs2-0213" title="KempSA , CollierDA , DatirRP , FerreiraIA , GayedS , JahunA , et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature2021;592:277-82. [DOI: 10.1038/s41586-021-03291-y]">Kemp 2021</a>). In unvaccinated nosocomial infections, passive immunisation with SARS‐CoV‐neutralising mAbs may be a possibility to prevent a severe disease course. </p> <p>Since November 2020, the emergence of several specific variants that have evolved independently from one another has caused concerns (<a href="./references#CD013825-bbs2-0270" title="World Health Organization. SARS-CoV-2 variants. www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/2020.">WHO 2020f</a>). Variant B.1.1.7 (also known as 20I/501Y.V1 or VOC 202012/01, now called alpha) was first identified in the UK and spread rapidly throughout the UK, becoming the dominant variant (<a href="./references#CD013825-bbs2-0259" title="VolzE , MishraS , ChandM , BarrettJC , JohnsonR , GeidelbergL , et al. Transmission of SARS-CoV-2 lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv [Preprint]. [DOI: 10.1101/2020.12.30.20249034]">Volz 2020</a>). It has now spread globally with 114 countries (<a href="./references#CD013825-bbs2-0259" title="VolzE , MishraS , ChandM , BarrettJC , JohnsonR , GeidelbergL , et al. Transmission of SARS-CoV-2 lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv [Preprint]. [DOI: 10.1101/2020.12.30.20249034]">Volz 2020</a>). B.1.1.7 is associated with increased transmissibility, and early evidence suggests an increase in disease severity (<a href="./references#CD013825-bbs2-0233" title="MuikA , WallischAK , SaengerB , SwansonKA , MuehlJ , ChenW , et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera. Science2021;371(6534):1152-3. [DOI: 10.1126/science.abg6105]">Muik 2021</a>; <a href="./references#CD013825-bbs2-0254" title="TangJW , TambyahPA , HuiDS . Emergence of a new SARS-CoV-2 variant in the UK. Journal of Infection2020;S0163-4453(20):30786-6. [DOI: 10.1016/j.jinf.2020.12.024]">Tang 2020</a>). Another variant, B.1.351 (also known as 20H/501Y.V2 and now called beta), was initially identified in South Africa. It may also be more transmissible, and has shown resistance to antibody neutralisation (<a href="./references#CD013825-bbs2-0278" title="ZhouD , Wanwisa DejnirattisaiW , SupasaP , LiuC , MentzerAJ , GinnHM , et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell2021;184(9):2348-61. [DOI: 10.1016/j.cell.2021.02.037]">Zhou 2021</a>) and some vaccine resistance (<a href="./references#CD013825-bbs2-0223" title="MadhiSA , BaillieV , CutlandCL , VoyseyM , KoenAL , FairlieL , et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384:1885-98. [DOI: 10.1056/NEJMoa2102214]">Madhi 2021</a>). Variant P.1 (now called gamma), first identified in Brazil, might reduce antibody neutralisation (<a href="./references#CD013825-bbs2-0260" title="WangP , CasnerRG , NairMS , WangM , YuJ , CeruttiG , et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. biorxiv [Preprint]. [DOI: 10.1101/2021.03.01.433466v2]">Wang 2021</a>). Early in vitro findings suggest that bamlanivimab may efficiently neutralise the lineage B.1.1.7. However, no neutralising effect could be detected against variant B.1.351 (<a href="./references#CD013825-bbs2-0274" title="WideraM , WilhelmA , HoehlS , PallasC , KohmerN , WolfT , et al. Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro. medRxiv [Preprint] (accessed 16 March 2021).">Widera 2021</a>). Variant B.1.617, first found in India and so far categorised by the WHO as a variant of interest, consists of double mutations on the spike protein of the virus. These mutations may decrease binding to mAbs and their neutralisation capability (<a href="./references#CD013825-bbs2-0184" title="CherianS , PotdarV , JadhavS , YadavP , GuptaN , DasM , et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv2021. [DOI: 10.1101/2021.04.22.440932]">Cherian 2021</a>; <a href="./references#CD013825-bbs2-0272" title="World Health Organization. Weekly epidemiological update on COVID-19 - 27 April 2021. www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---27-april-2021 (accessed 3 May 2021).">WHO 2021b</a>). Monoclonal antibody cocktails or broadly acting SARS‐CoV‐2 mAbs such as VIR‐7831 (<a href="./references#CD013825-bbs2-0251" title="StarrTN , CzudnochowskiN , ZattaF , ParkYJ , LiuZ , AddetiaA , et al. Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape. bioRxiv [Preprint]. [DOI: 10.1101/2021.04.06.438709]">Starr 2021</a>) may be developed to avoid virus escape. </p> <p>The urgent need to evaluate therapies with a theoretical mechanism of action against SARS‐CoV‐2 persists due to the limited range of therapeutic options once infected, and the prevalence of individuals who may show an inhibited response to vaccines (e.g. when undergoing chemotherapy) . mAbs are one such option. We will conduct this systematic review as a living evidence synthesis to identify, track, evaluate and update information quickly on research efforts regarding SARS‐CoV‐2‐neutralising mAbs. We will include information on SARS‐CoV‐2‐neutralising mAbs in the early stages of clinical development, as well as providing information on the effectiveness and safety of these mAbs from randomised controlled trials (RCTs) to gain a complete picture of the field. Extensive work in the field of systematic reviews for interventions for COVID‐19 has already been undertaken. This work has included immunomodulatory mAbs. There has been one Cochrane Review concerning interleukin‐6 agonists (<a href="./references#CD013825-bbs2-0199" title="GhosnL , ChaimaniA , EvrenoglouT , DavidsonM , GrañaC , SchmuckerC , et al. Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 3. Art. No: CD013881. [DOI: 10.1002/14651858.CD013881]">Ghosn 2021</a>) and a non‐Cochrane review that aimed to summarise all studies on immunotherapies (e.g. <a href="./references#CD013825-bbs2-0224" title="MansourabadiAH , SadeghalvadM , Mohammadi-Motlagh H-R, RezaeiN . The immune system as a target for therapy of SARS-CoV-2: a systematic review of the current immunotherapies for COVID-19. Life Sciences2020;258:118185. [DOI: 10.1016/j.lfs.2020.118185]">Mansourabadi 2020</a>)).  </p> <p>Various relevant projects may feed into the current undertaking. A research initiative supported by the World Health Organization (WHO) and Cochrane is mapping and evaluating all RCTs for COVID‐19, including studies on mAbs (<a href="./references#CD013825-bbs2-0262" title="WHO/Cochrane. COVID-NMA Initiative - a living mapping and living systematic review of COVID-19 trials. covid-nma.com (accessed 6 November 2020).">WHO/Cochrane 2020</a>). Another interesting resource is the COVID‐19 antibody therapeutics tracker (<a href="./references#CD013825-bbs2-0277" title="YangL , LiuW , YuX , WuM , ReichertJM , HoM . COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antibody Therapeutics2020;3(3):205-12. [DOI: 10.1093/abt/tbaa020]">Yang 2020</a>). This is a collaboration between the Chinese Antibody Society and the Antibody Society that includes mAb studies in different phases (<a href="./references#CD013825-bbs2-0173" title="ReichertJ . FDA approves inmazeb for ebola virus infection. www.antibodysociety.org/tag/approved-antibodies (accessed 5 November 2020).">Antibody Society 2020</a>; <a href="./references#CD013825-bbs2-0185" title="Chinese Antibody Society. chineseantibody.org (accessed 9 November 2020).">Chinese Antibody Society 2020</a>). In addition, the Australian clinical guideline is continually being updated for emerging treatments and already includes recommendations on bamlanivimab and casirivimab plus imdevimab  (<a href="./references#CD013825-bbs2-0234" title="National COVID-19 Clinical Evidence Taskforce. Caring for people with COVID-19: supporting Australia’s healthcare professionals with continually updated, evidence-based clinical guidelines. covid19evidence.net.au/#living-guidelines (accessed 7 December 2020).">National COVID‐19 Clinical Evidence Taskforce 2020</a>). </p> <p>The current systematic review will fill gaps by identifying, describing, evaluating, and (if available RCTs are identified), meta‐analysing all evidence for SARS‐CoV‐2‐neutralising mAbs. It will provide a frequently updated summary of the evidence on mAb development. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013825-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013825-sec-0014"></div> <p>To assess the effectiveness and safety of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐neutralising monoclonal antibodies (mAbs) for treating patients with COVID‐19 compared to an active comparator, placebo, or no intervention. To maintain the currency of the evidence, we will use a living systematic review approach. </p> <p>A secondary objective is to track newly developed SARS‐CoV‐2‐targeting mAbs from first tests in humans onwards. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013825-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013825-sec-0015"></div> <section id="CD013825-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013825-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) because this study design provides the best evidence for experimental therapies in highly‐controlled therapeutic settings. For RCT data, we used the methods recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013825-bbs2-0203" title="Higgins JP LiT , Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021a</a>). We had planned to include non‐standard RCT designs, such as cluster‐randomised studies (methods as recommended in Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013825-bbs2-0204" title="HigginsJP , EldridgeS , LiT . Higgins JP, Eldridge S, Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021b</a>)) and cross‐over studies, but have not identified any. In cross‐over studies, we would have only considered results from the first period before cross‐over because COVID‐19 is not a chronic condition, and its exact course and long‐term effects are yet to be defined. </p> <p>To track the development of specific mAbs targeting SARS‐CoV‐2, we included all prospectively registered studies, including non‐randomised studies of interventions (NRSIs) on SARS‐CoV‐2‐neutralising mAbs in humans. We excluded animal studies, pharmacokinetic studies, and in vitro studies. </p> <p>We included the following formats if sufficient information was available on study design, characteristics of participants, interventions, and outcomes. </p> <p> <ul id="CD013825-list-0002"> <li> <p>Full‐text publications.</p> </li> <li> <p>Preprint articles.</p> </li> <li> <p>Abstract publications.</p> </li> <li> <p>Results published in study registries.</p> </li> </ul> </p> <p>We included preprints and conference abstracts to have a complete overview of the ongoing research activity, especially for tracking newly emerging SARS‐CoV‐2‐neutralising antibodies. We did not apply any limitation with respect to the length of follow‐up. We screened platform trials and we are continually following these because they may add new treatment arms. </p> </section> <section id="CD013825-sec-0018"> <h4 class="title">Types of participants</h4> <p>For RCTs, we included participants with a confirmed diagnosis of COVID‐19 (virus antigens or RNA detected). We did not exclude any studies based on age, gender, ethnicity, disease severity, or setting (in‐ or outpatients). We excluded studies that evaluate mAbs for treatment of other coronavirus diseases such as severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS), or other viral diseases, such as influenza. If studies enrolled populations with mixed viral diseases, we had planned to only include them if study authors provided subgroup data for COVID‐19.    </p> <p>For tracking of emerging mAbs by listing non‐randomised studies, we also accepted studies in healthy individuals, which are often used for safety assessments in order to gain a complete picture of the current developments. </p> </section> <section id="CD013825-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included the following interventions.</p> <p> <ul id="CD013825-list-0003"> <li> <p>SARS‐CoV‐2‐neutralising mAbs.</p> </li> <li> <p>'Antibody cocktails' that include SARS‐CoV‐2‐neutralising mAbs.</p> </li> </ul> </p> <p>We included the following comparisons for studies with a control arm.</p> <p> <ul id="CD013825-list-0004"> <li> <p>Any mAb therapy compared with a control intervention, for example, drug treatments (including, but not limited to hydroxychloroquine, remdesivir), standard or hyperimmune immunoglobulin, convalescent plasma, or others. Co‐interventions were allowed but must have been comparable between intervention groups. </p> </li> <li> <p>Any mAb therapy compared with no treatment or placebo. Co‐interventions were allowed but must have been comparable between intervention groups. </p> </li> </ul> </p> <p>We also included studies that compare several mAbs with each other and another treatment, placebo or no treatment, and we included studies that compare several doses of one type of mAb with another treatment, placebo or no treatment. </p> <p>We excluded SARS‐CoV‐2‐neutralising mAbs used for prevention of COVID‐19 and we excluded mAbs that are not specifically designed to treat COVID‐19 (such as nivolumab, tocilizumab, canakinumab, etc.). </p> </section> <section id="CD013825-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We evaluated core outcomes based on the Core Outcome Measures in Effectiveness Trials (COMET) Initiative for COVID‐19 patients and additional outcomes (<a href="./references#CD013825-bbs2-0189" title="Core outcome set developers’ response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 2 November 2020).">COMET 2020</a>; <a href="./references#CD013825-bbs2-0226" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>). </p> <p>We stratified analyses by disease severity, thereby separating non‐hospitalised (asymptomatic or mild disease) and hospitalised individuals (moderate to severe disease) with COVID‐19 according to the WHO clinical progression scale (<a href="./references#CD013825-bbs2-0226" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>; see <a href="#CD013825-fig-0001">Figure 1</a>). At the later stage, reduction of viral replication may no longer be the main driver of the disease, instead, inflammation and coagulopathy may be more important (<a href="./references#CD013825-bbs2-0225" title="MarovichM , MascolaJR , CohenMS . Monoclonal antibodies for prevention and treatment of COVID-19. JAMA2020;324(2):131-2.">Marovich 2020</a>). </p> <div class="figure" id="CD013825-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="ECMO: extracorporeal membrane oxygenation; FiO2: fraction of inspired oxygen; NIV: non‐invasive ventilation; pO2: partial pressure of oxygen; RNA: ribonucleic acid; SpO2: oxygen saturationaWHO Clinical Progression Scale from The Lancet Infectious diseases: Marshall 2020. Copyright © 2020 Elsevier Ltd. All rights reserved: reproduced with permission.bIf hospitalised for isolation only, record status for ambulatory patient." data-id="CD013825-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>ECMO:</b> extracorporeal membrane oxygenation; <b>FiO<sub>2</sub>:</b> fraction of inspired oxygen; <b>NIV:</b> non‐invasive ventilation; <b>pO<sub>2</sub>:</b> partial pressure of oxygen; <b>RNA:</b> ribonucleic acid; <b>SpO<sub>2</sub>:</b> oxygen saturation </p> <p><sup>a</sup>WHO Clinical Progression Scale from The Lancet Infectious diseases: <a href="./references#CD013825-bbs2-0226" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>. Copyright © 2020 Elsevier Ltd. All rights reserved: reproduced with permission. </p> <p><sup>b</sup>If hospitalised for isolation only, record status for ambulatory patient. </p> </div> </div> </div> <section id="CD013825-sec-0021"> <h5 class="title">Timing of outcome measurement</h5> <p>In case of time‐to‐event analysis (e.g. for mortality, time to discharge from hospital, and time to improvement of symptoms), we included the outcome measure based on the longest follow‐up time. We also collected information on outcomes from all other time points reported in the publications. </p> <p>We included adverse events occurring during active treatment, as well as long‐term adverse events. If sufficient data were available, we grouped the measurement time points of eligible outcomes. For example, we grouped adverse events and serious adverse events into those measured directly after treatment (up to seven days after treatment), medium‐term outcomes (up to 15 days after treatment), and longer‐term outcomes (more than 30 days after treatment). </p> </section> <section id="CD013825-sec-0022"> <h5 class="title">Primary outcomes</h5> <section id="CD013825-sec-0023"> <h6 class="title">Effectiveness of SARS‐CoV‐2‐neutralising mAbs</h6> <p> <ul id="CD013825-list-0005"> <li> <p>All‐cause mortality at up to 30 days</p> </li> <li> <p>All‐cause mortality at up to 60 days</p> </li> <li> <p>Clinical progression, improvement of symptoms, or development of severe symptoms according to the WHO scale </p> <ul id="CD013825-list-0006"> <li> <p>WHO Clinical Progression Scale (<a href="./references#CD013825-bbs2-0226" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>), measured daily over the course of the study (<a href="#CD013825-fig-0001">Figure 1</a>); or </p> </li> <li> <p>assessed as individual items included in the Progression Scale (need for respiratory support, duration): </p> <ul id="CD013825-list-0007"> <li> <p>oxygen by mask or nasal prongs</p> </li> <li> <p>oxygen by non‐invasive ventilation or high‐flow nasal cannula</p> </li> <li> <p>intubation and mechanical ventilation</p> </li> <li> <p>mechanical ventilation or vasopressors, high‐flow oxygen</p> </li> <li> <p>mechanical ventilation and vasopressors, dialysis or extracorporeal membrane oxygenation (ECMO) </p> </li> </ul> </li> </ul> </li> <li> <p>Quality of life, including fatigue, assessed with standardised scales, for example, WHOQOL‐100, at up to seven days; up to 30 days, and longest follow‐up available </p> </li> <li> <p>Admission to hospital or death for non‐hospitalised and hospital discharge and alive for hospitalised participants </p> </li> </ul> </p> <section id="CD013825-sec-0024"> <p><b>Safety outcomes</b></p> <p> <ul id="CD013825-list-0008"> <li> <p>Number of participants with adverse events (all grades, grades 1 to 2, grades 3 to 4) </p> </li> <li> <p>Number of participants with serious adverse events</p> </li> </ul> </p> </section> </section> </section> <section id="CD013825-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013825-list-0009"> <li> <p>Length of hospital stay (for those admitted to hospital)</p> </li> <li> <p>Admission to intensive care unit (ICU)</p> </li> <li> <p>Length of ICU stay</p> </li> <li> <p>Viral clearance, assessed with reverse transcription‐polymerase chain reaction (RT‐PCR) test for SARS‐CoV‐2 at baseline, up to three, seven, and 15 days </p> </li> <li> <p>Time to sustained recovery (for hospitalised participants)</p> </li> <li> <p>Neurologic dysfunction (for hospitalised participants)</p> </li> <li> <p>Thromboembolic events</p> </li> <li> <p>Renal failure</p> </li> </ul> </p> </section> </section> </section> <section id="CD013825-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <p>We carried out weekly searches for completed and ongoing studies in all languages to limit language bias. We conducted weekly checks  for newly emerging mAbs and changing terminology regarding mAbs included in the search strategy. We adapted the strategy where necessary. </p> <section id="CD013825-sec-0027"> <h4 class="title">Electronic searches</h4> <p>For the identification of studies on the effectiveness and safety of SARS‐CoV‐2‐neutralising mAbs, we designed search strategies in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013825-bbs2-0217" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Lefebvre 2021</a>). Information Specialist Ina Monsef developed the search strategy based on input by clinicians. It was reviewed by Information Specialist Carolyn Dorée. Due to the international urgency for research on therapies for COVID‐19, we assumed that the abstracts of clinical studies would have been published in English. If the full‐text publication was published in a language that lay outside the abilities of our team (English, German, Dutch, French, Italian, Malay, and Spanish), we planned to involve Cochrane TaskExchange to identify people who are able to translate (<a href="https://taskexchange.cochrane.org/" target="_blank">taskexchange.cochrane.org</a>). We restricted the database search to records added since 1 January 2020, as the first studies on COVID‐19 were registered on 23 January 2020 (<a href="./references#CD013825-bbs2-0279" title="ZhuR , GaoY , RobertS , GaoJ , YangS , ZhuC . Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19). Journal of Translational Medicine2020;18:274. [DOI: 10.1186/s12967-020-02442-5]">Zhu 2020</a>). We searched the following databases up to 17 June 2021. </p> <p> <ul id="CD013825-list-0010"> <li> <p>MEDLINE (via Ovid; 1 January 2020 to 17 June 2021; <a href="./appendices#CD013825-sec-0166">Appendix 1</a>) </p> </li> <li> <p>Embase (via Ovid; 1 January 2020 to 17 June 2021; <a href="./appendices#CD013825-sec-0167">Appendix 2</a>) </p> </li> <li> <p>Cochrane COVID‐19 Study Register (<a href="https://covid-19.cochrane.org/" target="_blank">covid-19.cochrane.org</a>; inception to 17 June 2021; <a href="./appendices#CD013825-sec-0168">Appendix 3</a>) including: </p> <ul id="CD013825-list-0011"> <li> <p>PubMed, daily updates</p> </li> <li> <p>Embase.com, weekly updates</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), daily updates </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch</a>), weekly updates </p> </li> <li> <p>medRxiv (<a href="https://www.medrxiv.org/" target="_blank">www.medrxiv.org</a>), weekly updates </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), monthly updates</p> </li> </ul> </li> <li> <p>PubMed (for epublications ahead of print only; 1 January 2020 to 17 June 2021; <a href="./appendices#CD013825-sec-0169">Appendix 4</a>) </p> </li> <li> <p>Epistemonikos COVID‐19 L*VE Platform (<a href="https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d?utm=aile" target="_blank">app.iloveevidence.com/loves</a>; inception to 17 June 2021; <a href="./appendices#CD013825-sec-0170">Appendix 5</a>) </p> </li> <li> <p>World Health Organization COVID‐19 Global literature on coronavirus disease (<a href="https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov" target="_blank">bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov</a>; inception to 17 June 2021; <a href="./appendices#CD013825-sec-0171">Appendix 6</a>) </p> </li> </ul> </p> <p>To track ongoing research efforts and address the potential influence of publication bias on our conclusions, we searched relevant study registries to find ongoing and completed, but not yet published studies. If results were uploaded into the study registry that had not yet been published elsewhere, we integrated these data for the current review and will add or replace data in future updates of this review in case of publication. </p> <p>To identify prospectively registered platform trials that may add a mAb arm during the course of the study (such as the <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> trial (<a href="./references#CD013825-bbs2-0244" title="Randomised Evaluation of COVID-19 Therapy. www.recoverytrial.net (accessed 16 November 2020). [CT.GOV: NCT04381936]">RECOVERY 2020</a>) or the <a href="./references#CD013825-bbs2-0130" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomized embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]EUCTR2015-002340-14-NL. Adaptive trial in severe pneumonia (REMAP-CAP). clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/NL (first received 13 July 2015). ISRCTN67000769. An international platform trial for severely ill patients with community-acquired pneumonia or COVID-19. www.isrctn.com/ISRCTN67000769 (first received 9 July 2020). NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">REMAP‐CAP</a> study(<a href="./references#CD013825-bbs2-0245" title="A randomised, embedded, multi-factorial, adaptive platform trial for community-acquired pneumonia. www.remapcap.org (accessed 16 November 2020). [CT.GOV: NCT02735707]">REMAP‐CAP 2020</a>)), we conducted a separate search with monthly updates in the Cochrane COVID‐19 Study Register (<a href="./appendices#CD013825-sec-0172">Appendix 7</a>). We listed the eligible studies in the section named <a href="./references#CD013825-bbs1-0003" title="">Studies awaiting classification</a> and regularly checked whether they had added additional treatment arms that include mAbs. </p> <p>Between submission and publication, we conducted a shortened RCT‐only search up to 30 July 2021 (<a href="./appendices#CD013825-sec-0173">Appendix 8</a>). </p> </section> <section id="CD013825-sec-0028"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD013825-list-0012"> <li> <p>We checked the reference lists of:</p> <ul id="CD013825-list-0013"> <li> <p>all identified studies;</p> </li> <li> <p>relevant review articles; and</p> </li> <li> <p>current treatment guidelines for further literature.</p> </li> </ul> </li> <li> <p>We conducted forwards citation searching on the included studies via Google Scholar.</p> </li> <li> <p>We contacted experts in the field, drug manufacturers, and regulatory agencies in order to retrieve information on unpublished studies. </p> </li> <li> <p>We compared our results with results from projects that aim to track COVID‐19 intervention research, such as: </p> <ul id="CD013825-list-0014"> <li> <p><a href="https://www.covid-trials.org/" target="_blank">www.covid-trials.org</a>; </p> </li> <li> <p><a href="https://covid-nma.com/dataviz/" target="_blank">covid-nma.com/dataviz</a>; </p> </li> <li> <p><a href="https://chineseantibody.org/covid-19-track/" target="_blank">chineseantibody.org/covid-19-track</a>. </p> </li> </ul> </li> </ul> </p> </section> </section> <section id="CD013825-sec-0029"> <h3 class="title" id="CD013825-sec-0029">Data collection and analysis</h3> <section id="CD013825-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Two review authors (NK, CH, KLC, ZK, ET, MP, NS) independently screened search results for eligibility by reading the abstracts using the <a href="./references#CD013825-bbs2-0191" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, 2021. Available at covidence.org. [DOI: 10.1016/S1470-2045(20)30096-6]">Covidence</a> software (<a href="./references#CD013825-bbs2-0191" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, 2021. Available at covidence.org. [DOI: 10.1016/S1470-2045(20)30096-6]">Covidence</a>). Following the living review approach, we screened any new citations retrieved by the weekly searches immediately. Abstracts that both review authors found eligible, or abstracts that they disagreed upon or rated as uncertain, were obtained as full‐text publications for further discussion. Two review authors assessed the full‐text articles of selected studies. If the two review authors were unable to reach consensus, we consulted all review authors who were involved in study selection to reach a final decision. </p> <p>The search for platform trials was conducted every two months (from November 2020 to July 2021). To identify potential platform trials, two review authors (NK, NS, CH) independently screened the results in <a href="./references#CD013825-bbs2-0195" title="EndNote X9. EndNote. Clarivate, 2013.">Endnote X9</a>. </p> <p>We documented the study selection process in a flow chart, as recommended in the PRISMA statement (<a href="./references#CD013825-bbs2-0231" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>), and showed the total numbers of retrieved references and the numbers of included and excluded studies. We listed all studies that we excluded after full‐text assessment and the reasons for their exclusion in the <a href="./references#CD013825-sec-0196" title="">Characteristics of excluded studies</a> section. </p> </section> <section id="CD013825-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>We treated RCTs differently from non‐RCTs. For RCTs, we conducted data extraction according to the guidelines proposed by Cochrane (<a href="./references#CD013825-bbs2-0218" title="LiT , HigginsJP , DeeksJJ . Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Li 2020</a>). Two review authors (NK, MP, CH) independently extracted data using a customised data extraction form developed in Microsoft Excel (<a href="./references#CD013825-bbs2-0230" title="Mircosoft Excel. Microsoft Corporation. Microsoft Corporation, 2018. office.microsoft.com/excel.">Microsoft 2018</a>). We resolved disagreements by discussion. If no agreement was obtained, we involved a third review author to resolve the disagreement. </p> <p>We extracted the following information if reported.</p> <p> <ul id="CD013825-list-0015"> <li> <p>General information: author, title, source, publication date, country, language, duplicate publications. </p> </li> <li> <p>Study characteristics: study design, setting and dates, source of participants, inclusion/exclusion criteria, treatment cross‐overs, compliance with assigned treatment, length of follow‐up. </p> </li> <li> <p>Participant characteristics: age, gender, ethnicity, number of participants recruited/allocated/evaluated, additional diagnoses, the severity of disease, previous treatments, concurrent treatments, complementary medicine (e.g. quercetin, elderberry, zinc). </p> </li> <li> <p>Interventions: type of mAbs, the target of mAbs, dose, frequency, timing, duration and route of administration, setting (e.g. inpatient, ambulant), duration of follow‐up. </p> </li> <li> <p>For RCT studies: control intervention, dose, frequency, timing, duration and route of administration, setting, duration of follow‐up. </p> </li> <li> <p>Outcomes: as specified under <a href="#CD013825-sec-0020">Types of outcome measures</a>. </p> </li> <li> <p>'Risk of bias' assessment: study design, confounding, the definition of risk estimates, selection bias, attrition bias, detection bias, reporting bias. </p> </li> </ul> </p> <p>We included non‐RCTs for tracking of emerging mAbs from first‐in‐human studies onwards, without the aim to meta‐analyse, and extracted characteristics as outlined in <a href="#CD013825-tbl-0008">Table 1</a>. </p> <div class="table" id="CD013825-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Main study characteristics of included RCTs</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N randomised up to data cut‐off</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab (7.0 g)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inpatients, moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Denmark, Singapore, Spain, India, Poland, Switzerland, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interim analysis, bamlanivimab arm stopped for futility, recruitment ongoing for other arms </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab (0.7 g, 2.8 g, 7.0 g)</p> <p>bamlanivimab/etesevimab (2.8 g + 2.8 g)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outpatients, mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Puerto Rico (added after publication of interim results)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recruiting, estimated enrolment 4000 participants</p> <p>Estimated study completion: May 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casirivimab/imdevimab (REGN10933/ REGN10987; 2.4 g, 8 g)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outpatients, mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Chile, Mexico, Romania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interim analysis, recruiting, estimated enrolment 6420 participants</p> <p>Estimated study completion: August 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casirivimab/imdevimab (REGN10933/ REGN10987; 1200 mg, 2400 mg, )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outpatients, mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Mexico, Chile, Romania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interim analysis, recruiting, estimated enrolment 6420 participants</p> <p>Estimated study completion: August 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casivirimab/imdevimab (4g, 4g)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalised patients, moderate or severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preprint publication, recruiting, estimated enrolment 40000 participants, estimated study completion: December 2031 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab (VIR‐7831; GSK4182136; 500 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outpatients, mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Brazil, Canada, Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preprint publication, interim analysis, data collection ongoing;</p> <p>Estimated completion date: July 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regdanvimab (CT‐P59; 40 mg/kg, 80 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outpatients, mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>South Korea, Romania, Spain and USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>recruiting, estimated enrolment: 1020 participants</p> <p>Estimated completion date: September 2021</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD013825-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in RCTs by using the Risk of Bias 2.0 (RoB 2) tool (<a href="./references#CD013825-bbs2-0252" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweN , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898. [DOI: 10.1136/bmj.l4898]">Sterne 2019</a>), for the effect of the assignment to the intervention (the intention‐to‐treat (ITT) effect). The outcomes that we assessed were those specified for inclusion in the summary of findings tables. </p> <p>Two review authors (NK, CH, KLC, MP, ET, ZK, MN) independently assessed the risk of bias for each outcome. In case of discrepancies among judgments and inability to reach consensus, we consulted a third review author to reach a final decision. We assessed the following types of bias as outlined in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013825-bbs2-0205" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2021c</a>). </p> <p> <ul id="CD013825-list-0016"> <li> <p>Bias arising from the randomisation process</p> </li> <li> <p>Bias due to deviations from the intended interventions</p> </li> <li> <p>Bias due to missing outcome data</p> </li> <li> <p>Bias in measurement of the outcome</p> </li> <li> <p>Bias in selection of the reported result</p> </li> </ul> </p> <p>For cross‐over studies, we had planned to use the RoB 2 tool, as outlined in Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013825-bbs2-0204" title="HigginsJP , EldridgeS , LiT . Higgins JP, Eldridge S, Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021b</a>), because we would have only considered results from the first period before cross‐over. </p> <p>For cluster‐RCTs, we had planned to add a domain to assess bias arising from the timing of identification and recruitment of participants in relation to the timing of randomisation as recommended in the RoB 2 guidance for cluster‐randomised studies (<a href="./references#CD013825-bbs2-0193" title="EldridgeS , CampbellM , CampbellM , DahotaA , GiraudeauB , GiraudeauB , et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0). Additional considerations for cluster-randomized trials (RoB 2 CRT). https://www.riskofbias.info/welcome/rob-2-0-tool/rob-2-for-cluster-randomized-trials (accessed June 11, 2021).">Eldridge 2021</a>) and in Chapter 23 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013825-bbs2-0204" title="HigginsJP , EldridgeS , LiT . Higgins JP, Eldridge S, Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021b</a>). </p> <p>To address these types of bias, we used the signalling questions recommended in RoB 2 to reach a judgment using the following options. </p> <p> <ul id="CD013825-list-0017"> <li> <p>'Yes': if there is firm evidence that the question is fulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>Probably yes': a judgment has been made that the question is fulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'No': if there is firm evidence that the question is unfulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'Probably no': a judgment has been made that the question is unfulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'No information': if the study report does not provide sufficient information to allow any judgment. </p> </li> </ul> </p> <p>We used the algorithms proposed by RoB 2 to assign each domain one of the following levels of bias. </p> <p> <ul id="CD013825-list-0018"> <li> <p>Low risk of bias.</p> </li> <li> <p>Some concerns.</p> </li> <li> <p>High risk of bias.</p> </li> </ul> </p> <p>Subsequently, we derived an overall risk of bias rating for each prespecified outcome in each study in accordance with the following suggestions. </p> <p> <ul id="CD013825-list-0019"> <li> <p>'Low risk of bias': we judge the study to be at low risk of bias for all domains for this result. </p> </li> <li> <p>'Some concerns': we judge the study to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain. </p> </li> <li> <p>'High risk of bias': we judge the study to be at high risk of bias in at least one domain for the result or we judge the trial to have some concerns for multiple domains in a way that substantially lowers confidence in the results. </p> </li> </ul> </p> <p>We used the RoB 2 Excel tool to implement RoB 2 (available from <a href="https://www.riskofbias.info/" target="_blank">riskofbias.info</a>) and stored and presented our detailed RoB 2 assessments as supplementary online material (available at: <a href="https://zenodo.org/record/4746642#.YJl0OLUzY2w" target="_blank">zenodo.org/record/4746642#.YJl0OLUzY2w</a>). </p> </section> <section id="CD013825-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous outcomes, we planned to record the mean, standard deviation, and total number of participants in both treatment and control groups. Where continuous outcomes used the same scale, we performed analyses using the mean difference (MD) with 95% confidence intervals (CIs). For continuous outcomes measured with different scales, we had planned to perform analyses using the standardised mean difference (SMD). For interpreting SMDs, we would have re‐expressed SMDs in the original units of a particular scale with the most clinical relevance and impact (e.g. clinical symptoms with the WHO Clinical Progression Scale (<a href="./references#CD013825-bbs2-0226" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>)). </p> <p>For dichotomous outcomes, we recorded the number of events and participants in both treatment and control groups to obtain the pooled risk ratio (RR) with a 95% CI (<a href="./references#CD013825-bbs2-0192" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). We had planned to use Peto odds ratio (OR) if the number of observed events was small (less than 5% of sample per group, <a href="./references#CD013825-bbs2-0192" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). However, because there was very little difference in the effect estimate whether RR or Peto OR was used, for consistency and interpretability we decided to report RRs. </p> <p>If available, we extracted and reported hazard ratios (HRs) for time‐to‐event outcomes (e.g. time to death). If HRs were not available, we would have made every effort to estimate the HR as accurately as possible from available data using the methods proposed by Parmar and Tierney (<a href="./references#CD013825-bbs2-0240" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34. [DOI: 10.1002/(SICI)1097-0258(19981230)17:24&amp;lt;2815::AID-SIM110&amp;gt;3.0.CO;2-8]">Parmar 1998</a>; <a href="./references#CD013825-bbs2-0255" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [DOI: 10.1186/1745-6215-8-16]">Tierney 2007</a>). If sufficient studies provided HRs, we would have used HRs rather than RRs or MDs in a meta‐analysis, as they provide more information. </p> </section> <section id="CD013825-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>The aim of this review was to summarise studies that analyse data at the level of the individual. We would have accepted cluster‐randomised studies for inclusion. We collated multiple reports of one study so that the study, and not the report, was the unit of analysis. </p> <section id="CD013825-sec-0035"> <h5 class="title">Studies with multiple treatment groups</h5> <p>As recommended in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013825-bbs2-0203" title="Higgins JP LiT , Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021a</a>), for studies with multiple treatment groups of the same intervention (i.e. dose, route of administration), we evaluated whether study arms were sufficiently homogeneous to be combined. When arms could not be pooled, we compared each arm with the common comparator separately. For pairwise meta‐analyses, we had planned to split the ‘shared’ group into two or more groups depending on the number of treatment arms and included two or more (reasonably independent) comparisons. For this purpose, for dichotomous outcomes, both the number of events and the total number of participants would have been divided, and for continuous outcomes, the total number of participants would have been divided with unchanged means and standard deviations (SDs). </p> </section> </section> <section id="CD013825-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> suggests a number of potential sources for missing data, which we have taken into account: at study level, at outcome level, and at summary data level (<a href="./references#CD013825-bbs2-0192" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). At all levels, it is important to differentiate between data 'missing at random', which may often be unbiased, and 'not missing at random', which may bias the study and consequently, the review results. </p> <p>We contacted three principal investigators from included RCTs (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>) and requested data for our prioritised outcomes. We received two responses, from <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> and <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> that they would be unable to provide the requested information, but both stated that a more complete outcome set will be reported in follow‐up publications. The authors of <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> did not respond. As no additional data were provided, we explicitly decided that data were missing at random. </p> </section> <section id="CD013825-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess the heterogeneity of treatment effects between studies using a Chi² test with a significance level at P &lt; 0.1. We would have used the I² statistic (<a href="./references#CD013825-bbs2-0202" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>), to quantify possible heterogeneity (I² statistic between 30% and 60% may signify moderate heterogeneity, I² statistic between 50% and 90% may signify substantial heterogeneity, and I² &gt; 75% may signify considerable heterogeneity; <a href="./references#CD013825-bbs2-0192" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). If we considered heterogeneity to be substantial (I² &gt; 50%), we had planned to explore potential causes through sensitivity and subgroup analyses. If we could not find a reason for heterogeneity, we would not have performed a meta‐analysis but had planned to comment on results from all studies and presented these in tables. As we did not perform meta‐analyses, we could not assess heterogeneity. </p> </section> <section id="CD013825-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>As mentioned above, we searched study registries to identify completed trials that have not been published elsewhere to determine publication bias. </p> <p>We intended to explore potential publication bias by generating a funnel plot and statistically testing this by conducting a linear regression test for meta‐analyses involving at least 10 studies (<a href="./references#CD013825-bbs2-0239" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesiss. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Page 2021</a>). We would have considered P &lt; 0.1 as significant for this test. As we identified fewer than 10 studies per comparison and did not pool the data in meta‐analysis, and we did not generate a funnel plot. </p> </section> <section id="CD013825-sec-0039"> <h4 class="title">Data synthesis</h4> <p>If the clinical and methodological characteristics of individual studies had been sufficiently homogeneous, we would have pooled the data in meta‐analysis. However, th studies originate from different convalescents who were infected in different countries (e.g. China, USA) and at different time points. Although most of the included mAbs target the spike protein of the virus, they all target different epitopes on the spike protein. One mAb, sotrovimab, was derived from a SARS patient. Therefore, the affinity and stability might be very different from monoclonal antibody to monoclonal antibody. Due to the possibility of antibody‐dependent enhancement (<a href="./references#CD013825-bbs2-0174" title="ArvinAM , FinkK , SchmidMA , CathcartA , SpreaficoR , Havenar-DaughtonC , et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature2020;584:353-3. [DOI: 10.1038/s41586-020-2538-8]">Arvin 2020</a>), which may be dose‐dependent, we had decided at the beginning of the review process that for the current version, we would not pool different doses of mAbs. We may change this for future updates if doses seem to be sufficiently homogeneous. Based on these decisions, we reported results separately per substance and substance combination. We did not perform a meta‐analysis, because we had only one study per comparison. We commented on the results narratively, with the results from all studies presented in forest plots to prepare for future updates. We used Review Manager Web (<a href="./references#CD013825-bbs2-0246" title=" Cochrane CollaborationReview Manager Web (RevMan Web). Version 1.22.0.  Cochrane Collaboration, 2019. Available at revman.cochrane.org.">RevMan Web 2020</a>) software to create forest plots (<a href="./references#CD013825-bbs2-0246" title=" Cochrane CollaborationReview Manager Web (RevMan Web). Version 1.22.0.  Cochrane Collaboration, 2019. Available at revman.cochrane.org.">RevMan Web 2020</a>). One review author entered the data into the software, and a second review author checked the data for accuracy. </p> <p>If meta‐analysis had been possible, we would have used the random‐effects model for all analyses as we anticipated that true effects are related but are not the same for included studies. We planned to treat placebo and no treatment, which both usually include standard of care at different institutions and time points, as the same intervention. We would have performed analyses according to the recommendations of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013825-bbs2-0192" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). We planned to analyse studies including different disease stages separately, grouping them into mild, moderate, severe, and critical. However, for this review, we decided to follow the classification of the WHO Progression Scale (<a href="./references#CD013825-bbs2-0226" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>; <a href="#CD013825-fig-0001">Figure 1</a>) and group into mild versus moderate and severe disease (outpatients with mild disease; and inpatients who are classified with moderate or severe disease according to the WHO Progression Scale). We would have assessed the effects of potential biases in sensitivity analyses (see <a href="#CD013825-sec-0041">Sensitivity analysis</a>). For binary outcomes, we would have based our estimation on the between‐study variance on the calculation performed using the Mantel‐Haenszel method. We used the inverse variance method for continuous outcomes, outcomes that included data from cluster‐RCTs, or outcomes where HRs were available. We planned to explore heterogeneity where the I² statistic was more than 50% with subgroup analyses. If we could not find a cause for the heterogeneity, we planned to comment on the results as a narrative with the results from all studies presented in tables, instead of performing a meta‐analysis. </p> <p>We presented non‐randomised, prospectively registered studies narratively in table form (see <a href="./appendices#CD013825-sec-0174">Appendix 9</a>). </p> </section> <section id="CD013825-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>To explore heterogeneity, we planned to perform subgroup analyses of the following characteristics. The limited number of RCTs that provided results and the variation of SARS‐CoV‐2‐neutralising mAbs used across the studies prevented us from performing any pre‐planned subgroup analyses. </p> <p> <ul id="CD013825-list-0020"> <li> <p>Age of participants (divided into applicable age groups, e.g. children; 18 to 65 years, 65 years and older). </p> </li> <li> <p>Pre‐existing conditions (diabetes, respiratory disease, hypertension, immunosuppression).</p> </li> <li> <p>Timing of first dose administration since symptom onset (up to three days, four to seven days and more than seven days). </p> </li> <li> <p>Antibodies detected at baseline.</p> </li> </ul> </p> <p>We had planned to use the tests for interaction to test for differences between subgroup results. </p> <p>We could not perform subgroup analysis, because we identified only one study per comparison.</p> </section> <section id="CD013825-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to perform sensitivity analysis of the following characteristics for our primary outcomes. </p> <p> <ul id="CD013825-list-0021"> <li> <p>'Risk of bias' assessment components (studies with a low risk of bias or some concerns versus studies with a high risk of bias). </p> </li> <li> <p>Comparison of preprints of COVID‐19 interventions versus peer‐reviewed articles.</p> </li> <li> <p>Comparison of premature termination of studies with completed studies.</p> </li> </ul> </p> <p>We could not perform sensitivity analysis, because we identified only one study per comparison. </p> </section> <section id="CD013825-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD013825-sec-0043"> <h5 class="title">Summary of findings tables</h5> <p>We created summary of findings tables and evaluated GRADE for interventions evaluated in RCTs using the <a href="./references#CD013825-bbs2-0201" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at gradepro.org.">GRADEpro GDT</a> software, as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013825-bbs2-0249" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021</a>). We created a separate table per mAb type. </p> <p>For time‐to‐event outcomes, we calculated absolute effects at specific time points, as recommended in the GRADE guidance 27 (<a href="./references#CD013825-bbs2-0250" title="SkoetzN , GoldkuhleM , Van DalenEC , AklEA , TrivellaM , MustafaRA , et al. GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles. Journal of Clinical Epidemiology2020;118:124-31. [DOI: 10.1016/j.jclinepi.2019.10.015]">Skoetz 2020</a>). </p> <p>According to Chapter 14 of the updated <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, the “most critical and/or important health outcomes, both desirable and undesirable, limited to seven or fewer outcomes” should be included in the summary of findings table(s) (<a href="./references#CD013825-bbs2-0249" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021</a>). We included outcomes prioritised according to the Core Outcome Set for intervention studies (<a href="./references#CD013825-bbs2-0189" title="Core outcome set developers’ response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 2 November 2020).">COMET 2020</a>) and patient‐relevant outcomes. </p> <section id="CD013825-sec-0044"> <h6 class="title">Non‐hospitalised individuals with COVID‐19 and asymptomatic or mild disease</h6> <p> <ul id="CD013825-list-0022"> <li> <p>All‐cause mortality (up to 30 and 60 days)</p> </li> <li> <p>Clinical progression, improvement of symptoms, or development of severe symptoms according to the WHO Clinical Progression Scale (<a href="./references#CD013825-bbs2-0226" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>) </p> </li> <li> <p>Quality of life, assessed with standardised scales (e.g. WHOQOL‐100), at up to seven days, up to 30 days, and longest follow‐up available </p> </li> <li> <p>Admission to hospital</p> </li> <li> <p>Adverse events (all grades, grades 1 to 2, grades 3 to 4)</p> </li> <li> <p>Serious adverse events</p> </li> </ul> </p> </section> <section id="CD013825-sec-0045"> <h6 class="title">Hospitalised individuals with COVID‐19 and moderate to severe disease</h6> <p> <ul id="CD013825-list-0023"> <li> <p>All‐cause mortality (up to 30 and 60 days)</p> </li> <li> <p>Clinical progression, improvement of symptoms or development of severe symptoms according to the WHO Clinical Progression Scale (<a href="./references#CD013825-bbs2-0226" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>) </p> </li> <li> <p>Quality of life, assessed with standardised scales (e.g. WHOQOL‐100) at up to seven days, up to 30 days, and longest follow‐up available </p> </li> <li> <p>Hospital discharge</p> </li> <li> <p>Adverse events (all grades, grades 1 to 2, grades 3 to 4)</p> </li> <li> <p>Serious adverse events</p> </li> </ul> </p> </section> </section> <section id="CD013825-sec-0046"> <h5 class="title">Assessment of the certainty in the evidence</h5> <p>We used the GRADE approach to assess the certainty in the evidence for the outcomes listed in the previous section. </p> <p>The GRADE approach uses five domains (risk of bias, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty in the body of evidence for each prioritised outcome. We followed the current GRADE guidance for these assessments in their entirety as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Chapter 14 (<a href="./references#CD013825-bbs2-0249" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,et al (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021</a>). </p> <p>We used the overall 'Risk of bias' judgment, derived from the RoB 2 tool, to inform our decision on downgrading for risk of bias. We phrased the findings and certainty in the evidence as suggested in the informative statement guidance (<a href="./references#CD013825-bbs2-0248" title="SantessoN , GlentonC , DahmP , GarnerP , AklA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35. [DOI: 10.1016/j.jclinepi.2019.10.014]">Santesso 2020</a>). </p> </section> <section id="CD013825-sec-0047"> <h5 class="title">Methods for future updates</h5> <section id="CD013825-sec-0048"> <h6 class="title">Living systematic review considerations</h6> <p>Our information specialist (IM) will provide us with new records each week, which two review authors will screen, extract, evaluate, and integrate following the guidance for Cochrane living systematic reviews (<a href="./references#CD013825-bbs2-0188" title="Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode. community.cochrane.org/review-production/production-resources/living-systematic-reviews (accessed 2 November 2020).">Cochrane LSR</a>). We will run searches for platform trials monthly, and manually check platform trials that were previously identified and listed as 'studies awaiting classification' for additional treatment arms. </p> <p>We will wait until the accumulating evidence changes one or more of the following components of the review before republishing the review. </p> <p> <ul id="CD013825-list-0024"> <li> <p>The findings of one or more prioritised outcomes.</p> </li> <li> <p>The credibility (e.g. GRADE rating) of one or more prioritised outcomes.</p> </li> <li> <p>New settings, populations, interventions, comparisons, or outcomes studied.</p> </li> </ul> </p> <p>We will review the review scope and methods approximately monthly, or more frequently if appropriate, in light of potential changes in COVID‐19 research (for example, when additional comparisons, interventions, subgroups or outcomes, or new review methods become available). </p> </section> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013825-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013825-sec-0049"></div> <section id="CD013825-sec-0050"> <h3 class="title">Description of studies</h3> <section id="CD013825-sec-0051"> <h4 class="title">Results of the search</h4> <p>We searched all databases and screened the resulting records weekly up to 17 June 2021, and then undertook an RCT‐only top‐up search up to 30 July 2021. Based on newly developing SARS‐CoV‐2‐specific mAbs, we have added terms to our search strategy; see <a href="#CD013825-sec-0182">Differences between protocol and review</a> for the ongoing changes that are still continually being implemented. Our searches retrieved 14,408 records for the mAbs‐specific searches. After removing duplicates, we screened 11,516 records based on their titles and abstracts. We excluded 11,327 records that did not meet the prespecified inclusion criteria. Of the remaining 189 records, we included 95 records (of which 28 are listed for tracking; see <a href="./appendices#CD013825-sec-0174">Appendix 9</a>). </p> <p> <ul id="CD013825-list-0025"> <li> <p>6 RCTs (in 28 records) are included in this review, of which three are published as preprint only and one as journal publication with additional data from two preprints. </p> </li> <li> <p>31 RCTs (in 39 records) on 18 different mAbs or mAb combinations are currently ongoing.</p> </li> </ul> </p> <p>Our platform trial search yielded 2241 records. After removing 161 duplicates, we screened 2080 during title and abstract screening and looked at 138 registry records in more detail. Of these, we excluded 20 studies (27 records). We categorised the remaining studies as follows: </p> <p> <ul id="CD013825-list-0026"> <li> <p>2 platform trials (29 attached records) are included (already identified by mAbs‐specific search), one of these has added new treatment arms and is thus also listed as an ongoing study; </p> </li> <li> <p>4 platform trials (13 records) with at least one mAb as an experimental treatment are ongoing (already identified by mAbs‐specific search); </p> </li> <li> <p>30 platform trials (69 records) that may potentially add a mAb during the course of the study are ongoing. </p> </li> </ul> </p> <p>The study flow diagram in <a href="#CD013825-fig-0002">Figure 2</a> illustrates the study selection process according to PRISMA guidelines (<a href="./references#CD013825-bbs2-0231" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>). </p> <div class="figure" id="CD013825-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD013825-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-FIG-02.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> <section id="CD013825-sec-0052"> <h5 class="title">Update search between submission and peer review</h5> <p>To keep our review as updated as possible, we conducted an additional search for RCTs in infected individuals only (18 June to 30 July 2021, search strategy: <a href="./appendices#CD013825-sec-0173">Appendix 8</a>). From the 286 records, we assessed 13 full‐text articles (<a href="#CD013825-fig-0003">Figure 3</a>); of these, eight were press releases and one an ongoing RCT in healthy participants. We included the following four studies:  </p> <div class="figure" id="CD013825-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="PRISMA flow diagram RCT search between 18 June and 30 July 2021" data-id="CD013825-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-FIG-03.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram RCT search between 18 June and 30 July 2021</p> </div> </div> </div> <p> <ul id="CD013825-list-0027"> <li> <p>one ongoing RCT (<a href="./references#CD013825-bbs2-0171" title="NCT04952805. Clinical trial to select the dose and evaluate safety and efficacy of MAD0004J08 monoclonal antibody in adult patients with recently diagnosed asymptomatic to moderately severe COVID-19. ClinicalTrials.gov2021. ">NCT04952805</a>); </p> </li> <li> <p>one preprint from a not yet included study (<a href="./references#CD013825-bbs2-0126" title="O’BrienM , Forleo-NetoE , SarkarN , IsaF , HouP , MusserBJ , et al. Subcutaneous REGEN-COV antibody combination in early SARS-CoV-2 infection. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.14.21258569]">O’Brien 2021</a>); </p> </li> <li> <p>two publications with updated results (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>). </p> </li> </ul> </p> <p>We integrated the data from the already included studies with updated results. Results from <a href="./references#CD013825-bbs2-0126" title="O’BrienM , Forleo-NetoE , SarkarN , IsaF , HouP , MusserBJ , et al. Subcutaneous REGEN-COV antibody combination in early SARS-CoV-2 infection. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.14.21258569]">O’Brien 2021</a> will be integrated into the next version of this review, and we have listed the study under <a href="./references#CD013825-sec-0197" title="">Characteristics of studies awaiting classification</a>. </p> </section> </section> <section id="CD013825-sec-0053"> <h4 class="title">Included studies</h4> <section id="CD013825-sec-0054"> <h5 class="title">Randomised controlled trials in individuals with COVID‐19</h5> <section id="CD013825-sec-0055"> <h6 class="title">Design and sample size</h6> <p>We included six randomised controlled trials (RCTs) according to our inclusion criteria, involving 17,495 randomised participants (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>; <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>; <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>). Three studies were published as preprint only (<a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>; <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>), one study was published in three full‐text publications, one conference abstract (<a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>), another study was published as a journal article with additional data from one preprint (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>), and one study was published as a journal article with additional data from two preprints (<a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>).  </p> <p>All six included RCTs are still active or ongoing due to different reasons, e.g. follow‐up of participants (<a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>), addition of study arms with mAbs (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>; <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>), or part 2 or 3 of the study recruiting (<a href="./references#CD013825-bbs2-0010" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021 (80 mg/kg)</a>, <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>). The estimated study completion dates ranged from July 2021 to December 2031. All but one study (<a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>), were blinded. <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> and <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a> are part of a phase 2 to 3 study currently recruiting participants with completion planned in June 2022 with an estimated number of 3160 participants. Similarly, <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a> is a two‐part phase 2 to 3 study, currently recruiting participants into part 2 of the study with completion planned in September 2021 with 1020 participants. Results of a preplanned interim analysis of part 1 of the study were published in a preprint (<a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>). <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a> was a phase 2 to 3 study with an estimated completion date in July 2021. Recruitment was stopped on 10 March 2021 due to profound efficacy after 1057 participants had been randomised. There were separate data cut‐offs for efficacy and safety for the presented interim analysis. <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> and <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> was a continually enrolling phase 1 to 3 study currently recruiting new participants for phase 3. Phase 1 to 2 was completed and results were reported separately (<a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>). Based on results from phase 1 to 2, the trial was amended in November 2020 and only participants with at least one risk factor for severe COVID‐19 were included and no longer randomised to 8.0 g casirivimab and imdevimab.  In February 2021, participants were no longer randomised to placebo. <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> comprised three cohorts (cohort 1: ≥ 18 years, cohort 2: &lt; 18 years, cohort 3: pregnant at randomisation), but results were reported for cohort 1 only. Completion for phase 3 is planned for November 2021 with 6420 participants.  </p> <p>The studies <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> and <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> were platform trials with an adaptive design that allows adding and dropping experimental drugs during the course of the study. In <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>, the bamlanivimab arm was stopped after interim analysis for futility. This study has added additional SARS‐CoV‐2‐neutralising mAb arms, which are further described in the section on ongoing studies. The estimated completion date is July 2022 with 10,000 participants. <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> is an open‐label study with a planned completion date in December 2031 and an estimated enrolment of 40,000 participants. So far it has only one SARS‐CoV‐2 specific mAb treatment arm. The factorial design allowed randomisation of a single participant into between zero and four treatment arms based on predefined groups of treatment (i.e., convalescent plasma and casirivimab/imdevimab were in the same group, therefore mutually exclusive). An overview of included studies can be found in <a href="#CD013825-tbl-0008">Table 1</a>. A more detailed description of the methods, eligibility criteria, interventions, and outcomes is provided in the <a href="./references#CD013825-sec-0195" title="">Characteristics of included studies</a>.  </p> </section> <section id="CD013825-sec-0056"> <h6 class="title">Setting and participants</h6> <p>All studies were multicentre trials. The <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> study was conducted at different sites in the UK. The other studies were conducted at different global sites in the USA and Puerto Rico (this site was added after publication of the interim analysis; <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>), the USA, Chile, Mexico, and Romania (<a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>), the USA, South Korea, Romania, Spain (<a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>), the USA, Canada, Brazil, Spain (<a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>) and the USA, Denmark, and Singapore (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; sites in India, Poland, Spain, Switzerland, and the UK joined after publication of interim results).  </p> <p>In five studies, a confirmed SARS‐CoV‐2 infection was necessary for inclusion (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>; <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>). <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> included participants with confirmed or suspected SARS‐CoV‐2 infection. Positive polymerase chain reaction (PCR) rates at baseline ranged from 80% in <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> and <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> to more than 93% in <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> and <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>. No concerning mutations were identified in viral RNA sequences from 255 participants in <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>. In six participants deletions in codon 69‐70 were detected. Genomes in all but one person with alpha variant contained the B strain.  </p> <p>Four studies included non‐hospitalised participants with clinical symptoms of mild disease according to the definition of the WHO Clinical Progression Scale (<a href="#CD013825-fig-0001">Figure 1</a>; <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>; <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>). In <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, the median age ranged from 39 to 46 years between the treatment groups, and 56.4% of participants were female. In the phase 3 part (<a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>), the mean age was 53.8 standard deviation ((SD) = 16.8), and 52% were female. In <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>, the median age ranged from 51 to 52 years (interquartile range (IQR) 40 to 61 years), and 49.2% were female. In <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> and <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>, the median age of the participants was 42 years (IQR 30 to 53 years), 50 years (IQR 38 to 59 years), and 53 years (IQR 18 to 96 years), and 52.9%, 51.3% and 54% of participants were female. Risk factors for severe COVID‐19 progression were present in 60.5% in <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>, 67% in <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> and 99.7% in <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>. In <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> all participants had at least one risk factor for severe COVID‐19 and in <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a> 73.44% had comorbidities at baseline. </p> <p>Two studies included moderately to severely ill, hospitalised participants (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>). The median age of the participants in <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> was 61 years (IQR 49 to 71) and 44% of participants were female. Differences between the intervention and control groups in terms of co‐existing illnesses were observed in this study. More participants in the intervention group compared to the placebo group suffered from diabetes (33% versus 24%), renal impairment (15% versus 6%), and heart failure (7% versus 1%). At baseline, 27% did not require supplementary oxygen, 57% received oxygen (either &lt; 4 litres/minute or ≥ 4 litres/minute), and 15% received oxygen by noninvasive ventilation (NIV) or high‐flow device. No participants required invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at baseline. In <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> the median age of the participants was 61.9 years (IQR 14.4 to 14.6) and 37% were female. Fifty‐three percent of the participants had previous diseases, including diabetes (26.3%), heart disease (21%), chronic lung disease (23%), tuberculosis (0.35%), HIV (0.47%), severe liver disease (1.42%) and severe kidney impairment (5.2%). At baseline, 6.6% of the participants did not receive oxygen, 61.3% received simple oxygen, 26.2% received oxygen by NIV and 6% received invasive mechanical ventilation (IMV).   </p> <p>Baseline serum antibody status was negative for about 70% of the participants in <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>, 50% in <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>, and 30% in <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>. <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a> reported that less than 6% of the participants were tested positive for immunoglobulin G (IgG) on day 1. In <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>, 50% of the participants were tested positive for neutralising antibodies (nAb) and 59% had detectable anti‐nucleocapsid (N) antibodies. </p> </section> <section id="CD013825-sec-0057"> <h6 class="title">Interventions</h6> <p>We included six RCTs (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>; <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>; <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>; <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>). These included 17,495 randomised participants: 486 participants were assigned to receive varying doses of bamlanivimab (0.7 g, 2.8 g, 7.0 g, <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>), 632 participants were assigned to receive combination therapy of bamlanivimab and etesevimab (2.8 g each; <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>), 3600 participants were assigned to receive a combination of casirivimab and imdevimab at different doses (1.2 g, 2.4 g, 8.0 g; <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>), 430 participants were assigned to receive sotrovimab (<a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>), and 216 participants were assigned to receive regdanvimab (0.04 g/kg or 0.08 mg/kg, <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>). A total of 3150 control group participants were assigned to receive placebo infusions. In <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> 4839 participants were allocated to receive a combination of casirivimab and imdevimab (8.0 g). Ninety percent of participants with completed follow‐up at time of analysis received the combination and 4946 participants were allocated to receive standard of care. Less than 1% of participants with completed follow‐up at time of analysis received a combination of casirivimab and imdevimab (8.0 g). All included substances target the spike protein of SARS‐CoV‐2. </p> <p><a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> randomised participants into five groups who received either bamlanivimab monotherapy at a dose of 0.7 g, 2.8 g, 7.0 g, combination therapy of bamlanivimab and etesevimab in equal doses of 2.8 g, or placebo IV. Additional arms with different doses of bamlanivimab/etesevimab have been added during the course of the study, but do not have published results yet. In <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>, participants were treated with a combination of bamlanivimab and etesevimab in equal doses of 2.8 g, or placebo IV. Concomitant treatment was not reported in any phase. </p> <p>In <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>, participants were randomised to either 0.5 g sotrovimab (also known as VIR‐7831) or single dose of placebo IV. Concomitant treatment was not reported. </p> <p><a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a> randomised participants into three groups who were treated with regdanvimab (also known as CT‐P59) at a dose of 0.04 g/kg or 0.08 g/kg or a single dose of placebo IV. Concomitant medications were taken by more than 10% of the participants in the three study arms included analgesics, antibiotics, antithrombotic agents, agents acting on the renin‐angiotensin system, beta‐blocking agents, corticosteroids, cough and cold preparations, lipid‐modifying agents and vitamins.  </p> <p><a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> randomised participants into three groups who were treated with a combination of casirivimab and imdevimab (manufactured under the trade name REGN‐COV2) in equal doses, at a dose of 2.4 g or 8.0 g or a single dose of placebo IV. No concomitant treatment was reported. Similarly, in <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> participants were randomised to receive 1.2 g, 2.4 g or 8.0 g of casirivimab and imdevimab or placebo IV. Concomitant treatment was not reported. </p> <p>In <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>, participants were randomised to either 7.0 g bamlanivimab or a single dose of placebo IV. Pre‐ and concomitant treatments in both study arms included remdesivir and when indicated, antibiotic, antifungal, antiviral, angiotensin‐converting enzyme (ACE) inhibitor or angiotensin‐receptor blocker (ARB), antiplatelet/anticoagulant, immune‐modulating medication, or supplemental oxygen. </p> <p><a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> randomised participants into two groups to receive either a single dose casirivimab/imdevimab (8.0 g) or standard of care. Pre‐ and concomitant treatments in both study arms included corticosteroids, aspirin, colchicine, azithromycin, remdesivir, tocilizumab or sarilumab, hydroxychloroquine, lopinavir‐ritonavir. </p> </section> <section id="CD013825-sec-0058"> <h6 class="title">Funding and conflicts of interest</h6> <p>Three studies were funded by pharmaceutical companies (<a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>). <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> and <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> were supported by pharmaceutical companies and partly funded by public sources. In all four studies, the pharmaceutical company was involved in analysing and interpreting the data. Two studies were funded by public sources (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>), with donations of study medications by the manufacturing pharmaceutical companies. However, <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> explicitly reported that the medication sponsor had no role in study conduct and publication of results. Except for the preprints of <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> and <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>, all authors reported their conflicts of interest. </p> </section> <section id="CD013825-sec-0059"> <h6 class="title">Outcomes</h6> <p>In <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, the primary outcome was the change in SARS‐CoV‐2 viral load from baseline to day 11. Planned secondary outcomes were viral clearance at days 7, 11, 15, and 22 and time to SARS‐CoV‐2 clearance, symptom resolution and time to symptom resolution, symptom improvement and time to symptom improvement, COVID‐19‐related deterioration (hospitalisation, emergency room or death by days 29, 60 and 85), and change in symptom questionnaire score. Additional biocatalytic and pharmacokinetic/pharmacodynamic methods were conducted. Safety outcomes included treatment‐emergent adverse events rated according to the Medical Dictionary for Regulatory Activities (MedDRA) and serious adverse events. The term "treatment‐emergent adverse events" is used, which is defined as any "event that first occurred or worsened in severity after baseline", therefore we treated these as regular adverse events. The phase 3 publication reported the combined endpoint hospital admission or death as the primary outcome. Additional reported outcomes for bamlanivimab/etesevimab included: mortality, the combined endpoint hospitalisation, emergency department visit or death, change in viral load at day 7, time to sustained symptom resolution, reduction in viral load to days three and five, time to viral clearance, and adverse events. </p> <p>In <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>, the primary endpoint was hospitalisation ≥ 24 hours or death due to any cause up to day 29. Secondary efficacy endpoints included: the composite endpoint emergency room visit, hospitalisation or death, all‐cause mortality (at days 29, 60, 90), patient‐reported outcomes (mean change in inFLUenza Patient‐ Reported Outcome score (FLU PRO Plus)), changes in viral load, progression to supplemental oxygen up to day 29, incidence and titres of serum anti‐drug antibodies (ADA). Safety endpoints were adverse events (including adverse events of special interest) and serious adverse events. Patient‐reported outcomes, change in viral load, and various time points for all‐cause mortality and adverse events were not reported. Secondary and exploratory endpoints were excluded from this interim analysis, because the study was still ongoing. </p> <p>In <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>, the primary efficacy endpoint of part 1 was time to negative conversion up to day 28, time to clinical recovery up to day 14. Secondary efficacy endpoints (assessed up to days 7, 14, 28) were the proportion of patients with negative seroconversion; proportion of patients with clinical symptoms requiring hospitalisation, oxygen, therapy, or mortality; proportion of patients requiring supplemental oxygen; intensive care unit (ICU) transfer; all‐cause mortality; time to clinical recovery; duration of fever; hospital admission; need for IMV; patients requiring rescue therapy, time to National Early Warning Score 2 (NEWS2) of 0, scores of other known symptoms (vomiting, diarrhoea, loss of taste or smell), incidence of antibody‐dependent enhancement, viral serology for SARS‐CoV‐2 antibody. Safety outcomes were reported as treatment‐emergent adverse events (TEAEs; including TEAEs of special interest), treatment‐emergent serious adverse events (TESAEs). The endpoints duration of fever,  time to National Early Warning Score 2 (NEWS2) of 0, scores of other known symptoms (vomiting, diarrhoea, loss of taste or smell) were not reported in the preprint, and the outcome proportion of patients with negative seroconversion was not reported up to day 7.  </p> <p>In <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>, for the reported phase 2 data, the primary virological endpoint was time‐weighted average change in viral load from baseline through day 22, according to the statistical analysis plan; in the publication, this outcome was reported through day 7. Secondary endpoints were time to negative reverse transcription PCR (RT‐qPCR) test on nasopharyngeal swabs, change in viral shedding at each visit through day 29, time‐weighted average change from baseline in viral shedding (days 5, 7, 15, and 29), the percentage of participants with one or more and two or more medically attended visits through day 29, number of COVID‐19‐related medically attended visits by day 29, proportion of admissions to hospital, ICU admission, outpatient visits, percentage of participants requiring mechanical ventilation, days of hospitalisation due to COVID‐19 by day 29, all‐cause mortality, time to symptom onset and duration of symptoms. Only the primary virological endpoint, percentage of participants with one or more and two or more medically attended visits through day 29, number of COVID‐19‐related medically attended visits by day 29 and the proportion of admissions to hospital were reported in this final analysis of phase 1 to 2 in the form of a preprint. Safety outcomes were reported as TEAEs, adverse events of special interest and TESAEs. <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> reported for phase 3 the endpoints all‐cause mortality by day 29 (for the doses 1.2g and 2.4 g), percentage of participants requiring mechanical ventilation (for the doses 1.2 g and 2.4 g), hospital admissions, days of hospitalisation due to COVID‐19 by day 29 (for the doses 1.2 g and 2.4 g), admission to ICU (for the doses 1.2 g and 2.4 g), TEAEs all grades, TEAEs grades 3 to 4 and TESAEs. </p> <p>In the <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> study, the primary outcomes were time to sustained recovery up to 90 days, defined as hospital discharge and being alive and home for at least 14 days, and two outcomes (pulmonary and pulmonary plus outcome) measured on 7‐level ordinal scales, adapted from the WHO. The pulmonary outcome was based on oxygen requirements and the pulmonary plus outcome was based on oxygen requirements in combination with organ dysfunction associated with the progression of the disease. The secondary outcomes were death from any cause, composite of sustained recovery and mortality through day 90, time to hospital discharge, days alive outside of acute care hospital, ordinal outcomes on days 14 and 28, change in National Early Warning (NEW) score through day 5, clinical organ failure, composite of death and clinical organ failure, and a composite of cardiovascular and thromboembolic events. The primary safety outcome was a composite outcome of death, serious adverse events, or grades 3 or 4 adverse events assessed through day five. Secondary outcomes included all‐cause mortality through day 90 and a composite outcome considering time to sustained recovery and mortality through day 90. In addition, infusion‐related reactions, serious adverse events or death, adverse events of any grade through day 7 and at days 14 and 28 were planned. All preplanned outcomes for this stage have been reported except days alive outside of acute care hospital and change in NEW score (reported as odds ratio (OR)). </p> <p>In <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>, outcomes were reported at day 28 after randomisation. The primary outcome was all‐cause mortality. Secondary outcomes were time to hospital discharge, use of IMV or death. Subsidiary outcomes were use of ventilation, duration of IMV, use of renal dialysis or haemofiltration, thrombotic events. Safety outcomes included cause‐specific mortality, major cardiac arrhythmia, major bleeding, early safety of antibody‐based therapy and non‐coronavirus infection. All preplanned outcomes, except non‐coronavirus infection were reported in the preprint. </p> </section> </section> <section id="CD013825-sec-0060"> <h5 class="title">Ongoing randomised controlled trials testing SARS‐CoV‐2‐specific mAbs</h5> <p>We identified 36 ongoing studies in addition to the included platform trial <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> which have added new mAbs. These are listed in <a href="./appendices#CD013825-sec-0175">Appendix 10</a>, more information on each study can be found in the <a href="./references#CD013825-sec-0198" title="">Characteristics of ongoing studies</a>. Of these RCTs, four are ongoing platform trials without results on mAbs yet (<a href="./references#CD013825-bbs2-0137" title="NCT04518410. ACTIV-2: a study for outpatients with COVID-19. clinicaltrials.gov/ct2/show/NCT04518410 (first received 19 August 2020). ">ACTIV‐2</a>; <a href="./references#CD013825-bbs2-0138" title="EUCTR2020-001860-27. AGILE: seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment. A randomised phase I/II study to determine the safety and effectiveness of multiple drugs for the treatment of COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001860-27/GB (first received 17 April 2020). GriffithsG , FitzgeraldR , JakiT , CorkhillA , MarwoodE , ReynoldsH , et al. AGILE-ACCORD: a randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: a structured summary of a study protocol for a randomised platform trial. Trials2020;21(1):544. [DOI: 10.1186/s13063-020-04473-1]">AGILE</a>; <a href="./references#CD013825-bbs2-0139" title="AderF , Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ open2020;10(9):e041437. [DOI: 10.1136/bmjopen-2020-041437]NCT04315948. Trial of treatments for COVID-19 in hospitalised adults (DisCoVeRy). clinicaltrials.gov/ct2/show/NCT04315948 (first received 20 March 2020). ">DISCOVERY</a>; <a href="./references#CD013825-bbs2-0172" title="NCT04790786. UPMC OPTIMISE-C19 Trial, a COVID-19 Study (OPTIMISE-C19). clinicaltrials.gov/ct2/show/NCT04790786. ">OPTIMISE‐C19</a>) and 32 are standard RCTs (<a href="./references#CD013825-bbs2-0140" title="EUDRACT2020-003401-60. A phase 2/3, randomized, parallel-group, placebo-controlled, double-blind study to evaluate the efficacy and safety of CT-P59 in combination with standard of care in hospitalized patients with SARS-CoV-2 Iinfection (COVID19). www.clinicaltrialsregister.eu/ctr-search/trial/2020-003401-60/IT. ">EUDRACT2020‐003401‐60</a>; <a href="./references#CD013825-bbs2-0141" title="NCT04411628. A study of LY3819253 (LY-CoV555) in participants hospitalized for COVID-19. clinicaltrials.gov/ct2/show/NCT04411628 (first received 2 June 2020). ">NCT04411628</a>; <a href="./references#CD013825-bbs2-0142" title="NCT04426695. Safety, tolerability, and efficacy of anti-Spike (S) SARS-CoV-2 monoclonal antibodies for hospitalized adult patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04426695 (first received 11 June 2020). ">NCT04426695</a>; <a href="./references#CD013825-bbs2-0143" title="NCT04551898. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody BGB-DXP593 in participants with mild-to-moderate coronavirus disease 2019 (COVID-19). clinicaltrials.gov/ct2/show/NCT04551898 (first received 16 September 2020). ">NCT04551898</a>; <a href="./references#CD013825-bbs2-0144" title="NCT04584697. Study to evaluate the safety, pharmacokinetics and efficacy of STI-2020 (COVI-AMG™) in outpatients with COVID-19. clinicaltrials.gov/ct2/show/NCT04584697 (first received 14 October 2020). ">NCT04584697</a>; <a href="./references#CD013825-bbs2-0145" title="NCT04593641. A pilot phase 1, randomized, double-blind, placebo-controlled, parallel group, single ascending dose study to evaluate the safety, tolerability and virology of CT-P59 in patient with mild symptoms of SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04593641 (first received 20 October 2020). ">NCT04593641</a>; <a href="./references#CD013825-bbs2-0146" title="NCT04627584. A phase 2 clinical trial of MW33 injection to evaluate the efficacy and safety in patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04627584 (first received 13 November 2020). ">NCT04627584</a>; <a href="./references#CD013825-bbs2-0147" title="NCT04631666. COVID-19 - administration of the SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c (infusion). clinicaltrials.gov/ct2/show/NCT04631666 (first received 17 November 2020). ">NCT04631666</a>; <a href="./references#CD013825-bbs2-0148" title="NCT04631705. COVID-19 - administration of the SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c (inhalation). clinicaltrials.gov/ct2/show/NCT04631705 (first received 17 November 2020). ">NCT04631705</a>; <a href="./references#CD013825-bbs2-0149" title="NCT04634409. A study of immune system proteins in participants with mild to moderate COVID-19 Illness. clinicaltrials.gov/ct2/show/NCT04634409 (first received 18 November 2020). ">NCT04634409</a>; <a href="./references#CD013825-bbs2-0150" title="NCT04644120. Study to assess adverse events and how intravenous (IV) ABBV-47D11 moves through the body of adult participants hospitalized with coronavirus disease 2019 (COVID-19). clinicaltrials.gov/ct2/show/NCT04644120 (first received 25 November 2020). ">NCT04644120</a>; <a href="./references#CD013825-bbs2-0151" title="NCT04644185. The efficacy and safety of SCTA01 in hospitalized patients with severe COVID-19. clinicaltrials.gov/ct2/show/NCT04644185 (first received 25 November 2020). ">NCT04644185</a>; <a href="./references#CD013825-bbs2-0152" title="NCT04649515. Efficacy and safety of TY027, a treatment for COVID-19, in humans. clinicaltrials.gov/ct2/show/NCT04649515 (first received 2 December 2020). ">NCT04649515</a>; <a href="./references#CD013825-bbs2-0153" title="NCT04666441. A study to assess the virologic efficacy of REGN10933+REGN10987 across different dose regimens in adult outpatients with SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04666441 (first received 14 December 2020). ">NCT04666441</a>; <a href="./references#CD013825-bbs2-0154" title="Evaluation of safety and tolerability of COR-101 in hospitalized patients with moderate to severe COVID-19. clinicaltrials.gov/ct2/show/NCT04674566 (first received 19 December 2020). [NCT04748588]">NCT04674566</a>; <a href="./references#CD013825-bbs2-0155" title="NCT04683328. The safety and efficacy of SCTA01 against COVID-19 in patients admitted to high dependence or intensive care. clinicaltrials.gov/ct2/show/NCT04683328 (first received 24 December 2020). ">NCT04683328</a>; <a href="./references#CD013825-bbs2-0156" title="NCT04709328. An adaptive, randomized, double-blinded, placebo-controlled trial to evaluate SCTA01 in COVID-19. clinicaltrials.gov/ct2/show/NCT04709328 (first received 14 January 2021). ">NCT04709328</a>; <a href="./references#CD013825-bbs2-0157" title="NCT04723394. Phase III study of AZD7442 for treatment of COVID-19 in outpatient adults. clinicaltrials.gov/ct2/show/NCT04723394 (first received 25 January 2021). ">NCT04723394</a>; <a href="./references#CD013825-bbs2-0158" title="NCT04734860. Study to evaluate a single dose of STI-2020 (COVI-AMG™) in adults with mild COVID-19 symptoms. clinicaltrials.gov/ct2/show/NCT04734860 (first received 2 February 2021). ">NCT04734860</a>; <a href="./references#CD013825-bbs2-0159" title="NCT04748588. Treatment of nosocomial COVID-19. clinicaltrials.gov/ct2/show/NCT04748588 (first received 10 February 2021). ">NCT04748588</a>; <a href="./references#CD013825-bbs2-0160" title="NCT04770467. A safety and efficacy study of human monoclonal antibodies, BRII-196 and BRII-198 for the treatment of patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04770467 (first received 25 February 2021). [CLINICALTRIALS.GOV: NCT04770467] ">NCT04770467</a>; <a href="./references#CD013825-bbs2-0161" title="Study to evaluate a single dose of STI-2020 (COVI-AMG) in hospitalized adults with COVID-19. www.clinicaltrials.gov/ct2/show/NCT04771351 (first received 25 February 2021). [CLINICALTRIALS.GOV: NCT04771351] ">NCT04771351</a>; <a href="./references#CD013825-bbs2-0162" title="Safety, tolerability and pharmacokinetics of second generation VIR-7831 material in non-hospitalized participants with mild to moderate COVID-19 (COMET-PEAK). clinicaltrials.gov/ct2/show/NCT04779879 (first received 3 March 2021). ">NCT04779879</a>; <a href="./references#CD013825-bbs2-0163" title="JS016 (anti-SARS-CoV-2 monoclonal antibody) with mild and moderate COVID-19 or SARS-CoV-2 asymptomatic infection subjects. clinicaltrials.gov/ct2/show/NCT04780321 (first received 3 March 2021). ">NCT04780321</a>; <a href="./references#CD013825-bbs2-0164" title="NCT04787211. A phase 2 study of human monoclonal antibodies, BRII-196 and BRII-198. clinicaltrials.gov/ct2/show/NCT04787211. ">NCT04787211</a>; <a href="./references#CD013825-bbs2-0164" title="NCT04787211. A phase 2 study of human monoclonal antibodies, BRII-196 and BRII-198. clinicaltrials.gov/ct2/show/NCT04787211. ">NCT04787211</a>; <a href="./references#CD013825-bbs2-0165" title="NCT04796402. A study to assess if a medicine called bamlanivimab is safe and effective in reducing hospitalization due to COVID-19 (B-EPIC). clinicaltrials.gov/ct2/show/NCT04796402. ">NCT04796402</a>; <a href="./references#CD013825-bbs2-0165" title="NCT04796402. A study to assess if a medicine called bamlanivimab is safe and effective in reducing hospitalization due to COVID-19 (B-EPIC). clinicaltrials.gov/ct2/show/NCT04796402. ">NCT04796402</a>; <a href="./references#CD013825-bbs2-0166" title="NCT04805671. Evaluation of ADG20 for the treatment of mild or moderate COVID-19 (STAMP). clinicaltrials.gov/ct2/show/NCT04805671. ">NCT04805671</a>; <a href="./references#CD013825-bbs2-0166" title="NCT04805671. Evaluation of ADG20 for the treatment of mild or moderate COVID-19 (STAMP). clinicaltrials.gov/ct2/show/NCT04805671. ">NCT04805671</a>; <a href="./references#CD013825-bbs2-0167" title="NCT04822701. A study to test BI 767551 in people with mild to moderate symptoms of COVID-19. clinicaltrials.gov/ct2/show/NCT04822701. ">NCT04822701</a>; <a href="./references#CD013825-bbs2-0167" title="NCT04822701. A study to test BI 767551 in people with mild to moderate symptoms of COVID-19. clinicaltrials.gov/ct2/show/NCT04822701. ">NCT04822701</a>; <a href="./references#CD013825-bbs2-0168" title="NCT04840459. Use of monoclonal antibodies for the treatment of mild to moderate COVID-19 in non-hospitalized setting. clinicaltrials.gov/ct2/show/NCT04840459. ">NCT04840459</a>; <a href="./references#CD013825-bbs2-0168" title="NCT04840459. Use of monoclonal antibodies for the treatment of mild to moderate COVID-19 in non-hospitalized setting. clinicaltrials.gov/ct2/show/NCT04840459. ">NCT04840459</a>; <a href="./references#CD013825-bbs2-0169" title="NCT04900428. Study to evaluate a single intranasal dose of STI-2099 (COVI-DROPS™) in outpatient adults with COVID-19 (UK). clinicaltrials.gov/ct2/show/NCT04900428. ">NCT04900428</a>; <a href="./references#CD013825-bbs2-0169" title="NCT04900428. Study to evaluate a single intranasal dose of STI-2099 (COVI-DROPS™) in outpatient adults with COVID-19 (UK). clinicaltrials.gov/ct2/show/NCT04900428. ">NCT04900428</a>; <a href="./references#CD013825-bbs2-0170" title="NCT04913675. Intramuscular VIR-7831 (sotrovimab) for mild/moderate COVID-19. clinicaltrials.gov/ct2/show/NCT04913675. ">NCT04913675</a>; <a href="./references#CD013825-bbs2-0171" title="NCT04952805. Clinical trial to select the dose and evaluate safety and efficacy of MAD0004J08 monoclonal antibody in adult patients with recently diagnosed asymptomatic to moderately severe COVID-19. ClinicalTrials.gov2021. ">NCT04952805</a>), which evaluated 23 different SARS‐CoV‐2‐specific mAb types or mAb combinations (e.g., AZD7442, MAD0004J08, BRII‐196/BRII‐198, casirivimab/imdevimab, bamlanivimab/etesevimab, C135‐LS/C144‐LS). Most SARS‐CoV‐neutralising mAbs in humans have proceeded to phase 2 studies onwards. </p> <p>Two of the <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> arms, BRII‐196/BRII‐198, and sotrovimab, were closed with 343 and 344 randomised participants each for futility, and results have not yet been published (<a href="./references#CD013825-bbs2-0237" title="National Institutes of Health. NIH-sponsored ACTIV-3 clinical trial closes enrollment into two sub-studies. Available from: https://www.nih.gov/news-events/news-releases/nih-sponsored-activ-3-clinical-trial-closes-enrollment-into-two-sub-studies (accessed 29.07.2021).">NIH 2021</a>). </p> <section id="CD013825-sec-0061"> <h6 class="title">Ongoing platform trials</h6> <p><a href="./references#CD013825-bbs2-0137" title="NCT04518410. ACTIV-2: a study for outpatients with COVID-19. clinicaltrials.gov/ct2/show/NCT04518410 (first received 19 August 2020). ">ACTIV‐2</a> is being conducted in outpatients and has five active mAbs treatment arms (bamlanivimab, BRII‐196/BRII‐198, AZD7442 (IV or IM), C135‐LS/C144‐LS). The estimated study completion date is May 2023.  </p> <p>The studies <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>, <a href="./references#CD013825-bbs2-0138" title="EUCTR2020-001860-27. AGILE: seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment. A randomised phase I/II study to determine the safety and effectiveness of multiple drugs for the treatment of COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001860-27/GB (first received 17 April 2020). GriffithsG , FitzgeraldR , JakiT , CorkhillA , MarwoodE , ReynoldsH , et al. AGILE-ACCORD: a randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: a structured summary of a study protocol for a randomised platform trial. Trials2020;21(1):544. [DOI: 10.1186/s13063-020-04473-1]">AGILE</a>, and <a href="./references#CD013825-bbs2-0139" title="AderF , Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ open2020;10(9):e041437. [DOI: 10.1136/bmjopen-2020-041437]NCT04315948. Trial of treatments for COVID-19 in hospitalised adults (DisCoVeRy). clinicaltrials.gov/ct2/show/NCT04315948 (first received 20 March 2020). ">DISCOVERY</a> include hospitalised patients and randomise(d) into various mAb treatment arms (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>: AZD7442, bamlanivimab, BRII‐196/BRII‐198 and VIR‐7831; <a href="./references#CD013825-bbs2-0138" title="EUCTR2020-001860-27. AGILE: seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment. A randomised phase I/II study to determine the safety and effectiveness of multiple drugs for the treatment of COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001860-27/GB (first received 17 April 2020). GriffithsG , FitzgeraldR , JakiT , CorkhillA , MarwoodE , ReynoldsH , et al. AGILE-ACCORD: a randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: a structured summary of a study protocol for a randomised platform trial. Trials2020;21(1):544. [DOI: 10.1186/s13063-020-04473-1]">AGILE</a>: VIR‐7832 and VIR‐7831; <a href="./references#CD013825-bbs2-0139" title="AderF , Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ open2020;10(9):e041437. [DOI: 10.1136/bmjopen-2020-041437]NCT04315948. Trial of treatments for COVID-19 in hospitalised adults (DisCoVeRy). clinicaltrials.gov/ct2/show/NCT04315948 (first received 20 March 2020). ">DISCOVERY</a>: AZD7442). In <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>, the bamlanivimab arm was stopped for futility after an interim analysis. We included the published results in this review. Randomisation to VIR‐7831 and BRI196/BRII/198 has stopped, but participants are still being recruited for the AZD7442 arm. Results had not been published by the time of review writing. The estimated study completion date is July 2022. <a href="./references#CD013825-bbs2-0138" title="EUCTR2020-001860-27. AGILE: seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment. A randomised phase I/II study to determine the safety and effectiveness of multiple drugs for the treatment of COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001860-27/GB (first received 17 April 2020). GriffithsG , FitzgeraldR , JakiT , CorkhillA , MarwoodE , ReynoldsH , et al. AGILE-ACCORD: a randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: a structured summary of a study protocol for a randomised platform trial. Trials2020;21(1):544. [DOI: 10.1186/s13063-020-04473-1]">AGILE</a> is expected to complete by April 2022. <a href="./references#CD013825-bbs2-0139" title="AderF , Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ open2020;10(9):e041437. [DOI: 10.1136/bmjopen-2020-041437]NCT04315948. Trial of treatments for COVID-19 in hospitalised adults (DisCoVeRy). clinicaltrials.gov/ct2/show/NCT04315948 (first received 20 March 2020). ">DISCOVERY</a> is planned to complete in March 2023. </p> <p><a href="./references#CD013825-bbs2-0172" title="NCT04790786. UPMC OPTIMISE-C19 Trial, a COVID-19 Study (OPTIMISE-C19). clinicaltrials.gov/ct2/show/NCT04790786. ">OPTIMISE‐C19</a> includes any COVID‐19 positive patient who is eligible for the examined mAbs under US Food and Drug Administration (FDA) emergency use authorization (EUA), which may change over time. Currently, the study randomises patients into bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab treatment arms and is estimated to have completed by December 2022. </p> </section> </section> <section id="CD013825-sec-0062"> <h5 class="title">Studies awaiting classification: ongoing platform trials without SARS‐CoV‐2‐specific mAbs </h5> <p>To facilitate rapid testing of emerging treatments, adaptive platform trials have become more frequent, because they allow more flexibility in adding new treatment arms and dropping futile treatment arms without registration of a new study. From our specific search for these studies, we have identified five ongoing platform trials with at least one SARS‐CoV‐2‐specific mAb as a treatment arm (<a href="./references#CD013825-bbs2-0137" title="NCT04518410. ACTIV-2: a study for outpatients with COVID-19. clinicaltrials.gov/ct2/show/NCT04518410 (first received 19 August 2020). ">ACTIV‐2</a>; <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0138" title="EUCTR2020-001860-27. AGILE: seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment. A randomised phase I/II study to determine the safety and effectiveness of multiple drugs for the treatment of COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001860-27/GB (first received 17 April 2020). GriffithsG , FitzgeraldR , JakiT , CorkhillA , MarwoodE , ReynoldsH , et al. AGILE-ACCORD: a randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: a structured summary of a study protocol for a randomised platform trial. Trials2020;21(1):544. [DOI: 10.1186/s13063-020-04473-1]">AGILE</a>; <a href="./references#CD013825-bbs2-0139" title="AderF , Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ open2020;10(9):e041437. [DOI: 10.1136/bmjopen-2020-041437]NCT04315948. Trial of treatments for COVID-19 in hospitalised adults (DisCoVeRy). clinicaltrials.gov/ct2/show/NCT04315948 (first received 20 March 2020). ">DISCOVERY</a>; <a href="./references#CD013825-bbs2-0172" title="NCT04790786. UPMC OPTIMISE-C19 Trial, a COVID-19 Study (OPTIMISE-C19). clinicaltrials.gov/ct2/show/NCT04790786. ">OPTIMISE‐C19</a>), which are also listed above as included studies. We identified an additional 30 ongoing platform trials without any SARS‐CoV‐2‐specific mAb treatment arms (<a href="./references#CD013825-bbs2-0106" title="EUCTR2020-001736-95. ACCORD 2: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID 19 in hospitalised patients. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001736-95/GB (first received 23 April 2020). WilkinsonT , DixonR , PageC , CarrollM , GriffithsG , HoLP , et al. ACCORD: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):691. [DOI: 10.1186/s13063-020-04584-9]">ACCORD &amp; ACCORD 2</a>; <a href="./references#CD013825-bbs2-0107" title="Euctr2020-001302-30/AT. A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with a lung disease caused by coronavirus infection. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001302-30/AT (first received 9 April 2020). NCT04351724. Austrian corona virus adaptive clinical trial (COVID-19). clinicaltrials.gov/ct2/show/NCT04351724 (first received 2 March 2021). ">ACOVACT</a>; <a href="./references#CD013825-bbs2-0108" title="NCT04593940. Immune modulators for treating COVID-19. clinicaltrials.gov/ct2/show/NCT04593940 (first received 20 October 2020). ">ACTIV‐1 IM</a>; <a href="./references#CD013825-bbs2-0109" title="NCT04640168. Adaptive COVID-19 treatment trial 4 (ACTT-4). clinicaltrials.gov/ct2/show/NCT04640168 (first received 23 November 2020). ">ACTT‐4</a>; <a href="./references#CD013825-bbs2-0110" title="PACTR202006537901307. An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19. pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12150 (first received 24 June 2020). ">ANTICOV</a>; <a href="./references#CD013825-bbs2-0111" title="EU/CTR/2020-001528-32. Adaptive randomised trial for therapy of corona virus disease 2019 at home with oral antivirals. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001528-32/IT (first received 24 June 2020). ">ARCO‐Home</a>; <a href="./references#CD013825-bbs2-0112" title="ACTRN12620000566932. Randomised clinical trial of interventions for the treatment of COVID-19 in the community setting for high risk older people. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379801&amp;isReview=true (first received 10 May 2020). ">BEAT COVID‐19</a>; <a href="./references#CD013825-bbs2-0113" title="NCT04583956. Big effect trial (BET-A) for the treatment of COVID-19. www.clinicaltrials.gov/ct2/show/NCT04583956 (first received 12 October 2020). ">BET‐A (ACTIV‐5)</a>; <a href="./references#CD013825-bbs2-0114" title="NCT04583969. Big effect trial (BET-B) for the treatment of COVID-19. www.clinicaltrials.gov/ct2/show/NCT04583969 (first received 12 October 2020). ">BET‐B (ACTIV‐5)</a>; <a href="./references#CD013825-bbs2-0115" title="ISRCTN40580903. Which treatment could lessen the severity of a coronavirus infection when compared with usual care in an NHS setting?www.isrctn.com/ISRCTN40580903 (first received 14 May 2020). ">CATALYST</a>; <a href="./references#CD013825-bbs2-0116" title="NCT04345289. Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. clinicaltrials.gov/ct2/show/NCT04345289 (first received 14 April 2020). ">CCAP</a>; <a href="./references#CD013825-bbs2-0117" title="NCT04355143. Colchicine to reduce myocardial injury in COVID-19 (COLHEART-19). clinicaltrials.gov/ct2/show/NCT04355143 (first received 12 April 2020). ">COLHEART‐19</a>; <a href="./references#CD013825-bbs2-0118" title="NCT04662086. COVID-19 outpatient pragmatic platform study (COPPS) - master protocol. clinicaltrials.gov/ct2/show/NCT04662086 (first received 10 December 2020). ">COPPS</a>; <a href="./references#CD013825-bbs2-0119" title="NCT04324047. Cohort multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04324047 (first received 27 March 2020). ">CORIMUNO</a>; <a href="./references#CD013825-bbs2-0120" title="NCT04328012. Comparison of therapeutics for hospitalized patients infected with SARS-CoV-2 in a pragmatic adaptive randomized clinical trial during the COVID-19 pandemic (COVID MED Trial). clinicaltrials.gov/show/NCT04328012 (first received 31 March 2020). ">COVID MED</a>; <a href="./references#CD013825-bbs2-0121" title="NCT04473053. Rapid experimental medicine for COVID-19. clinicaltrials.gov/ct2/show/NCT04473053 (first received 16 July 2020). ">DEFINE</a>; <a href="./references#CD013825-bbs2-0122" title="NCT04891133. EU SolidAct: an adaptive pandemic and emerging infection platform trial. clinicaltrials.gov/ct2/show/NCT04891133. ">EU SolidAct</a>; <a href="./references#CD013825-bbs2-0123" title="NCT04488081. I-SPY COVID-19 trial: an adaptive platform trial for critically ill patients. clinicaltrials.gov/ct2/show/NCT04488081 (first received 27 July 2020). ">I‐SPY</a>; <a href="./references#CD013825-bbs2-0124" title="NCT04359095. Effectiveness and safety of medical treatment for SARS-CoV-2 (COVID-19) in Colombia. clinicaltrials.gov/ct2/show/NCT04359095 (first received 24 April 2020). ">NCT04359095</a>; <a href="./references#CD013825-bbs2-0125" title="NCT04590586. Study of multiple candidate agents for the treatment of COVID-19 in hospitalized patients. clinicaltrials.gov/ct2/show/NCT04590586 (first received 19 October 2020). ">NCT04590586</a>; <a href="./references#CD013825-bbs2-0127" title="NCT04703608. Prevention and treatment for COVID -19 (severe acute respiratory syndrome coronavirus 2 SARS-CoV-2) associated severe pneumonia in the Gambia (PaTS-COVID). clinicaltrials.gov/ct2/show/NCT04703608 (first received 11 January 2021). ">PaTS‐COVID</a>; <a href="./references#CD013825-bbs2-0128" title="ISRCTN86534580. A trial evaluating treatments for suspected coronavirus infection in people aged 50 years and above with pre-existing conditions and those aged 65 years and above. www.isrctn.com/ISRCTN86534580 (first received 20 March 2020). ">PRINCIPLE</a>; <a href="./references#CD013825-bbs2-0129" title="EUCTR2020-001448-24-GB. Preventing pulmonary complications in surgical patients at risk of COVID-19. clinicaltrialsregister.eu/ctr-search/trial/2020-001448-24/GB (first received 17 April 2020). NCT04386070. Preventing pulmonary complications in surgical patients at risk of COVID-19. clinicaltrials.gov/ct2/show/NCT04386070 (first received 13 May 2020). ">PROTECT‐Surg</a>; <a href="./references#CD013825-bbs2-0130" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , Van Bentum-PuijkW , et al. The randomized embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]EUCTR2015-002340-14-NL. Adaptive trial in severe pneumonia (REMAP-CAP). clinicaltrialsregister.eu/ctr-search/trial/2015-002340-14/NL (first received 13 July 2015). ISRCTN67000769. An international platform trial for severely ill patients with community-acquired pneumonia or COVID-19. www.isrctn.com/ISRCTN67000769 (first received 9 July 2020). NCT02735707. Randomized, embedded, multifactorial adaptive platform trial for community- acquired pneumonia (REMAP-CAP). clinicaltrials.gov/ct2/show/NCT02735707 (first received 13 April 2016). ">REMAP‐CAP</a>; <a href="./references#CD013825-bbs2-0131" title="ISRCTN83971151. SOLIDARITY: an international randomized controlled trial to evaluate non-licensed COVID-19 treatments in addition to standard of care among hospitalised patients. www.isrctn.com/ISRCTN83971151 (first received 25 March 2020). NCT04330690. Treatments for COVID-19: Canadian arm of the SOLIDARITY trial. clinicaltrials.gov/ct2/show/NCT04330690 (first received 1 April 2020). NCT04575064. An International randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-Germany. clinicaltrials.gov/ct2/show/NCT04575064 (first received 5 October 2020). SotoA , Quinones-LaverianoDM , GarciaPJ , GotuzzoE , Henao-RestrepoAM . Rapid responses to the COVID-19 pandemic through science and global collaboration: the solidarity clinical trial. Revista Peruana de Medicina Experimental y Salud Publica2020;37(2):356-60. [DOI: 10.17843/rpmesp.2020.372.5546]">SOLIDARITY</a>; <a href="./references#CD013825-bbs2-0132" title="NCT04826588. Randomised evaluation of COVID-19 therapy (RECOVERY) in children with PIMS-TS in Switzerland (SWISSPED-RECOVERY). clinicaltrials.gov/ct2/show/NCT04826588. ">SWISSPED‐RECOVERY</a>; <a href="./references#CD013825-bbs2-0133" title="NCT04393246. Multi-arm therapeutic study in pre-ICU patients admitted with COVID-19 - experimental drugs and mechanisms. clinicaltrials.gov/ct2/show/NCT04393246 (first received 19 May 2020). ">TACTIC‐E</a>; <a href="./references#CD013825-bbs2-0134" title="KulkarniS , FiskM , KostapanosM , Banham-HallE , BondS , Hernan-SanchoE , et al. Repurposed immunomodulatory drugs for COVID-19 in pre-ICU patients - multi-arm therapeutic study in pre-ICU patients admitted with COVID-19 - repurposed drugs (TACTIC-R): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):626. [DOI: 10.1186/s13063-020-04535-4]NCT04390464. Multi-arm therapeutic study in pre-ICU patients admitted with COVID-19 - repurposed drugs (TACTIC-R). clinicaltrials.gov/ct2/show/NCT04390464 (first received 15 May 2020). ">TACTIC‐R</a>; <a href="./references#CD013825-bbs2-0135" title="PACTR202007700757139. TOGETHER 3 trial. COVID-19. pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12194 (first received 14 July 2020). ">TOGETHER‐3</a>; <a href="./references#CD013825-bbs2-0136" title="NCT04445467. An adaptive clinical trial of antivirals for COVID-19 infection (VIRCO). clinicaltrials.gov/ct2/show/NCT04445467 (first received 24 June 2020). ">VIRCO</a>). For regular tracking, we decided to list them under the <a href="./references#CD013825-bbs1-0003" title="">Studies awaiting classification</a> section. </p> </section> </section> <section id="CD013825-sec-0063"> <h4 class="title">Excluded studies</h4> <section id="CD013825-sec-0064"> <h5 class="title">Tracking of SARS‐CoV‐2‐specific mAbs under development</h5> <p>We excluded 27 studies (29 records) from our search on SARS‐CoV‐2‐specific mAbs because they were conducted on healthy participants; however, we listed these studies for tracking (details in <a href="./appendices#CD013825-sec-0174">Appendix 9</a>). </p> <p> <ul id="CD013825-list-0028"> <li> <p>23 RCTs (25 records) were excluded because they are being done on healthy participants (<a href="./references#CD013825-bbs2-0101" title="NCT04852978. COVID-19 study to assess immunogenicity, safety, and tolerability of Moderna mRNA-1273 vaccine administered with casirivimab+imdevimab in healthy adult volunteers. clinicaltrials.gov/ct2/show/NCT04852978. ">Track: NCT04852978</a>; <a href="./references#CD013825-bbs2-0077" title="ChiCTR2100042150. Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic profile and immunogenicity of JMB-2002 injection in Chinese healthy subjects after intravenous infusion of single dose. www.chictr.org.cn/showprojen.aspx?proj=66096. ">Track: ChiCTR2100042150</a>; <a href="./references#CD013825-bbs2-0078" title="jRCT2071200117. A phase 1 study of casavirimab and imdevimab in Japanese adult volunteers. rctportal.niph.go.jp/en/detail?trial_id=jRCT2071200117. ">Track: jRCT2071200117</a>; <a href="./references#CD013825-bbs2-0102" title="NCT04896541. Phase I double-blind, placebo-controlled study of AZD7442. https://clinicaltrials.gov/ct2/show/NCT04896541. ">Track: NCT04896541</a>; <a href="./references#CD013825-bbs2-0079" title="NCT04429529. Safety of TY027, a treatment for COVID-19, in humans. clinicaltrials.gov/ct2/show/NCT04429529 (first received 12 June 2020). ">Track: NCT04429529</a>; <a href="./references#CD013825-bbs2-0080" title="NCT04441918. Tolerability, safety, pharmacokinetic profile and immunogenicity of a recombinant humanized anti-SARS-CoV-2 monoclonal antibody (JS016) for injection in Chinese health subjects. clinicaltrials.gov/ct2/show/NCT04441918 (first received 22 June 2020). ">Track: NCT04441918</a>; <a href="./references#CD013825-bbs2-0081" title="NCT04441931. A study of LY3832479 (LY-CoV016) in healthy participants. clinicaltrials.gov/ct2/show/NCT04441931 (first received 22 June 2020). ">Track: NCT04441931</a>; <a href="./references#CD013825-bbs2-0082" title="NCT04479631. Safety, tolerability, and pharmacokinetics study of human monoclonal antibody BRII-196. clinicaltrials.gov/ct2/show/NCT04479631 (first received 21 July 2020). ">Track: NCT04479631</a>; <a href="./references#CD013825-bbs2-0083" title="NCT04479644. Safety, tolerability, and pharmacokinetics study of human monoclonal antibody BRII-198. clinicaltrials.gov/ct2/show/NCT04479644 (first received 21 July 2020). ">Track: NCT04479644</a>; <a href="./references#CD013825-bbs2-0084" title="NCT04483375. Safety, tolerability and pharmacokinetics of SCTA01, an anti-COVID-19 monoclonal antibody, in healthy Chinese subjects. clinicaltrials.gov/ct2/show/NCT04483375 (first received July 2020). ">Track: NCT04483375</a>; <a href="./references#CD013825-bbs2-0085" title="NCT04507256. Study to evaluate the safety, tolerability and pharmacokinetics of AZD7442 in healthy adults. clinicaltrials.gov/ct2/show/NCT04507256 (first received 11 August 2020). ">Track: NCT04507256</a>; <a href="./references#CD013825-bbs2-0086" title="NCT04519437. Study assessing the safety, tolerability, pharmacokinetics, and immunogenicity of repeated subcutaneous doses of anti-spike (S) SARS-CoV-2 monoclonal antibodies (REGN10933+REGN10987) in adult volunteers as related to COVID-19. clinicaltrials.gov/ct2/show/NCT04519437 (first received 19 August 2020). ">Track: NCT04519437</a>; <a href="./references#CD013825-bbs2-0087" title="NCT04525079. To evaluate the safety, tolerability and pharmacokinetics of CT-P59 in healthy subjects. clinicaltrials.gov/ct2/show/NCT04525079 (first received 25 August 2020). ">Track: NCT04525079</a>; <a href="./references#CD013825-bbs2-0088" title="NCT04532294. Safety, tolerability, pharmacokinetics, and immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody in healthy subjects. clinicaltrials.gov/ct2/show/NCT04532294 (first received 31 August 2020). ">Track: NCT04532294</a>; <a href="./references#CD013825-bbs2-0089" title="NCT04533048. A clinical study to evaluate MW33 injection. clinicaltrials.gov/ct2/show/NCT04533048 (first received 31 August 2020). ">Track: NCT04533048</a>; <a href="./references#CD013825-bbs2-0090" title="NCT04537910. A study of LY3819253 (LY-CoV555) in healthy participants. clinicaltrials.gov/ct2/show/NCT04537910 (first received 3 September 2020). ">Track: NCT04537910</a>; <a href="./references#CD013825-bbs2-0091" title="NCT04561076. Evaluate safety and pharmacokinetics of HLX70 in healthy adult volunteers. clinicaltrials.gov/ct2/show/NCT04561076 (first received 23 September 2020). ">Track: NCT04561076</a>; <a href="./references#CD013825-bbs2-0092" title="NCT04567810. Safety, tolerability, and pharmacokinetics of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) chicken egg antibody (IgY) (COVID-19). clinicaltrials.gov/ct2/show/NCT04567810 (first received 29 September 2020). ">Track: NCT04567810</a>; <a href="./references#CD013825-bbs2-0093" title="NCT04590430. Study to assess the safety, tolerability, and pharmacokinetics of HFB30132A against COVID-19 in healthy adults. clinicaltrials.gov/ct2/show/NCT04590430 (first received 19 October 2020). ">Track: NCT04590430</a>; <a href="./references#CD013825-bbs2-0094" title="NCT04592549. Study of monoclonal antibody cocktail being tested for the prevention of COVID-19 [A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, pharmacokinetics, and immunogenicity of ADM03820 in adults]. clinicaltrials.gov/ct2/show/NCT04592549 (first received 19 October 2020). ">Track: NCT04592549</a>; <a href="./references#CD013825-bbs2-0098" title="NCT04691180. A phase 1 study of human monoclonal antibodies, BRII-196 and BRII-198. clinicaltrials.gov/ct2/show/NCT04691180 (first received 31 December 2020). [CLINICALTRIALS.GOV: NCT04691180] ">Track: NCT04691180</a>; <a href="./references#CD013825-bbs2-0099" title="NCT04700163. RU anti-SARS-CoV-2 mAbs in healthy volunteers. clinicaltrials.gov/ct2/show/NCT04700163 (first received 7 January 2021). ">Track: NCT04700163</a>; <a href="./references#CD013825-bbs2-0103" title="NCT04932850. Study to evaluate the safety and concentrations of monoclonal antibody against virus that causes COVID-19 disease. clinicaltrials.gov/ct2/show/NCT04932850. ">Track: NCT04932850</a>) </p> </li> <li> <p>4 studies (4 records) are non‐randomised studies (<a href="./references#CD013825-bbs2-0096" title="NCT04617535. Compassionate use of REGN-COV2 for the treatment of COVID-19. clinicaltrials.gov/ct2/show/NCT04617535 (first received 5 November 2020). ">Track: NCT04617535</a>; <a href="./references#CD013825-bbs2-0100" title="NCT04701658. A real world study of bamlanivimab in participants with mild-to-moderate coronavirus disease 2019 (COVID-19). clinicaltrials.gov/ct2/show/NCT04701658 (first received 8 January 2021). ">Track: NCT04701658</a>; <a href="./references#CD013825-bbs2-0095" title="NCT04603651. Expanded access program to provide bamlanivimab (LY3819253) for the treatment of COVID-19. clinicaltrials.gov/ct2/show/NCT04603651 (first received 27 October 2020). ">Track: NCT04603651</a>; <a href="./references#CD013825-bbs2-0097" title="NCT04656691. At-home infusion using bamlanivimab in participants with mild to moderate COVID-19 (UNITED). clinicaltrials.gov/ct2/show/NCT04656691. ">Track: NCT04656691</a>) </p> </li> </ul> </p> <section id="CD013825-sec-0065"> <h6 class="title">Randomised controlled trials in healthy participants</h6> <p>The 23 RCTs on healthy participants examined 19 different mAbs or mAb combinations (ADM03820, anti‐SARS‐CoV‐2 chicken egg IgY, AZD7442, bamlanivimab, BGB‐DXP593, BRII‐196, BRII‐196/BRII‐199, BRII‐198, casirivimab/imdevimab, CT‐P59, C144‐LS/C‐135‐LS, etesevimab, HFB30132A, HLX70, JMB2002, MW33, SCTA01, TY027, MAD0004J08). Studies planned to include between 16 and 974 participants. All except ADM03820, anti‐SARS‐CoV‐2 chicken egg IgY, HFB30132A, JMB2002, and HLX70 are also being investigated in infected individuals (<a href="./appendices#CD013825-sec-0174">Appendix 9</a>). </p> <p> <div class="table" id="CD013825-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Year of completion</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2020</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (<a href="./references#CD013825-bbs2-0080" title="NCT04441918. Tolerability, safety, pharmacokinetic profile and immunogenicity of a recombinant humanized anti-SARS-CoV-2 monoclonal antibody (JS016) for injection in Chinese health subjects. clinicaltrials.gov/ct2/show/NCT04441918 (first received 22 June 2020). ">Track: NCT04441918</a>; <a href="./references#CD013825-bbs2-0081" title="NCT04441931. A study of LY3832479 (LY-CoV016) in healthy participants. clinicaltrials.gov/ct2/show/NCT04441931 (first received 22 June 2020). ">Track: NCT04441931</a>; <a href="./references#CD013825-bbs2-0087" title="NCT04525079. To evaluate the safety, tolerability and pharmacokinetics of CT-P59 in healthy subjects. clinicaltrials.gov/ct2/show/NCT04525079 (first received 25 August 2020). ">Track: NCT04525079</a>; <a href="./references#CD013825-bbs2-0089" title="NCT04533048. A clinical study to evaluate MW33 injection. clinicaltrials.gov/ct2/show/NCT04533048 (first received 31 August 2020). ">Track: NCT04533048</a>; <a href="./references#CD013825-bbs2-0090" title="NCT04537910. A study of LY3819253 (LY-CoV555) in healthy participants. clinicaltrials.gov/ct2/show/NCT04537910 (first received 3 September 2020). ">Track: NCT04537910</a>; <a href="./references#CD013825-bbs2-0092" title="NCT04567810. Safety, tolerability, and pharmacokinetics of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) chicken egg antibody (IgY) (COVID-19). clinicaltrials.gov/ct2/show/NCT04567810 (first received 29 September 2020). ">Track: NCT04567810</a>; <a href="./references#CD013825-bbs2-0084" title="NCT04483375. Safety, tolerability and pharmacokinetics of SCTA01, an anti-COVID-19 monoclonal antibody, in healthy Chinese subjects. clinicaltrials.gov/ct2/show/NCT04483375 (first received July 2020). ">Track: NCT04483375</a>), of these, 5 show completed but without results </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (<a href="./references#CD013825-bbs2-0077" title="ChiCTR2100042150. Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic profile and immunogenicity of JMB-2002 injection in Chinese healthy subjects after intravenous infusion of single dose. www.chictr.org.cn/showprojen.aspx?proj=66096. ">Track: ChiCTR2100042150</a><a href="./references#CD013825-bbs2-0079" title="NCT04429529. Safety of TY027, a treatment for COVID-19, in humans. clinicaltrials.gov/ct2/show/NCT04429529 (first received 12 June 2020). ">Track: NCT04429529</a>; <a href="./references#CD013825-bbs2-0082" title="NCT04479631. Safety, tolerability, and pharmacokinetics study of human monoclonal antibody BRII-196. clinicaltrials.gov/ct2/show/NCT04479631 (first received 21 July 2020). ">Track: NCT04479631</a>; <a href="./references#CD013825-bbs2-0083" title="NCT04479644. Safety, tolerability, and pharmacokinetics study of human monoclonal antibody BRII-198. clinicaltrials.gov/ct2/show/NCT04479644 (first received 21 July 2020). ">Track: NCT04479644</a>; <a href="./references#CD013825-bbs2-0085" title="NCT04507256. Study to evaluate the safety, tolerability and pharmacokinetics of AZD7442 in healthy adults. clinicaltrials.gov/ct2/show/NCT04507256 (first received 11 August 2020). ">Track: NCT04507256</a>; <a href="./references#CD013825-bbs2-0086" title="NCT04519437. Study assessing the safety, tolerability, pharmacokinetics, and immunogenicity of repeated subcutaneous doses of anti-spike (S) SARS-CoV-2 monoclonal antibodies (REGN10933+REGN10987) in adult volunteers as related to COVID-19. clinicaltrials.gov/ct2/show/NCT04519437 (first received 19 August 2020). ">Track: NCT04519437</a>; <a href="./references#CD013825-bbs2-0088" title="NCT04532294. Safety, tolerability, pharmacokinetics, and immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody in healthy subjects. clinicaltrials.gov/ct2/show/NCT04532294 (first received 31 August 2020). ">Track: NCT04532294</a>; <a href="./references#CD013825-bbs2-0091" title="NCT04561076. Evaluate safety and pharmacokinetics of HLX70 in healthy adult volunteers. clinicaltrials.gov/ct2/show/NCT04561076 (first received 23 September 2020). ">Track: NCT04561076</a>; <a href="./references#CD013825-bbs2-0093" title="NCT04590430. Study to assess the safety, tolerability, and pharmacokinetics of HFB30132A against COVID-19 in healthy adults. clinicaltrials.gov/ct2/show/NCT04590430 (first received 19 October 2020). ">Track: NCT04590430</a>; <a href="./references#CD013825-bbs2-0094" title="NCT04592549. Study of monoclonal antibody cocktail being tested for the prevention of COVID-19 [A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, pharmacokinetics, and immunogenicity of ADM03820 in adults]. clinicaltrials.gov/ct2/show/NCT04592549 (first received 19 October 2020). ">Track: NCT04592549</a>; <a href="./references#CD013825-bbs2-0098" title="NCT04691180. A phase 1 study of human monoclonal antibodies, BRII-196 and BRII-198. clinicaltrials.gov/ct2/show/NCT04691180 (first received 31 December 2020). [CLINICALTRIALS.GOV: NCT04691180] ">Track: NCT04691180</a>) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (<a href="./references#CD013825-bbs2-0101" title="NCT04852978. COVID-19 study to assess immunogenicity, safety, and tolerability of Moderna mRNA-1273 vaccine administered with casirivimab+imdevimab in healthy adult volunteers. clinicaltrials.gov/ct2/show/NCT04852978. ">Track: NCT04852978</a>; <a href="./references#CD013825-bbs2-0102" title="NCT04896541. Phase I double-blind, placebo-controlled study of AZD7442. https://clinicaltrials.gov/ct2/show/NCT04896541. ">Track: NCT04896541</a>; <a href="./references#CD013825-bbs2-0099" title="NCT04700163. RU anti-SARS-CoV-2 mAbs in healthy volunteers. clinicaltrials.gov/ct2/show/NCT04700163 (first received 7 January 2021). ">Track: NCT04700163</a>; <a href="./references#CD013825-bbs2-0103" title="NCT04932850. Study to evaluate the safety and concentrations of monoclonal antibody against virus that causes COVID-19 disease. clinicaltrials.gov/ct2/show/NCT04932850. ">Track: NCT04932850</a>) </p> </td> </tr> </tbody> </table> </div> </p> <p>One study did not report a planned completion date.</p> </section> <section id="CD013825-sec-0066"> <h6 class="title">Non‐randomised studies</h6> <p>All four non‐randomised studies are US‐based prospective cohorts or expanded access studies that investigate single dose infusions (IV) of mAbs or mAb combinations in outpatients; three of these in participants with risk factors (<a href="./references#CD013825-bbs2-0100" title="NCT04701658. A real world study of bamlanivimab in participants with mild-to-moderate coronavirus disease 2019 (COVID-19). clinicaltrials.gov/ct2/show/NCT04701658 (first received 8 January 2021). ">Track: NCT04701658</a>; <a href="./references#CD013825-bbs2-0095" title="NCT04603651. Expanded access program to provide bamlanivimab (LY3819253) for the treatment of COVID-19. clinicaltrials.gov/ct2/show/NCT04603651 (first received 27 October 2020). ">Track: NCT04603651</a>; <a href="./references#CD013825-bbs2-0096" title="NCT04617535. Compassionate use of REGN-COV2 for the treatment of COVID-19. clinicaltrials.gov/ct2/show/NCT04617535 (first received 5 November 2020). ">Track: NCT04617535</a>). </p> <p><a href="./references#CD013825-bbs2-0100" title="NCT04701658. A real world study of bamlanivimab in participants with mild-to-moderate coronavirus disease 2019 (COVID-19). clinicaltrials.gov/ct2/show/NCT04701658 (first received 8 January 2021). ">Track: NCT04701658</a> provides bamlanivimab (IV) and will compare the treatment with matched controls for their primary outcome hospitalisation or death by day 29. Completion is planned for June 2021 with 3000 participants. <a href="./references#CD013825-bbs2-0095" title="NCT04603651. Expanded access program to provide bamlanivimab (LY3819253) for the treatment of COVID-19. clinicaltrials.gov/ct2/show/NCT04603651 (first received 27 October 2020). ">Track: NCT04603651</a> provides expanded access to bamlanivimab (IV), however, expanded access is no longer available according to clinicaltrials.gov. <a href="./references#CD013825-bbs2-0097" title="NCT04656691. At-home infusion using bamlanivimab in participants with mild to moderate COVID-19 (UNITED). clinicaltrials.gov/ct2/show/NCT04656691. ">Track: NCT04656691</a> provided at‐home infusions of bamlanivimab by registered nurses and examines the frequency of hospitalisations and safety in 4000 participants (study completed according to clinicaltrials.gov). <a href="./references#CD013825-bbs2-0096" title="NCT04617535. Compassionate use of REGN-COV2 for the treatment of COVID-19. clinicaltrials.gov/ct2/show/NCT04617535 (first received 5 November 2020). ">Track: NCT04617535</a> provides expanded access to casirivimab/imdevimab (IV), no further information regarding sample size or outcomes is reported. </p> <p> </p> </section> </section> <section id="CD013825-sec-0067"> <h5 class="title">Excluded studies</h5> <p>From the main search, we excluded 94 records (26 press releases and 48 studies) that did not match our inclusion criteria (<a href="#CD013825-fig-0002">Figure 2</a>): </p> <p> <ul id="CD013825-list-0029"> <li> <p>7 studies (17 records) investigated mAbs as prevention of SARS‐CoV‐2 infection (<a href="./references#CD013825-bbs2-0025" title="NCT04497987. A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in preventing SARS-CoV-2 infection and COVID-19 in nursing home residents and staff (BLAZE-2). clinicaltrials.gov/ct2/show/NCT04497987 (first received 4 August 2020). ">BLAZE‐2</a>; <a href="./references#CD013825-bbs2-0052" title="NCT04452318. Study assessing the efficacy and safety of anti-spike SARS CoV-2 monoclonal antibodies for prevention of SARS CoV-2 infection asymptomatic in healthy adults who are household contacts to an individual with a positive SARS-CoV-2 RT-PCR assay. clinicaltrials.gov/ct2/show/NCT04452318 (first received 30 June 2020). ">NCT04452318</a>; <a href="./references#CD013825-bbs2-0065" title="NCT04625725. Phase III double-blind, placebo-controlled study of AZD7442 for pre-exposure prophylaxis of COVID-19 in adult. clinicaltrials.gov/ct2/show/NCT04625725 (first received 12 November 2020). ">NCT04625725</a>; <a href="./references#CD013825-bbs2-0076" title="NCT04625972. Phase III double-blind, placebo-controlled study of AZD7442 for post- exposure prophylaxis of COVID-19 in adults (STORM CHASER). clinicaltrials.gov/show/NCT04625972 (first received 12 November 2020). ">STORM CHASER</a>; <a href="./references#CD013825-bbs2-0068" title="NCT04859517. Evaluation of ADG20 for the prevention of COVID-19. clinicaltrials.gov/show/NCT04859517. ">NCT04859517</a>; <a href="./references#CD013825-bbs2-0069" title="NCT04894474. A study to test whether BI 767551 can prevent COVID-19 in people who have been exposed to SARS-CoV-2. clinicaltrials.gov/show/NCT04894474. ">NCT04894474</a>) or mAb fragments (<a href="./references#CD013825-bbs2-0060" title="NCT04514302. Safety and efficacy of anti-SARS-CoV-2 equine antibody fragments (INOSARS) for hospitalized patients with COVID-19. clinicaltrials.gov/show/NCT04514302 (first received 14 August 2020). ">NCT04514302</a>); </p> </li> <li> <p>2 studies (3 records) were no longer available in the study registry (<a href="./references#CD013825-bbs2-0067" title="NCT04766671. An exploratory study to describe virological effect, safety, and pharmacokinetics of VIR-7831 monoclonal antibody in hospitalized participants with COVID-19. inclinicaltrials.com/covid-19/NCT04766671/. ">NCT04766671</a>; <a href="./references#CD013825-bbs2-0054" title="NCT04454398. A randomized placebo-controlled study to evaluate STI-1499 (COVI-GUARD) in hospitalized patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04454398 (first received 1 July 2020). ">NCT04454398</a>); </p> </li> <li> <p>20 studies (25 records) with irrelevant interventions (9 studies not SARS‐CoV‐2‐specific mAb: <a href="./references#CD013825-bbs2-0039" title="EUDRACT2020-002713-17. A study to evaluate the safety and efficacy of MSTT1041A or UTTR1147A in patients with severe COVID-19 pneumonia. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002713-17 (first received 13 July 2020). ">EUDRACT2020‐002713‐17</a>; <a href="./references#CD013825-bbs2-0040" title="NCT04371367. Avdoralimab an anti-C5aR antibody, in patients with COVID-19 severe pneumonia. clinicaltrials.gov/show/NCT04371367 (first received 1 May 2020). ">FORCE</a>; <a href="./references#CD013825-bbs2-0046" title="NCT04275245. Clinical study of anti-CD147 humanized meplazumab for injection to treat with 2019-nCoV pneumonia. ClinicalTrials.gov/show/NCT04275245 (first received 19 February 2020). ">NCT04275245</a>; <a href="./references#CD013825-bbs2-0047" title="NCT04341116. Study of TJ003234 (anti-GM-CSF monoclonal antibody) in subjects with severe coronavirus disease 2019 (COVID-19). clinicaltrials.gov/show/NCT04341116 (first received 10 April 2020). ">NCT04341116</a>; <a href="./references#CD013825-bbs2-0049" title="NCT04369469. Efficacy and safety study of IV ravulizumab in patients with COVID-19 severe pneumonia. clinicaltrials.gov/show/NCT04369469 (first received 30 April 2020). ">NCT04369469</a>; <a href="./references#CD013825-bbs2-0051" title="NCT04415073. A phase 2 study to evaluate axatilimab for hospitalized patients with respiratory involvement secondary to COVID-19. clinicaltrials.gov/show/NCT04415073 (first received 4 June 2020). ">NCT04415073</a>; <a href="./references#CD013825-bbs2-0056" title="NCT04494724. Clazakizumab vs. placebo - COVID-19 infection. clinicaltrials.gov/show/NCT04494724 (first received 31 July 2020). ">NCT04494724</a>; <a href="./references#CD013825-bbs2-0061" title="A study of AK119 (anti-CD73 antibody), a treatment for COVID-19, in healthy subjects. clinicaltrials.gov/show/NCT04516564 (first received 18 August 2020). ">NCT04516564</a>; <a href="./references#CD013825-bbs2-0064" title="NCT04586153. Study to assess the effect of meplazumab on COVID-19. clinicaltrials.gov/show/NCT04586153 (first received 14 October 2020). ">NCT04586153</a>; 2 studies polyclonal Abs: <a href="./references#CD013825-bbs2-0053" title="NCT04453384. Study to evaluate the safety and efficacy of XAV-19 in patients with COVID-19 induced moderate pneumonia. clinicaltrials.gov/show/NCT04453384 (first received 1 July 2020). ">NCT04453384</a>; <a href="./references#CD013825-bbs2-0055" title="NCT04469179. Safety, tolerability, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19. clinicaltrials.gov/ct2/show/NCT04469179 (first received 13 July 2020). ">NCT04469179</a>; 9 studies other interventions: <a href="./references#CD013825-bbs2-0028" title="NCT04602260. Functional recovery of hospitalised patients with COVID-19: the COREG extension study. clinicaltrials.gov/show/NCT04602260 (first received 26 October 2020). ">COREG</a>; <a href="./references#CD013825-bbs2-0029" title="DuvignaudA , LhommeE , PistoneT , OnaisiR , SittaR , JournotV , et al. Home treatment of older people with symptomatic SARS-CoV-2 infection (COVID-19): a structured summary of a study protocol for a multi-arm multi-stage (MAMS) randomized trial to evaluate the efficacy and tolerability of several experimental treatments to reduce the risk of hospitalisation or death in outpatients aged 65 years or older (COVERAGE trial). Trials2020;21(1):846. NCT04356495. Treatments to decrease the risk of hospitalization or death in elderly outpatients with symptomatic SARS-CoV-2 infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04356495 (first received 22 April 2020). ">COVERAGE</a>; <a href="./references#CD013825-bbs2-0033" title="NCT04534725. COVID-19 prevention and treatment in cancer; a sequential multiple assignment randomised trial. clinicaltrials.gov/show/NCT04534725 (first received 1 September 2020). ">C‐SMART</a>; <a href="./references#CD013825-bbs2-0045" title="NCT04382651. Study of efficacy and safety of MAS825 in patients with COVID-19 (MAS-COVID). clinicaltrials.gov/ct2/show/NCT04382651 (first received 11 May 2020). ">MAS‐COVID</a>; <a href="./references#CD013825-bbs2-0053" title="NCT04453384. Study to evaluate the safety and efficacy of XAV-19 in patients with COVID-19 induced moderate pneumonia. clinicaltrials.gov/show/NCT04453384 (first received 1 July 2020). ">NCT04453384</a>; <a href="./references#CD013825-bbs2-0057" title="NCT04494984. A study to investigate the pharmacokinetics, efficacy and safety of INM005 in patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04494984 (first received 31 July 2020). ">NCT04494984</a>; <a href="./references#CD013825-bbs2-0062" title="Dose ranging trial to assess safety and immunogenicity of V590 (COVID-19 vaccine) in healthy adults (V590-001). clinicaltrials.gov/show/NCT04569786 (first received 30 September 2020). ">NCT04569786</a>; <a href="./references#CD013825-bbs2-0063" title="NCT04574869. A study of RLS-0071 in patients with acute lung injury due to COVID-19 pneumonia in early respiratory failure. clinicaltrials.gov/ct2/show/NCT04574869 (first received 5 October 2020). ">NCT04574869</a>; <a href="./references#CD013825-bbs2-0070" title="NCT04333420. Randomized, controlled study of IFX-1 in patients with severe COVID-19 pneumonia (PANAMO). clinicaltrials.gov/ct2/show/NCT04333420 (first received 3 April 2020). ">PANAMO</a>); </p> </li> <li> <p>16 studies (16 records) with ineligible study design (<a href="./references#CD013825-bbs2-0026" title="ChiCTR2000030012. Development of anti-2019-nCoV therapeutic antibody from the recovered novel coronavirus pneumonia patients (COVID-19). www.chictr.org.cn/showproj.aspx?proj=49718 (first received 19 February 2020). ">ChiCTR2000030012</a>; <a href="./references#CD013825-bbs2-0035" title="DhandA , LoboSA , WolfeK , FeolaN , NaborsC . Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: early single-center experience. Clinical Transplantation2021;35(4):00:e14245. [DOI: 10.1111/ctr.14245]">Dhand 2021a</a>; <a href="./references#CD013825-bbs2-0037" title="DongJ , ZostSJ , GreaneyAJ , StarrTN , DingensAS , ChenEC , et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv [Preprint]2021. [DOI: 10.1101/2021.01.27.428529]">Dong 2021</a>; <a href="./references#CD013825-bbs2-0020" title="AlamMM , MahmudS , AggarwalS , FathmaS , Al MahiN , ShibliMS , et al. Clinical impact of the early use of monoclonal antibody LY-CoV555 (bamlanivimab) on mortality and hospitalization among elderly nursing home patients: a multicenter retrospective study. Cureus2021;13(5):e14933. [DOI: 10.7759/cureus.14933]">Alam 2021</a>; <a href="./references#CD013825-bbs2-0023" title="BariolaJR , McCrearyEK , WadasRJ , KipKE , MarroquinOC , MinnierT , et al. Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection. Open Forum Infectious Diseases2021;8(7):ofab254. [DOI: 10.1093/ofid/ofab254]">Bariola 2021</a>; <a href="./references#CD013825-bbs2-0024" title="BeamE , Destro BorgenMJ , RazonableRR . Infection prevention and control considerations for safe outpatient monoclonal antibody infusions in patients with coronavirus disease 2019 (COVID-19). Infection Control &amp; Hospital Epidemiology2021;-:1-2. [DOI: 10.1017/ice.2021.106]">Beam 2021</a>; <a href="./references#CD013825-bbs2-0027" title="CohenMS , WohlDA , FischerWA , SmithDJ , EronJJ . Outpatient treatment of SARS-CoV-2 infection to prevent COVID-19 progression. Clinical Infectious Diseases2021;-:ciab494. [DOI: 10.1093/cid/ciab494]">Cohen 2021</a>; <a href="./references#CD013825-bbs2-0034" title="DaleAP , HudsonM , CullenT , EllingsonK , DavisK , ArmentaD , et al. Administration of bamlanivimab to skilled nursing facility residents during a COVID-19 outbreak, January-February 2021, Arizona. Journal of the American Medical Directors Association2021;S1525-8610(21):00422-9. [DOI: 10.1016/j.jamda.2021.04.023]">Dale 2021</a>; <a href="./references#CD013825-bbs2-0036" title="DhandA , LoboSA , WolfeK , FeolaN , LeeL , NogR , et al. Casirivimab-imdevimab for treatment of COVID-19 in solid organ transplant recipients: an early experience. Transplantation2021;105(7):e68-e69. [DOI: 10.1097/TP.0000000000003737]">Dhand 2021b</a>; <a href="./references#CD013825-bbs2-0041" title="GaneshR , PawlowskiC , O'HoroJC , ArndtLL , ArndtR , BellSJ , et al. Association of intravenous bamlanivimab use with reduced hospitalization, intensive care unit admission, and mortality in patients with mild to moderate COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.23.21257670]">Ganesh 2021</a>; <a href="./references#CD013825-bbs2-0043" title="KarrE , ChungT , BurtsonK , MarkertR , KellyD . Bamlanivimab use in a military treatment facility. Military Medicine2021;-:usab188. [DOI: 10.1093/milmed/usab188]">Karr 2021</a>; <a href="./references#CD013825-bbs2-0044" title="KutzlerHL , KuzaroHA , SerranoOK , FeingoldA , MorganG , CheemaF , et al. Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients. Transplant Infectious Disease2021;-:e13662. [DOI: 10.1111/tid.13662]">Kutzler 2021</a>; <a href="./references#CD013825-bbs2-0073" title="Rainwater-LovettK , ReddJT , StewartMA , CallesNE , CluffT , FangM , et al. Real-world effect of monoclonal antibody treatment in COVID-19 patients in a diverse population in the United States. medRxiv [Preprint]2021. [DOI: 10.1101/2021.04.08.21254705]">Rainwater‐Lovett 2021</a>; <a href="./references#CD013825-bbs2-0075" title="ShirkS , KerrD , SaraceniC , HandG , TerrenziM , McDermottA , et al. The challenging but imperative path to monoclonal antibody use against COVID-19 for a small overseas military hospital. Military Medicine2021;-:usab193. [DOI: 10.1093/milmed/usab193]">Shirk 2021</a>; <a href="./references#CD013825-bbs2-0104" title="WebbBJ , Buckel W, VentoT , ButlerAM , GriselN , BrownSM , et al. Real-world effectiveness and tolerability of monoclonal antibodies for ambulatory patients with early COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.03.15.21253646]">Webb 2021</a>; <a href="./references#CD013825-bbs2-0105" title="YangX , PanY , SongG , WangJ , ZhanS , WuX , et al. Anti-SARS-CoV-2 monoclonal antibody 1E10. www.lens.org/lens/patent/147-382-786-055-6412020. [EPISTEMONIKOS ID: 563468dd70e91a939051abfc89e7d250ead2636a]">Yang 2020</a>); </p> </li> <li> <p>3 studies (7 records) were duplicates;</p> </li> <li> <p>26 press releases of included or ongoing studies.</p> </li> </ul> </p> <p>From the platform trial search, we excluded 20 studies (27 records) for the following reasons (<a href="#CD013825-fig-0002">Figure 2</a>): </p> <p> <ul id="CD013825-list-0030"> <li> <p>5 platform trials (5 records) explored treatments for prevention of SARS‐CoV‐2 or other drug classes only (<a href="./references#CD013825-bbs2-0016" title="NCT04505774. Anti-thrombotics for adults hospitalized with COVID-19 (ACTIV-4). clinicaltrials.gov/ct2/show/NCT04505774 (first received 10 August 2020). ">ACTIV‐4</a>; <a href="./references#CD013825-bbs2-0030" title="NCT04561063. COVID-19 prophylaxis South Africa (COVER HCW). clinicaltrials.gov/ct2/show/NCT04561063 (first received 23 September 2020). ">COVER HCW</a>; <a href="./references#CD013825-bbs2-0032" title="NCT04333732. Crown coronation: COVID-19 research outcomes worldwide network for CORONAvirus prevention (CROWN CORONA). clinicaltrials.gov/ct2/show/NCT04333732 (first received 3 April 2020). ">CROWN CORONA</a>; <a href="./references#CD013825-bbs2-0059" title="NCT04498273. COVID-19 positive outpatient thrombosis prevention in adults aged 40-80. clinicaltrials.gov/ct2/show/NCT04498273 (first received 4 August 2020). ">NCT04498273</a>; <a href="./references#CD013825-bbs2-0072" title="NCT04621149. An outpatient study investigating non-prescription treatments for COVID-19 (PROFACT-01). clinicaltrials.gov/ct2/show/NCT04621149 (first received 9 November 2020). ">PROFACT‐01</a>); </p> </li> <li> <p>9 studies (13 records) did not plan to add treatment arms (<a href="./references#CD013825-bbs2-0021" title="EUCTR2020-001854-23. A study with immunotherapy for moderate COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001854-23/IT (first received 26 June 2020). ">AMMURAVID</a>; <a href="./references#CD013825-bbs2-0022" title="ACTRN12620000445976. Australasian COVID-19 trial: an adaptive platform trial (ASCOT-ADAPT). A multi-centre randomised adaptive platform clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19). anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620000445976 (first received 2 April 2020). NCT04483960. Australasian COVID-19 trial (ASCOT) adaptive platform trial. clinicaltrials.gov/ct2/show/NCT04483960 (first received 23 July 2020). ">ASCOT‐ADAPT</a>; <a href="./references#CD013825-bbs2-0029" title="DuvignaudA , LhommeE , PistoneT , OnaisiR , SittaR , JournotV , et al. Home treatment of older people with symptomatic SARS-CoV-2 infection (COVID-19): a structured summary of a study protocol for a multi-arm multi-stage (MAMS) randomized trial to evaluate the efficacy and tolerability of several experimental treatments to reduce the risk of hospitalisation or death in outpatients aged 65 years or older (COVERAGE trial). Trials2020;21(1):846. NCT04356495. Treatments to decrease the risk of hospitalization or death in elderly outpatients with symptomatic SARS-CoV-2 infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04356495 (first received 22 April 2020). ">COVERAGE</a>; <a href="./references#CD013825-bbs2-0031" title="EUCTR2020-001303-16-FR. Efficacy of hydroxychloroquine, telmisartan and azithromycin on survival in elderly hospitalized patients with VIDOC-19: a randomized, multi-centre, adaptive, blinded study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001303-16/FR (first received 29 March 2020). ">COVID_Aging</a>; <a href="./references#CD013825-bbs2-0033" title="NCT04534725. COVID-19 prevention and treatment in cancer; a sequential multiple assignment randomised trial. clinicaltrials.gov/show/NCT04534725 (first received 1 September 2020). ">C‐SMART</a>; <a href="./references#CD013825-bbs2-0042" title="jRCT2031190264. A multicenter, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults. jrct.niph.go.jp/latest-detail/jRCT20311902642020. ">jRCT2031190264</a>; <a href="./references#CD013825-bbs2-0066" title="NCT04629703. Double-blind, randomized, placebo-controlled, adaptive design, multi-center phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects. clinicaltrials.gov/ct2/show/NCT04629703 (first received 16 November 2020). ">NCT04629703</a>; <a href="./references#CD013825-bbs2-0071" title="EUCTR2020-001782-37-SK. A multi-centre, adaptive, randomized, double-blind, placebo-controlled comparative clinical study of the safety and efficacy of 12 mg Polyoxidonium®, lyophilizate solution for injections (NPO Petrovax Pharm LLC, Russia) in patients with coronavirus disease (COVID-19). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001782-37/SK (first received 15 June 2020). ">PO‐COV‐III‐20</a>; <a href="./references#CD013825-bbs2-0074" title="EUCTR2020-002120-37-GB. An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301+SOC vs SOC in hospitalized participants with COVID-19 requiring supplemental oxygen. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001072-15/GB (first received 19 March 2020). ">RESP301‐002</a>); </p> </li> <li> <p>6 platform trials (in 9 records) were completed without having added a mAb (<a href="./references#CD013825-bbs2-0017" title="Euctr2020-001052-18-de. A multicenter, adaptive, randomised blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults - version for European Union/United Kingdom sites. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/DK (first received 20 March 2020). GaliutoL , PatronoC . Conflicting results on the efficacy of remdesivir in hospitalized COVID-19 patients: comment on the adaptive COVID-19 treatment trial. European Heart Journal2020;41(46):4387-8. ISRCTN13035264. Adaptive COVID-19 treatment trial in the EU &amp; UK. www.isrctn.com/ISRCTN13035264 (first received 11 July 2020). NCT04280705. Adaptive COVID-19 treatment trial. clinicaltrials.gov/ct2/show/NCT04280705 (first received 25 September 2020). ">ACTT</a>; <a href="./references#CD013825-bbs2-0018" title="NCT04401579. Adaptive COVID-19 treatment trial 2 (ACTT-II). clinicaltrials.gov/ct2/show/NCT04401579 (first received 26 May 2020). ">ACTT‐2</a>; <a href="./references#CD013825-bbs2-0019" title="NCT04492475. Adaptive COVID-19 treatment trial 3 (ACTT-3). clinicaltrials.gov/ct2/show/NCT04492475 (first received 30 July 2020). ">ACTT‐3</a>; <a href="./references#CD013825-bbs2-0038" title="EUCTR2020-001243-15-BE. COVID-19: a randomized, open-label, adaptive, proof-of-concept clinical trial of new antiviral drug candidates against SARS-CoV-2. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001243-15/BE (first received 27 March 2020). ">EUCTR2020‐001243‐15‐BE</a>; <a href="./references#CD013825-bbs2-0048" title="NCT04354428. Treatment for SARS-CoV-2 in high-risk adult outpatients. clinicaltrials.gov/ct2/show/NCT04354428 (first received 21 April 2020). ">NCT04354428</a>; <a href="./references#CD013825-bbs2-0050" title="NCT04370262. Multi-site adaptive trials for COVID-19. clinicaltrials.gov/ct2/show/NCT04370262 (first received 30 April 2020). ">NCT04370262</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD013825-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD013825-sec-0069"> <h4 class="title">Risk of bias in randomised controlled trials</h4> <p>We assessed methodological quality and risk of bias for each comparison and outcome of the six RCTs (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>; <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>; <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>) that provided outcomes relevant for this review using the Risk of Bias 2.0 (RoB 2) tool (<a href="./references#CD013825-bbs2-0252" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweN , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898. [DOI: 10.1136/bmj.l4898]">Sterne 2019</a>), recommended in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013825-bbs2-0205" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2021c</a>)<i>.</i> Since there were separate publications as preprints on phases 1 to 2 (<a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>) and phase 3 (<a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>) for the Weinreich study, we assessed risk of bias separately for the relevant outcomes provided. </p> <p>Please refer to the risk of bias table section after the 'Characteristics of studies' section for more detailed information on the risk of bias assessments for each outcome. The completed RoB 2 tool with responses to all assessed signalling questions is available online at: <a href="https://zenodo.org/record/5159915#.YQq7pYgzY2w" target="_blank">https://zenodo.org/record/5159915#.YQq7pYgzY2w</a>. </p> </section> <section id="CD013825-sec-0070"> <h4 class="title">Risk of bias in randomised controlled trials in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </h4> <section id="CD013825-sec-0071"> <h5 class="title">Bamlanivimab compared with placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </h5> <p>We judged the risk of bias for <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, the only study assessing bamlanivimab (LY3819253, LY‐CoV555) in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease), to be low across outcomes: all‐cause mortality up to 30 days (see <a href="./references#CD013825-tblf-0090" title="">Risk of bias table for Analysis 1.1</a>), admission to hospital or death (see <a href="./references#CD013825-tblf-0091" title="">Risk of bias table for Analysis 1.2</a>), viral clearance at days 7 and 15 (see <a href="./references#CD013825-tblf-0092" title="">Risk of bias table for Analysis 1.3</a>; <a href="./references#CD013825-tblf-0093" title="">Risk of bias table for Analysis 1.4</a>), all grades of adverse events (see <a href="./references#CD013825-tblf-0094" title="">Risk of bias table for Analysis 1.5</a>), and serious adverse events (see <a href="./references#CD013825-tblf-0095" title="">Risk of bias table for Analysis 1.6</a>). We could not assess the risk of bias for all‐cause mortality up to 60 days, clinical progression/improvement of symptoms or development of severe symptoms, length of hospital stay, admission to ICU and length of ICU stay, viral clearance at day 3, adverse events (grades 1 to 2, and grades 3 to 4), quality of life (up to7 days, 30 days and longest follow‐up), renal failure and thromboembolic events, as <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> did not report these outcomes. </p> </section> <section id="CD013825-sec-0072"> <h5 class="title">Bamlanivimab/etesevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </h5> <p>We judged the risk of bias for <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, the only study assessing the combination of bamlanivimab and etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) to be high at the study level, and thus across the outcomes (all‐cause mortality by day 30, hospital admission or death, viral clearance at days 7 and 15, all grades adverse events and serious adverse events) because the staggered start of treatment arms caused the bamlanivimab/etesevimab arm to be randomised later than the placebo arm due to adjustment of the allocation ratio. As the standard of care is evolving quickly, groups may not be comparable. We could not assess the risk of bias for all‐cause mortality up to 60 days, clinical progression/improvement of symptoms or development of severe symptoms, length of hospital stay, admission to ICU and length of ICU stay, viral clearance at day 3, adverse events (grades 1 to 2, and grades 3 to 4), quality of life (up to seven days, 30 days and longest follow‐up), renal failure and thromboembolic events, as <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> did not report these outcomes. Due to the high risk of bias, reported outcomes were not included in the analysis but reported narratively instead. </p> <p>For <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>, we judged the risk of bias to be low across the outcomes: all‐cause mortality up to 30 days (see <a href="./references#CD013825-tblf-0096" title="">Risk of bias table for Analysis 2.1</a>), admission to hospital or death (see <a href="./references#CD013825-tblf-0097" title="">Risk of bias table for Analysis 2.2</a>), length of hospital stay, viral clearance at days 3, 7, and 15 (see <a href="./references#CD013825-tblf-0098" title="">Risk of bias table for Analysis 2.3</a>; <a href="./references#CD013825-tblf-0099" title="">Risk of bias table for Analysis 2.4</a>; <a href="./references#CD013825-tblf-0100" title="">Risk of bias table for Analysis 2.5</a>), all grades adverse events (see <a href="./references#CD013825-tblf-0101" title="">Risk of bias table for Analysis 2.6</a>) and serious adverse events (see <a href="./references#CD013825-tblf-0102" title="">Risk of bias table for Analysis 2.7</a>). We could not assess the risk of bias for all‐cause mortality up to 60 days, clinical progression or development of severe symptoms, admission to ICU and length of ICU stay, viral clearance (at days 3, 7, and 15), adverse events (grades 1 to 2 and grades 3 to 4), quality of life (up to seven days, 30 days and longest follow‐up), renal failure and thromboembolic events, as <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a> did not report these outcomes. </p> </section> <section id="CD013825-sec-0073"> <h5 class="title">Casirivimab/imdevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </h5> <p>We judged the risk of bias for <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> (preprint), the only study assessing the combination of casirivimab and imdevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) to be of low risk of bias across the outcomes grades 3 to 4 adverse events (see <a href="./references#CD013825-tblf-0104" title="">Risk of bias table for Analysis 3.2</a>), and serious adverse events (see <a href="./references#CD013825-tblf-0105" title="">Risk of bias table for Analysis 3.3</a>). For the outcome hospital admission or death (see <a href="./references#CD013825-tblf-0103" title="">Risk of bias table for Analysis 3.1</a>) we judged the risk of bias to be of some concern because the statistical analysis plan and protocol were not provided with the preprint. We could not assess the risk of bias for: all‐cause mortality at up to 30 and 60 days, clinical progression/improvement of symptoms, length of hospital stay, admission to ICU and length of ICU stay, clinical progression/improvement of symptoms or development of severe symptoms, viral clearance (at days 3, 7, 15) and adverse events (all grades and grades 1 to 2), quality of life (up to seven days, 30 days and longest follow‐up), renal failure and thromboembolic events, as <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> did not report these outcomes. </p> <p>For <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> (preprint), we judged the risk of bias to be high across the outcomes: mortality by day 30, clinical progression/improvement of symptoms, admission to hospital or death, length of hospital stay, admission to ICU, adverse events (all grades and grades 3 to 4) and serious adverse events, because participants without risk factors were excluded from analysis and it was unclear which participants were included in the analysis set. More participants were missing than the ones not receiving or discontinuing treatment. Furthermore, data for participants who received casirivimab/imdevimab at a dose of 8.0 g were not reported on all relevant outcomes. We could not assess the risk of bias for all‐cause mortality at up 60 days, length of ICU stay, development of severe symptoms, viral clearance (at days 3,7 and 15) and adverse events grades 1 to 2, quality of life (up to day 7 days, 30 days and longest follow‐up), renal failure and thromboembolic events, as <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> did not report these outcomes. Due to the high risk of bias, reported outcomes were not included in the analysis but reported narratively instead. </p> </section> <section id="CD013825-sec-0074"> <h5 class="title">Sotrovimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </h5> <p>We judged the risk of bias for <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>, the only study assessing sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) to be some concerns across the outcomes: all‐cause mortality up to 30 days (see  <a href="./references#CD013825-tblf-0106" title="">Risk of bias table for Analysis 4.1</a>), development of severe symptoms according to WHO scale (see <a href="./references#CD013825-tblf-0107" title="">Risk of bias table for Analysis 4.2</a>; <a href="./references#CD013825-tblf-0108" title="">Risk of bias table for Analysis 4.3</a>), admission to hospital or death (see <a href="./references#CD013825-tblf-0109" title="">Risk of bias table for Analysis 4.4</a>), admission to ICU (see <a href="./references#CD013825-tblf-0110" title="">Risk of bias table for Analysis 4.5</a>) and for safety outcomes (adverse events (all grades and grades 3 to 4), and serious adverse events; see <a href="./references#CD013825-tblf-0111" title="">Risk of bias table for Analysis 4.6</a>; <a href="./references#CD013825-tblf-0112" title="">Risk of bias table for Analysis 4.7</a>; <a href="./references#CD013825-tblf-0113" title="">Risk of bias table for Analysis 4.8</a>), because the trial was stopped preliminary and protocol or statistical analysis plan were not available. We could not assess the risk of bias for all‐cause mortality up to 60 days, clinical progression/improvement of symptoms, length of hospital stay, length of ICU stay, viral clearance (at days 3, 7, 15), adverse events grades 1 to 2, quality of life (up to seven days, 30 days and longest follow‐up), renal failure and thromboembolic events, as <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a> did not report these outcomes.  </p> </section> </section> <section id="CD013825-sec-0075"> <h4 class="title">Regdanvimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </h4> <p>We judged the risk of bias for <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>, the only study assessing regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) to be low across the outcomes: mortality up to 30 days (see <a href="./references#CD013825-tblf-0114" title="">Risk of bias table for Analysis 5.1</a>), development of severe symptoms (see <a href="./references#CD013825-tblf-0115" title="">Risk of bias table for Analysis 5.2</a>), admission to hospital or death (see <a href="./references#CD013825-tblf-0116" title="">Risk of bias table for Analysis 5.3</a>), admission to ICU (see <a href="./references#CD013825-tblf-0117" title="">Risk of bias table for Analysis 5.4</a>) and viral clearance at day 15 (see <a href="./references#CD013825-tblf-0118" title="">Risk of bias table for Analysis 5.5</a>), and safety outcomes (adverse events all grades (see <a href="./references#CD013825-tblf-0119" title="">Risk of bias table for Analysis 5.6</a>), adverse events grades 3 to 4 (see <a href="./references#CD013825-tblf-0120" title="">Risk of bias table for Analysis 5.7</a>) and serious adverse events (see <a href="./references#CD013825-tblf-0121" title="">Risk of bias table for Analysis 5.8</a>)). We could not assess the risk of bias for all‐cause mortality up to 60 days, clinical progression/improvement of symptoms, length of hospital stay, length of ICU stay, viral clearance at days three and seven, adverse events grades 1 to 2, quality of life (up to seven days, 30 days and longest follow‐up), renal failure and thromboembolic events, as <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a> did not report these outcomes. </p> </section> <section id="CD013825-sec-0076"> <h4 class="title">Risk of bias in randomised controlled trials in hospitalised individuals with COVID‐19 (moderate to severe disease) </h4> <section id="CD013825-sec-0077"> <h5 class="title">Bamlanivimab compared to placebo in hospitalised individuals with COVID‐19 (moderate and severe disease) </h5> <p>Overall, we judged the risk of bias for <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>, the only study that assessed bamlanivimab in hospitalised individuals, to be low across outcomes: all‐cause mortality by days 30 and 90 (see <a href="./references#CD013825-tblf-0122" title="">Risk of bias table for Analysis 6.1</a>; <a href="./references#CD013825-tblf-0123" title="">Risk of bias table for Analysis 6.2</a>), clinical progression/improvement of symptoms or development of severe symptoms (see <a href="./references#CD013825-tblf-0124" title="">Risk of bias table for Analysis 6.3</a>; <a href="./references#CD013825-tblf-0125" title="">Risk of bias table for Analysis 6.4</a>), hospital discharge (time‐to‐event and at day 5; see <a href="./references#CD013825-tblf-0126" title="">Risk of bias table for Analysis 6.5</a>; <a href="./references#CD013825-tblf-0127" title="">Risk of bias table for Analysis 6.6</a>), adverse events grades 3 to 4 (see <a href="./references#CD013825-tblf-0128" title="">Risk of bias table for Analysis 6.7</a>), and serious adverse events by days 30 and 90 (see <a href="./references#CD013825-tblf-0129" title="">Risk of bias table for Analysis 6.8</a>; <a href="./references#CD013825-tblf-0130" title="">Risk of bias table for Analysis 6.9</a>), time to sustained recovery by day 90 (see <a href="./references#CD013825-tblf-0131" title="">Risk of bias table for Analysis 6.10</a>), neurological dysfunction at day 28 (transient ischemic events see <a href="./references#CD013825-tblf-0132" title="">Risk of bias table for Analysis 6.11</a>, acute delirium CVA see <a href="./references#CD013825-tblf-0133" title="">Risk of bias table for Analysis 6.12</a> and cerebrovascular event see <a href="./references#CD013825-tblf-0134" title="">Risk of bias table for Analysis 6.13</a>), thromboembolic events (see <a href="./references#CD013825-tblf-0135" title="">Risk of bias table for Analysis 6.14</a>) and renal dysfunction (see <a href="./references#CD013825-tblf-0136" title="">Risk of bias table for Analysis 6.15</a>). We noted differences in the baseline characteristics of the participants between treatment groups, but we assumed that these differences are unlikely to indicate problems with the randomisation process. We could not assess the risk of bias for the outcome quality of life (up to 7 days, 30 days and longest follow‐up), admission to ICU and length of ICU stay, viral clearance (at days three, seven, and 15), and adverse events (all grades and grades 1 to 2) as these were not reported in the study. </p> </section> <section id="CD013825-sec-0078"> <h5 class="title">Casirivimab/imdevimab compared to placebo in hospitalised individuals with COVID‐19 (moderate and severe disease) </h5> <p>We judged the risk of bias for <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>, the only study assessing casirivimab/imdevimab in hospitalised individuals to be high across the outcomes: all‐cause mortality up to 30 days (see <a href="./references#CD013825-tblf-0137" title="">Risk of bias table for Analysis 7.1</a>), development of severe symptoms according to WHO scale (see  <a href="./references#CD013825-tblf-0138" title="">Risk of bias table for Analysis 7.2</a>), hospital discharge alive by day 30 (see <a href="./references#CD013825-tblf-0139" title="">Risk of bias table for Analysis 7.3</a>), thromboembolic events (see <a href="./references#CD013825-tblf-0140" title="">Risk of bias table for Analysis 7.4</a>) and renal dysfunction (need for dialysis) (see <a href="./references#CD013825-tblf-0141" title="">Risk of bias table for Analysis 7.5</a>), because of the open‐label design of the study control group participants may have received concomitant treatment more quickly. We could not assess the risk of bias for the outcomes: all‐cause mortality at up to 60 days, clinical progression/improvement of symptoms, quality of life (up to seven days, 30 days, and longest follow‐up), safety outcomes (adverse events (all grades, grades 1 to 2, grades 3 to 4) and serious adverse events), length of hospital stay, admission to ICU, length of ICU stay, viral clearance (at days 3, 7, 15), time to sustained recovery, and neurologic dysfunction, as <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> did not report these outcomes. </p> </section> </section> </section> <section id="CD013825-sec-0079"> <h3 class="title" id="CD013825-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD013825-tbl-0001"><b>Summary of findings 1</b> Bamlanivimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)</a>; <a href="./full#CD013825-tbl-0002"><b>Summary of findings 2</b> Bamlanivimab/etesevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</a>; <a href="./full#CD013825-tbl-0003"><b>Summary of findings 3</b> Casirivimab/imdevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)</a>; <a href="./full#CD013825-tbl-0004"><b>Summary of findings 4</b> Sotrovimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</a>; <a href="./full#CD013825-tbl-0005"><b>Summary of findings 5</b> Regdanvimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</a>; <a href="./full#CD013825-tbl-0006"><b>Summary of findings 6</b> Bamlanivimab compared to placebo in hospitalised individuals with COVID‐19 (moderate to severe disease)</a>; <a href="./full#CD013825-tbl-0007"><b>Summary of findings 7</b> Casirivimab/imdevimab compared to usual care alone in hospitalised individuals with COVID‐19 (moderate to severe disease)</a> </p> <section id="CD013825-sec-0080"> <h4 class="title">SARS‐CoV‐2‐specific mAbs in non‐hospitalised individuals with COVID‐19 and asymptomatic or mild disease </h4> <section id="CD013825-sec-0081"> <h5 class="title">Bamlanivimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </h5> <p>We present our certainty in the evidence for prioritised outcomes for the comparison bamlanivimab and placebo in non‐hospitalised individuals in <a href="./full#CD013825-tbl-0001">summary of findings Table 1</a>. We included only one study for this comparison, which did not report the outcomes mortality by day 60, clinical progression or development of severe symptoms, and quality of life (<a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>). Since all outcomes were evaluated separately for each treatment arm (0.7 g, 2.8 g, 7.0 g of bamlanivimab), we did not pool the data. </p> <section id="CD013825-sec-0082"> <h6 class="title">Primary outcomes</h6> <section id="CD013825-sec-0083"> <p><b>All‐cause mortality (by days 30 and 60)</b></p> <p>One RCT (<a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>) reported all‐cause mortality at day 29 for 465 participants. </p> <p>None of the participants died by day 29 (101 participants in dose 0.7 g arm, 107 participants in 2.8 g arm, 101 participants in 7.0 g arm and 156 participants in placebo arm; effect estimates not estimable, low‐certainty evidence for all arms; <a href="./references#CD013825-fig-0004" title="">Analysis 1.1</a>). For each comparison, our main reason for downgrading was very serious imprecision due to no observed events in any of the groups. <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> did not report all‐cause mortality at up to 60 days. </p> </section> <section id="CD013825-sec-0084"> <p><b>Admission to hospital or death</b></p> <p>Admission to hospital was reported for 465 participants at day 29 (<a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>). Data indicate that treatment with 0.7 g, 2.8 g or 7.0 g bamlanivimab may result in a decrease in admissions to hospital compared to treatment with placebo, with 10, 18 and 20 admissions per 1000 for the bamlanivimab groups as compared to 58 per 1000 in the placebo group (risk ratio (RR) 0.17, 95% confidence interval (CI) 0.02 to 1.33; RR 0.32, 95% CI 0.07 to 1.47; and RR 0.34, 95% CI 0.08 to 1.56, respectively; 1 RCT). For each comparison, our main reason for downgrading was very serious imprecision due to low sample size and low number of events. </p> </section> <section id="CD013825-sec-0085"> <p><b>Adverse events (all grades, grades 1 to 2, grades 3 to 4)</b></p> <p><a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> reported the number of participants with one or more adverse events, which first occurred or worsened in severity after baseline measurement, for 465 participants. Since the data were evaluated separately for each treatment arm (0.7 g, 2.8 g, and 7.0 g bamlanivimab), we did not pool the data.  </p> <p>Treatment with 0.7 g, 2.8 g or 7.0 g bamlanivimab may result in little to no difference in the occurrence of adverse events (267, 242 and 218 per 1000) compared to treatment with placebo (269 per 1000; RR 0.99, 95% CI 0.66 to 1.50; RR 0.90, 95% CI 0.59 to 1.38; and RR 0.81, 95% CI 0.52 to 1.27, respectively; 1 RCT, 257, 263 and 257 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0008" title="">Analysis 1.5</a>). </p> <p>For each comparison, our main reason for downgrading was very serious imprecision due to low sample size, low number of events, and wide confidence intervals. Adverse events were coded according to MedDRA, the Medical Dictionary for Regulatory Activities, and were classified as mild, moderate and severe. Therefore, we could not summarise grades 1 to 2 and grades 3 to 4 adverse events. </p> </section> <section id="CD013825-sec-0086"> <p><b>Serious adverse events</b></p> <p><a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> assessed serious adverse events for 465 participants. Since the data were evaluated separately for each treatment arm that received different doses of bamlanivimab (0.7 g, 2.8 g, 7.0 g), we have not pooled the data.  </p> <p>There were too few participants who experienced serious adverse events to determine whether treatment with 0.7 g, 2.8 g or 7.0 g bamlanivimab has an effect on serious adverse events (3 per 1000 for all arms) compared to treatment with placebo (6 per 1000; RR 0.51, 95% CI 0.02 to 12.47; RR 0.48, 95% CI 0.02 to 11.78; and RR 0.51, 95% CI 0.02 to 12.47, respectively; 1 RCT; low‐certainty evidence; <a href="./references#CD013825-fig-0009" title="">Analysis 1.6</a>). For each comparison, our main reason for downgrading was very serious imprecision due to low sample size, very low number of events, and very wide confidence intervals. </p> </section> </section> <section id="CD013825-sec-0087"> <h6 class="title">Additional outcomes</h6> <p><a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> did not report length of hospital stay, admission to ICU, length of ICU stay, thromboembolic events, or renal failure. </p> <section id="CD013825-sec-0088"> <p><b>Viral clearance (up to days 3, 7 and 15)</b></p> <p>We defined viral clearance as a negative RT‐PCR test after treatment and planned to include clearance up to three, seven and 15 days. <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, defined viral clearance as two consecutive negative RT‐PCR test results for SARS‐CoV‐ 2. Since the data were evaluated separately for each treatment arm that received different doses of bamlanivimab (0.7 g, 2.8 g, 7.0 g), we did not pool the data.  </p> <p> <ul id="CD013825-list-0031"> <li> <p><b>Viral clearance up to day 3:</b> <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> did not report viral clearance up to day 3. </p> </li> <li> <p><b>Viral clearance up to day 7:</b> <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> assessed viral clearance up to day 7 for 444 participants in total. Evidence suggests that treatment with 0.7 g, 2.8 g, or 7.0 g bamlanivimab may have little to no effect on viral clearance at days 7, with 10 out of 99 participants in the 0.7 g arm, 12 out of 101 participants in the 2.8 g arm, and 8 out of 99 participants in the 7.0 g arm achieving viral clearance compared to 16 out of 145 in the placebo arm (RR 0.92, 95% CI 0.43 to 1.93; RR 1.08, 95% CI 0.53 to 2.18; and RR 0.73, 95% CI 0.33 to 1.65, respectively; 1 RCT; <a href="./references#CD013825-fig-0006" title="">Analysis 1.3</a>). The evidence is uncertain due to the small sample size and wide confidence intervals. </p> </li> <li> <p><b>Viral clearance up to day 15:</b> <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> assessed viral clearance at day 15 for 414 participants. Evidence suggests that treatment with 0.7 g, 2.8 g, or 7.0 g bamlanivimab may have little to no effect on viral clearance at day 15, with 25 out of 91 participants in the 0.7 g arm, 30 out of 97 participants in the 2.8 g arm, and 25 out of 94 participants in the 7.0 g arm achieving viral clearance compared to 34 out of 132 in the placebo group (RR 1.07, 95% CI 0.69 to 1.66; RR 1.20, 95% CI 0.79 to 1.82; and RR 1.03, 95% CI 0.66 to 1.61, respectively; 1 RCT; <a href="./references#CD013825-fig-0007" title="">Analysis 1.4</a>). The evidence is uncertain due to the small sample size and wide confidence intervals. </p> </li> </ul> </p> </section> </section> </section> <section id="CD013825-sec-0089"> <h5 class="title">Bamlanivimab/etesevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </h5> <p>We present our certainty in the evidence for prioritised outcomes for bamlanivimab/etesevimab compared with placebo in non‐hospitalised individuals in <a href="./full#CD013825-tbl-0002">summary of findings Table 2</a>. This comparison was examined in a two‐part study (<a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>), reported in two separate publications and one conference abstract. We decided to not include the phase 2 part of the study, because the start of treatment arms was staggered, and the allocation ratio was adjusted. This resulted in a late start of the bamlanivimab/etesevimab arm on 22 August 2021, while the placebo group was mainly enrolled up to 21 August 2021, with only 13 participants having been enrolled and analysed after this date. Therefore, we report on phase 2 narratively only. The outcomes mortality by day 60, clinical progression or development of severe symptoms and quality of life were not reported.  </p> <section id="CD013825-sec-0090"> <h6 class="title">Primary outcomes</h6> <section id="CD013825-sec-0091"> <p><b>All‐cause mortality (by days 30 and 60)</b></p> <p>The phase 3 part reported data on 1035 participants. Bamlanivimab/etesevimab may reduce overall mortality by day 30 as compared with placebo (1 death per 1000 participants as compared to 19 per 1000 in the placebo group; RR 0.05, 95% CI 0.00 to 0.81; 1 RCT, 1035 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0010" title="">Analysis 2.1</a>). Our main reason for downgrading was very serious imprecision due to the low number of events. <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a> did not report all‐cause mortality by day 60. </p> <p>In <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, no deaths occurred by day 29 (112 in bamlanivimab/etesevimab arm, 151 in placebo arm), mortality by day 60 was not reported. </p> </section> <section id="CD013825-sec-0092"> <p><b>Admission to hospital or death</b></p> <p><a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a> reported the outcome admissions to hospital for 1035 participants by day 29. Treatment with bamlanivimab/etesevimab (21 per 1000) may result in a decrease in admissions to hospital by day 29 compared to treatment with placebo (70 per 1000; RR 0.30, 95% CI 0.16 to 0.59; 1 RCT, 1035 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0011" title="">Analysis 2.2</a>). Our main reason for downgrading was very serious imprecision due to low number of events. </p> <p>In <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, 1 out of 112 in the bamlanivimab/etesevimab and 9 out of 156 in the non‐concurrent placebo arm were hospitalised. </p> </section> <section id="CD013825-sec-0093"> <p><b>Adverse events (all grades, grades 1 to 2, grades 3 to 4)</b></p> <p><a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a> reported the number of participants with one or more adverse events, whichever first occurred or worsened in severity after baseline measurement for 1035 participants in this comparison. </p> <p>Treatment with bamlanivimab/etesevimab may have little to no effect on the occurrence of adverse events (133 per 1000) compared to treatment with placebo (116 per 1000; RR 1.15, 95% CI 0.83 to 1.59; 1 RCT, 1035 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0015" title="">Analysis 2.6</a>). Our main reason for downgrading was very serious imprecision due to the low sample size. Adverse events were coded according to MedDRA, the Medical Dictionary for Regulatory Activities, and were classified as mild, moderate, and severe. Therefore, we could not summarise grades 1 to 2 and grades 3 to 4 adverse events. </p> <p>In <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, 12 out of 112 in the bamlanivimab/etesevimab arm and 42 out of 156 in the non‐concurrent placebo arm experienced at least one adverse event. </p> </section> <section id="CD013825-sec-0094"> <p><b>Serious adverse events</b></p> <p><a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a> assessed serious adverse events for 1035 participants. Treatment with bamlanivimab/etesevimab may increase the occurrence of serious adverse events (14 per 1000) as compared with placebo (10 per 1000; RR 1.40, 95% CI 0.45 to 4.37; 1 RCT, 1035 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0016" title="">Analysis 2.7</a>). Our main reason for downgrading was very serious imprecision due to the low number of events and wide confidence interval. </p> <p>In <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, 1 out of 112 participants in the bamlanivimab/etesevimab arm and 1 out of 156 in the placebo arm experienced an event. </p> </section> </section> <section id="CD013825-sec-0095"> <h6 class="title">Additional outcomes</h6> <p><a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a> did not report the additional outcomes admission to ICU, length of ICU stay, thromboembolic events, and renal failure. </p> <section id="CD013825-sec-0096"> <p><b>Length of hospital stay</b></p> <p>The mean duration of hospitalisation was 7.3 days (SD = 6.4 days; 11 participants) in the bamlanivimab/etesevimab arm and 11.2 days (SD = 10.1 days, 33 participants) in the placebo arm. </p> </section> <section id="CD013825-sec-0097"> <p><b>Viral clearance (up to days 3, 7, and 15)</b></p> <p>The study defined viral clearance as two consecutive negative RT‐PCR test results for SARS‐CoV‐ 2. </p> <p><a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a> reported a Kaplan‐Meier graph including the number of events per day, which we used to calculate cumulative frequency of viral clearance. Evidence from <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a> suggests that more people may achieve viral clearance at days 3, 7, and 15 when treated with bamlanivimab/etesevimab compared with placebo (day 3: RR 2.12, 95% CI 1.16 to 3.86; day 7: RR 1.81, 95% CI 1.27 to 2.60; day 15: RR 1.34, 95% CI 1.07 to 1.67; 1 RCT, 968 participants). </p> <p>In <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, 14 out of 100 in the experimental group and 16 out of 145 in the placebo group achieved viral clearance at day 7, and 34 out of 98 in the experimental group compared to 34 out of 132 participants in the placebo arm achieved viral clearance. </p> </section> </section> </section> <section id="CD013825-sec-0098"> <h5 class="title">Casirivimab/imdevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </h5> <p>For the comparison casirivimab/imdevimab versus placebo in non‐hospitalised individuals with COVID‐19, we identified one phase 1/2/3 study with published results (<a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>) from phase 1/2 in one full‐text and one preprint publication, and phase 3 in an additional preprint. The first part of the study randomised participants to either 2.4 g or 8.0 g treatment or placebo. In the course of phase 3 of the study on 14 November 2020, the treatment doses were amended, the 8 g arm was stopped and a 1.2 g arm was added. In addition, the eligibility was amended from participants with and without participants to participants with at least one risk factor for severe disease. For the first part of the study, we have considered the preprint with updated data, including 799 randomised participants. Of these, 665 were included in the modified full analysis set which included only participants who tested positive on central RT‐qPCR. </p> <p>Due to very serious risk of bias, we decided to not pool the data from phase 3 with the remaining data and report these narratively only. In particular, we could not follow the participant flow throughout the study; it was unclear whether the 1040 participants without risk factors were initially randomised and if so, why data were not reported. In addition, the origin of the number of participants in the placebo group of the safety set is not clearly documented, and results for the 8.0 g casirivimab/imdevimab arm are reported arbitrarily. Only data for cohort 1 were provided. The concurrent placebo groups vary but participants overlap with each other. Results based on phase 1 are presented in <a href="./full#CD013825-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD013825-sec-0099"> <h6 class="title">Primary outcomes</h6> <section id="CD013825-sec-0100"> <p><b>All‐cause mortality (by days 30 and 60)</b></p> <p>The phase 1/2 part of the study by <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> did not report all‐cause mortality by days 30 or 60. </p> <p>In the phase 3 part of the study, the number of events in all treatment arms (1.2 g, 2.4 g and 8.0 g) was very low and does not allow us to explore whether casirivimab/imdevimab may have an effect on all‐cause mortality by day 29 when compared with placebo. In both the 1.2 g and 2.4 g treatment arms, one participant died out of 736 and 1355 participants, in the 8.0 g, no one died out of 625. The reported concurrent placebo groups varied, in the combined placebo group, 3 out of 1341 participants died. </p> </section> <section id="CD013825-sec-0101"> <p><b>Clinical progression or development of severe symptoms according to the WHO scale</b></p> <p>The phase 1/2 part of the study did not report any data on clinical progression or development of severe symptoms that could be translated into an outcome based on the WHO progression scale, although IMV requirement was planned at the protocol stage. </p> <p>The phase 3 part reported the number of participants that require IMV (WHO scale 7, 8, 9), which does not explicitly includes deaths, for the 1.2 g and 2.4 g casirivimab/imdevimab arms. The number of events was too low to explore the direction of the effect of casirivimab/imdevimab. </p> <p> <div class="table" id="CD013825-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Clinical progression to IMV</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Casirivimab/imdevimab</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants analysed</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants analysed</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>736</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>748</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1355</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1341</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0 g</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> </tbody> </table> </div> </p> <p>In addition to the very serious bias, it is not explicitly mentioned whether the outcome includes death events and may therefore be prone to effect distortion in case people died before receiving IMV.  </p> </section> <section id="CD013825-sec-0102"> <p><b>Admission to hospital or death</b></p> <p>In the phase 1/2 part of the study, casirivimab/imdevimab at 2.4 g or 8.0 g may reduce the frequency of hospital admission or death compared with placebo (9 and 5 per 1000 compared to 22 per 1000 in the placebo group; 2.4 g: RR 0.43, 95% CI 0.08 to 2.19, 446 participants; 8.0 g: RR 0.21, 95% CI 0.02 to 1.79, 450 participants; 1 RCT; low‐certainty evidence; <a href="./references#CD013825-fig-0017" title="">Analysis 3.1</a>). Our main reason for downgrading was the low sample size and low number of events. </p> <p>The phase 3 part of the study reported the number of participants admitted to hospital or dead by day 29: </p> <p> <div class="table" id="CD013825-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Hospital admission or death</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Casirivimab/imdevimab</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants analysed</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants analysed</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>736</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>748</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1355</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1341</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>625</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>593</p> </td> </tr> </tbody> </table> </div> </p> <p>Due to the very serious risk of bias, we are uncertain whether casirivimab/imdevimab has an effect on hospital admissions or death.  </p> </section> <section id="CD013825-sec-0103"> <p><b>Adverse events</b></p> <p>The phase 1/2 part of the study reported grades 3 to 4 adverse events only. There were too few events to determine whether casiribimab/imdevimab at 2.4 g or 8.0 g has an effect on the occurrence of grades 3 to 4 adverse events (12 and 8 per 1000 compared to 15 per 1000 for the placebo arm; 2.4 g: RR 0.76, 95% CI 0.17 to 3.37, 520 participants; 8.0 g: RR 0.50, 95% CI 0.09 to 2.73, 522 participants; 1 RCT; low‐certainty evidence; <a href="./references#CD013825-fig-0018" title="">Analysis 3.2</a>). We graded down due to very serious imprecision, the sample size was small with a low number of events. </p> <p>Part 3 of the study reported all grades adverse events and grades 3 to 4 adverse events separately:  </p> <p> <div class="table" id="CD013825-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign=""> <p><b>Adverse events</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Casirivimab/imdevimab</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Placebo</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants analysed</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Participants analysed</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>All grades</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>827</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>189</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>1843</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>142</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1849</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1012</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Grades 3 to 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>827</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>62</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>1843</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1849</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1012</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>827</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>1843</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1849</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0 g</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1012</p> </td> </tr> </tbody> </table> </div> </p> <p>We are uncertain whether casiriviamb/imdevimab 1.2 g, 2.4 g or 8.0 g has an effect on adverse events or serious adverse events. </p> </section> <section id="CD013825-sec-0104"> <p><b>Serious adverse events</b></p> <p>The number of events in phase 1/2 of the study was too small to determine whether any dose of casirivimab/imdevimab (2.4 g, 8.0 g) may have an effect on the occurrence of serious adverse events compared with placebo (16 and 8 per 1000 as compared to 23 per 1000; 2.4 g: RR 0.68, 95% CI 0.19 to 2.37, 520 participants; 8.0 g: RR 0.34, 95% CI 0.07 to 1.65; 1 RCT, 522 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0019" title="">Analysis 3.3</a>). We downgraded two levels for very serious imprecision; the sample size was low with a small number of events. </p> <p>Serious adverse events reported in the phase 3 preprint publication are listed under adverse events.  </p> </section> </section> <section id="CD013825-sec-0105"> <h6 class="title">Additional outcomes</h6> <p>For this comparison, the following outcomes were not reported in any of the preprints: length of ICU stay, viral clearance, frequency of thromboembolic events, and frequency of renal failure. </p> <section id="CD013825-sec-0106"> <p><b>Length of hospital stay</b></p> <p>The phase 3 portion of the trial reported on the length of hospital stay for dose 1.2 and 2.4 g as mean days and standard deviation, however, the number of participants who contributed to this outcome was very low (1.2 g: N = 7, concurrent placebo N = 24; 2.4 g: N =18, concurrent placebo N = 62). The data for 8.0 g are not reported. It is unclear whether patients who died were accounted for (i.e., earlier death means a shorter hospital stay). </p> </section> <section id="CD013825-sec-0107"> <p><b>Admission to ICU</b></p> <p>The phase 3 part of the trial reported the number of participants admitted to the ICU. However, the number of events was too low to explore whether casirivimab/imdevimab has an effect on this outcome (1.2 g: 3 out of 736, 7 out of 749 in the concurrent placebo arm; 2.4 g: 6 out of 1355 as compared to 18 out of 1341 in the concurrent placebo arm). The results for the 8.0 g arm was not reported and it is unclear whether competing events (i.e. deaths) were accounted for. </p> <p> </p> </section> </section> </section> <section id="CD013825-sec-0108"> <h5 class="title">Sotrovimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </h5> <p>We present our certainty in the evidence for prioritised outcomes for the comparison sotrovimab compared with placebo in non‐hospitalised individuals in <a href="./full#CD013825-tbl-0004">summary of findings Table 4</a>. The one eligible trial with results (<a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>) for this comparison has been stopped for profound efficacy by the data monitoring committee on 10 March 2021 with 1057 participants enrolled. The preprint, uploaded on 28 May 2021, included participants up to 19 January 2021 for efficacy (583) and up to 17 February 2021 for safety (868) for preplanned interim analysis, the sets vary substantially in the number of participants analysed. </p> <section id="CD013825-sec-0109"> <h6 class="title">Primary outcomes</h6> <section id="CD013825-sec-0110"> <p><b>All‐cause mortality (by days 30 and 60)</b></p> <p>Only one participant in the placebo group had died by day 29 (291 participants in sotrovimab arm, 292 in placebo arm; 1 RCT, 583 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0020" title="">Analysis 4.1</a>), therefore, there were too few events to determine whether treatment with 0.5 g sotrovimab has an effect on mortality at 30 days. Our main reason for downgrading was very serious imprecision due to few events, which led to a very wide confidence interval. <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a> did not report all‐cause mortality at up to 60 days. </p> </section> <section id="CD013825-sec-0111"> <p><b>Clinical progression or development of severe symptoms according to the WHO scale</b></p> <p><a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a> reported provided information on several stages of severe or critical progression. Based on relevance, we decided to include two related endpoints that translate to development of severe symptoms based on the WHO progression scale, requirement of oxygen (≥ 5) and requirement of invasive mechanical ventilation (≥ 7), both including deaths.  </p> <p>Included in both analyses were 583 participants. Evidence suggests that sotrovimab may reduce the number of participants with oxygen requirement (WHO ≥ 5; 7 per 1000 participants) compared with placebo (65 per 1000; RR 0.11, 95% CI 0.02 to 0.45; 1 RCT, 583 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0021" title="">Analysis 4.2</a>). For the outcome IMV requirement or death, the number of events was too small to determine whether sotrovimab may have an effect (1 per 1000 as compared to 10 per 1000 in the placebo group; RR 14, 95% CI 0.01 to 2.76; 1 RCT, 583 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0022" title="">Analysis 4.3</a>). Our main reason for downgrading was the low sample size and low number of events.  </p> </section> <section id="CD013825-sec-0112"> <p><b>Admission to hospital or death </b></p> <p>Sotrovimab may reduce the number of hospital admissions or death (10 per 1000) compared to placebo (72 per 1000; RR 0.14, 95% CI 0.04 to 0.48; 1 RCT, 583 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0023" title="">Analysis 4.4</a>). Our main reason for grading down was the small sample size and low number of events. </p> </section> <section id="CD013825-sec-0113"> <p><b>Adverse events (all grades, grades 1 to 2, grades 3 to 4)</b></p> <p>Evidence suggests that treatment with sotrovimab compared to placebo may have little to no effect on the occurrence of any grade adverse events (169 per 1000 as compared to 194 per 1000 with placebo; RR 0.87, 95% CI 0.66 to 1.16; 1 RCT, 868 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0025" title="">Analysis 4.6</a>). Occurrence of grades 3‐4 adverse events may be reduced by treatment with sotrovimab compared to placebo (16 versus 62 per 1000 for sotrovimab and placebo, respectively; RR 0.26, 95% CI 0.12 to 0.60; 1 RCT, 868 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0026" title="">Analysis 4.7</a>). Grades 1 to 2 adverse events were not reported separately. We downgraded two levels due to the low sample size. </p> </section> <section id="CD013825-sec-0114"> <p><b>Serious adverse events</b></p> <p>Treatment with sotrovimab may reduce the occurrence of serious adverse events compared to placebo (16 per 1000 compared to 59 per 1000 participants with placebo; RR 0.27, 95% CI 0.12 to 0.63; 1 RCT, 868 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0027" title="">Analysis 4.8</a>). We downgraded two levels due to very serious imprecision; the sample size was low with a small number of events. </p> </section> </section> <section id="CD013825-sec-0115"> <h6 class="title">Additional outcomes</h6> <p>For the comparison sotrovimab versus placebo in non‐hospitalised individuals, we did not identify data for the outcomes length of hospital stay, length of ICU stay, viral clearance, thromboembolic events and renal failure. </p> <section id="CD013825-sec-0116"> <p><b>Admission to ICU</b></p> <p>The number of events is too low to determine whether treatment with sotrovimab reduces the number of participants admitted to ICU by day 29 (0 out of 291 in the sotrovimab group compared to 5 out of 292 in the sotrovimab group; RR 0.09, 95% CI 0.01 to 1.64; <a href="./references#CD013825-fig-0024" title="">Analysis 4.5</a>).  </p> </section> </section> </section> </section> <section id="CD013825-sec-0117"> <h4 class="title">Regdanvimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </h4> <p>We present our certainty in the evidence for prioritised outcomes for the comparison regdanvimab compared with placebo in non‐hospitalised individuals in <a href="./full#CD013825-tbl-0005">summary of findings Table 5</a>. We included only one study (<a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>) which reported on part 1 of a two‐part phase 2/3 study in form of a preprint. Mortality by day 60 and quality of life were not measured or reported, serious adverse events were reported as treatment‐emergent SAE; however, we considered this outcome as unreliable because no events were reported although hospitalisation events took place. </p> <section id="CD013825-sec-0118"> <h5 class="title">Primary outcomes</h5> <section id="CD013825-sec-0119"> <h6 class="title">All‐cause mortality (by day 30 and 60)</h6> <p>None of the participants had died by day 28 (101 in the CT‐P59 40 mg/kg arm, 103 in the regdanvimab 80 mg/kg arm and 103 participants in placebo arm; effect estimate was not estimable; low‐certainty evidence; <a href="./references#CD013825-fig-0028" title="">Analysis 5.1</a>). Our main reason for downgrading was very serious imprecision due to no observed events in any group.  </p> <p><a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a> did not report all‐cause mortality at up to 60 days. </p> </section> <section id="CD013825-sec-0120"> <h6 class="title">Clinical progression or development of severe symptoms according to the WHO scale</h6> <p>The study reported the number of participants who had progressed to invasive mechanical ventilation or death, which translates into a WHO score of ≥ 7.  </p> <p>In the regdanvimab 40 mg/kg arm and placebo arm, no one required mechanical ventilation (among 101 participants in regdanvimab 40 mg/kg arm and 103 participants in placebo arm, effect not estimable; low‐certainty evidence; <a href="./references#CD013825-fig-0029" title="">Analysis 5.2</a>). There were too few participants who experienced progress to invasive mechanical ventilation to determine whether treatment with CT‐P59 80 mg/kg has an effect (1 in 103 in regdanvimab 80 mg arm, 0 in 103 in placebo arm; RR 3.00, 95% CI 0.12 to 72.89; 1 RCT, 206 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0029" title="">Analysis 5.2</a>). </p> <p>For both comparisons, the main reason for downgrading was very serious imprecision due to very low number of events and resulting in very wide confidence intervals. </p> </section> <section id="CD013825-sec-0121"> <h6 class="title">Admission to hospital or death by day 30</h6> <p>Treatment with either 40 mg/kg or 80 mg per kg regdanvimab may decrease the frequency of hospital admission or death by day 30 compared to placebo (39 or 49 per 1000 in the regdanvimab arms versus 87 per 1000 in the placebo arm; 40 mg/kg: RR 0.45, 95% CI 0.14 to 1.42; 1 RCT, 204 participants; 80 mg/kg: RR 0.56, 95% CI 0.19 to 1.60; 1 RCT, 206 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0030" title="">Analysis 5.3</a>). Our main reason for downgrading was very serious imprecision due to the small sample size and small number of events. </p> </section> <section id="CD013825-sec-0122"> <h6 class="title">Adverse events (all grades, grades 1 to 2, grades 3 to 4)</h6> <p>Treatment with 40 mg/kg regdanvimab may have little to no effect on the occurrence of any grade adverse events compared with placebo (297 versus 309 per 1000 for regdanvimab and placebo, respectively; RR 0.96, 95% CI 0.64 to 1.43; 1 RCT, 215 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0033" title="">Analysis 5.6</a>). Treatment with 80 mg/kg regdanvimab may reduce the occurrence of any grade adverse events compared with placebo (244 versus 309 per 1000; RR 0.79, 95% CI 0.52 to 1.22; 1 RCT, 220 participants; low‐certainty evidence). Our main reason for downgrading was the low sample size. </p> <p>Treatment with either 40 mg/kg or 80 mg/kg regdanvimab may increase the occurrence of grade 3 adverse events compared to placebo, no grade 4 adverse events took place (48 and 36 per 1000 compared to 18 per 1000 in the placebo group; 40 mg/kg: RR 2.62, 95% CI 0.52 to 13.12; 1 RCT, 215 participants; 80 mg/kg: RR 2.00, 95% CI 0.37 to 10.70; 1 RCT, 220 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0034" title="">Analysis 5.7</a>). Our main reason for downgrading was the small sample size and low number of events. </p> </section> </section> <section id="CD013825-sec-0123"> <h5 class="title">Additional outcomes</h5> <p>The outcomes length of hospital stay, length of ICU stay, frequency of thromboembolic events, and frequency of renal failure were not available for this comparison.  </p> <section id="CD013825-sec-0124"> <h6 class="title">Admission to ICU or death</h6> <p>None of the participants had been admitted to ICU by day 28 (101 in the CT‐P59 40 mg/kg arm, 103 in the CT‐P59 80 mg/kg arm and 103 participants in placebo arm; effect not estimable; <a href="./references#CD013825-fig-0031" title="">Analysis 5.4</a>).  </p> </section> <section id="CD013825-sec-0125"> <h6 class="title">Viral clearance (up to day 3, 7 and 15)</h6> <p> <ul id="CD013825-list-0032"> <li> <p><b>Viral clearance up to day 3 and 7:</b> not reported. </p> </li> <li> <p><b>Viral clearance up to day 15:</b> <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a> assessed viral clearance at day 15 for 309 participants. Evidence suggests that treatment with regdanvimab may have little to no effect on viral clearance at day 15, with 68 participants in each treatment arm, as compared to 62 out of 103 participants in the placebo arm achieving viral clearance (RR 1.12, 95% CI 0.91 to 1.38 for 40 mg/kg; RR 1.10, 95% CI 0.89 to 1.35 for 80 mg/kg, respectively; 1 RCT; <a href="./references#CD013825-fig-0032" title="">Analysis 5.5</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD013825-sec-0126"> <h4 class="title">SARS‐CoV‐2‐specific mAbs in hospitalised individuals with COVID‐19 (moderate to severe disease) </h4> <section id="CD013825-sec-0127"> <h5 class="title">Bamlanivimab compared to placebo in individuals with COVID‐19 (moderate to severe disease) </h5> <p>We present the certainty in the evidence for our prioritised outcomes for the comparison bamlanivimab versus placebo in hospitalised individuals with COVID‐19 in <a href="./full#CD013825-tbl-0006">summary of findings Table 6</a>. We included one study published as one full text and one preprint publication. The preprint with the final analysis reported the subgroups for seronegative and seropositive participants at baseline for mortality at 90 days, sustained recovery and serious adverse events. Quality of life was not reported. </p> <section id="CD013825-sec-0128"> <h6 class="title">Primary outcomes</h6> <section id="CD013825-sec-0129"> <p><b>All‐cause mortality (by days 30 and 60)</b></p> <p>One RCT reported all‐cause mortality by days 28 and 90 for 314 participants (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>).  </p> <p>We are uncertain whether bamlanivimab has an effect on all‐cause mortality at 28 days (37 per 1000) when compared to treatment with placebo (26 per 1000; RR 1.39, 95% CI 0.40 to 4.83; 1 RCT, 314 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0036" title="">Analysis 6.1</a>). Our main reason for downgrading was very serious imprecision due to wide confidence interval, low sample size, and the low number of events.  </p> <p>The 90‐day follow‐up resulted in a hazard ratio (HR) of 1.09 (95% CI 0.49 to 2.43; 1 RCT, 314 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0037" title="">Analysis 6.2</a>), indicating that bamlanivimab may have little to no effect on mortality compared with placebo (79 per 1000 compared to 73 per 1000 with placebo). Our certainty in the evidence was low due to very serious imprecision; the sample size was small, resulting in a low number of events and large confidence intervals. </p> <p>The subgroup analysis of the primary study authors suggests that the effect may differ between seronegative and seropositive participants at baseline. In seronegative participants, 5.4% of participants with bamlanivimab as compared to 11.4% with placebo experienced an event (HR 0.46, 95% CI 0.14 to 1.48). In contrast, in the seropositive arm, 9.6% in the bamlanivimab arm as compared to 2.9% in the placebo arm experienced an event (HR 3.52, 95% CI 0.75 to 16.58).  </p> </section> <section id="CD013825-sec-0130"> <p><b>Clinical progression or development of severe symptoms according to the WHO scale</b></p> <p><a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> reported the proportion of participants in each pulmonary clinical status category at day 5 for 311 participants per category. From this, we extracted severe symptoms based on the need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (category 5 to 7 on the pulmonary‐plus scale).  </p> <p>Bamlanivimab may result in a slight increase in severe symptoms at day 5 (211 per 1000) compared to placebo (180 per 1000; RR 1.17, 95% CI 0.75 to 1.85; 1 RCT, 311 participants; very low‐certainty evidence; <a href="./references#CD013825-fig-0038" title="">Analysis 6.3</a>). Our main reason for downgrading was serious indirectness due to a short time frame of five days and serious imprecision due to wide confidence interval and low sample size, and for indirectness due to the short time frame of five days only. </p> <p>We additionally extracted clinical status at day 5 by the need for intubation (which corresponds to category six at the pulmonary scale). From 161 participants treated with bamlanivimab, eight needed intubation, compared to five out of 150 participants in the control group. Treatment with bamlanivimab may result in a slight increase in the need for intubation at day 5 compared to placebo (RR 1.49, 95% CI 0.50 to 4.46; 1 RCT, 311 participants; <a href="./references#CD013825-fig-0039" title="">Analysis 6.4</a>). </p> </section> <section id="CD013825-sec-0131"> <p><b>Hospital discharge and alive</b></p> <p><a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> reported the HR for hospital discharge until data cut‐off (26 October 2020) for 314 participants, stratified by disease severity and study site pharmacy and using the Fine and Gray method to correct for competing risks. Treatment with bamlanivimab may have little to no effect on time to hospital discharge (751 per 1000, based on control group risk at day 10) compared to treatment with placebo (762 per 1000; HR 0.97, 95% CI 0.78 to 1.20; 1 RCT, 314 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0041" title="">Analysis 6.6</a>). Our main reason for downgrading was serious imprecision due to the low sample size.  </p> <p>In addition to the HR, the study reported hospital discharge at day 5 for 314 participants. Evidence suggests there may be little to no difference between participants receiving bamlanivimab and placebo (RR 0.98, 95% CI 0.81 to 1.19; 1 RCT, 314 participants; <a href="./references#CD013825-fig-0040" title="">Analysis 6.5</a>).  </p> </section> <section id="CD013825-sec-0132"> <p><b>Quality of life (at up to seven and 30 days, and longest follow‐up, including fatigue)</b></p> <p>We did not identify any study reporting this outcome.</p> </section> <section id="CD013825-sec-0133"> <p><b>Adverse events (all grades, grades 1 to 2, grades 3 to 4)</b></p> <p><a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> reported grades 3 to 4 adverse events at day 28 for 314 participants. Bamlanivimab may result in a slight increase of grades 3 to 4 adverse events (227 per 1000) compared to treatment with placebo (179 per 1000; RR 1.27, 95% CI 0.81 to 1.98; 1 RCT, 314 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0042" title="">Analysis 6.7</a>). Our main reason for downgrading was very serious imprecision due to wide confidence interval and low sample size. <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> did not report adverse events of all grades and grades 1 to 2. </p> </section> <section id="CD013825-sec-0134"> <p><b>Serious adverse events</b></p> <p><a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> reported serious adverse events by day 28 for 314 participants. It is uncertain whether treatment with bamlanivimab has an effect on the occurrence of serious adverse events (31 per 1000) compared to treatment with placebo (33 per 1000); RR 0.93, 95% CI 0.27 to 3.14; 1 RCT, 314 participants; low‐certainty evidence; <a href="./references#CD013825-fig-0042" title="">Analysis 6.7</a>). Our main reason for downgrading was very serious imprecision due to wide confidence interval, low sample size, and low number of events. </p> <p>Treatment with bamlanivimab may reduce the occurrence of SAE by day 90 compared to placebo (9 out of 163 compared to 12 out of 151; RR 0.7, 95% CI 0.29 to 1.67). However, the number of events is low, resulting in a broad confidence interval. The effect may differ between seronegative and seropositive participants as reported in the primary publication; in the seronegative group, 5.4% of participants who received bamlanivimab experienced an SAE compared with 10.1% in the placebo arm (HR 0.51, 95% CI 0.15 to 1.70). In the seropositive group, 6% of those allocated to bamlanivimab experienced an SAE compared to 5.8% in the placebo arm (RR 1.1, 95% CI 0.3 to 4.11). </p> </section> </section> <section id="CD013825-sec-0135"> <h6 class="title">Additional outcomes</h6> <p><a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> did not report results on length of hospital stay, admission to ICU, length of ICU stay, or viral clearance. </p> <section id="CD013825-sec-0136"> <p><b>Time to sustained recovery</b></p> <p><a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> assessed time to sustained recovery up to day 90. Treatment with bamlanivimab may result in little to no difference in time to sustained recovery compared to treatment with placebo (HR 0.99, 95% CI 0.80 to 1.23; 1 RCT, 314 participants; <a href="./references#CD013825-fig-0045" title="">Analysis 6.10</a>). The evidence is uncertain due to the small sample size. </p> </section> <section id="CD013825-sec-0137"> <p><b>Neurological dysfunction</b></p> <p>This outcome was reported by <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> for 293 participants at day 28. Transient ischaemic events, acute delirium, and cerebrovascular events were reported separately. No transient ischaemic event occurred at day 28 in either group (RR not estimable; <a href="./references#CD013825-fig-0046" title="">Analysis 6.11</a>). Too few participants experienced acute delirium (4 out of 152 participants; RR 3.71, 95% CI 0.42 to 32.80) and cerebrovascular events (0 out of 152 participants; RR 0.31, 95% CI 0.01 to 7.53) to determine whether bamlanivimab has an effect compared to placebo (1 out of 141 participants; 1 RCT, 293 participants; <a href="./references#CD013825-fig-0047" title="">Analysis 6.12</a>; <a href="./references#CD013825-fig-0048" title="">Analysis 6.13</a>). The evidence is very uncertain due to the low number of events, small sample size and very wide confidence intervals. </p> </section> <section id="CD013825-sec-0138"> <p><b>Thromboembolic events</b></p> <p><a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> assessed thromboembolic events until data cut‐off for 293 participants. Too few participants experienced thromboembolic events to determine whether bamlanivimab has an effect (3 out of 152 participants) compared with placebo (1 out of 141 participants; RR 2.78, 95% CI 0.29 to 26.44; 1 RCT, 293 participants; <a href="./references#CD013825-fig-0049" title="">Analysis 6.14</a>). The evidence is very uncertain due to the low number of events, small sample size, and very wide confidence intervals. </p> </section> <section id="CD013825-sec-0139"> <p><b>Renal failure</b></p> <p><a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> reported the need for dialysis at data cut‐off for 293 participants. Too few participants experienced need for dialysis to determine whether bamlanivimab has an effect (2 out of 152 participants) compared with placebo (0 out of 141 participants; RR 4.64, 95% CI 0.22 to 95.83; 1 RCT, 293 participants; <a href="./references#CD013825-fig-0050" title="">Analysis 6.15</a>). The evidence is very uncertain due to the low number of events, small sample size, and very wide confidence intervals. </p> <p> </p> </section> </section> </section> <section id="CD013825-sec-0140"> <h5 class="title">Casirivimab/imdevimab and usual care compared to usual care alone in hospitalised individuals with COVID‐19 (moderate and severe disease) </h5> <p>The certainty in the evidence for our prioritised outcomes for the comparison casirivimab/imdevimab versus usual care in hospitalised individuals with COVID‐19 can be found in <a href="./full#CD013825-tbl-0007">summary of findings Table 7</a>. The one inlcuded study, published as a preprint with 9785 participants enrolled to either casirivimab/imdevimab or usual care, did not report mortality at 60 days, quality of life, adverse events and serious adverse events. This study reported a hierarchical analysis, testing participants who have not produced antibodies at baseline first, and upon significance testing all participants including seropositive and participants with unknown status, we will report on this subgroup for prioritised outcomes, taken over from the preprint, narratively as well (serostatus: negative, positive, unknown). </p> <p>The outcomes mortality by day 60, quality of life, adverse events and serious adverse events were not planned to be reported. </p> <section id="CD013825-sec-0141"> <h6 class="title">Primary outcomes</h6> <section id="CD013825-sec-0142"> <p><b>All‐cause mortality (by day 30 and 60)</b></p> <p>Casirivimab/imdevimab has probably little to no effect on all‐cause mortality by day 28 when compared with usual care (221 per 1000 participants died as compared to 236 per 1000 in the usual care group; RR 0.94, 95% CI 0.87 to 1.02; 1 RCT, 9785 participants; moderate‐certainty evidence; <a href="./references#CD013825-fig-0051" title="">Analysis 7.1</a>). We downgraded one level due to serious risk of bias, which we rated as high based on the lack of blinding and a yet undefined standard of care, which may have led to differences in concomitant treatment (i.e. the timing of concomitant treatment). </p> <p>The subgroup analysis of the primary study authors suggests that in seronegative participants, mortality was lower in the casirivimab/imdevimab arm with 24% mortality compared to 30% mortality in the usual care group (RR 0.80, 95% CI 0.70 to 0.91). Among participants who were seropositive or with unknown serostatus, there was no difference between the treatment groups (seropositive: 16% compared to 15%, RR 1.09, 95% CI 0.95 to 1.26; unknown: 24% compared to 24%, RR 0.98, 95% CI 0.78 to 1.22; for casirivimab/imdevimab versus placebo). </p> </section> <section id="CD013825-sec-0143"> <p><b>Clinical progression or development of severe symptoms according to the WHO scale</b></p> <p><a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> reported the number of participants who required invasive mechanical ventilation or death by day 28 for those who were not yet ventilated at baseline. Casirivimab/imdevimab has probably little to no effect on IMV requirement by day 28 compared to usual care in the complete enrolled sample (238 in the casirivimab/imdevimab arm compared to 248 per 1000 receiving usual care; RR 0.96, 95% CI 0.90 to 1.04; 1 RCT, 9198 participants; moderate‐certainty evidence; <a href="./references#CD013825-fig-0052" title="">Analysis 7.2</a>). We downgraded one level due to serious risk of bias, which we rated as high based on the lack of blinding and a yet undefined standard of care, which may have led to differences in concomitant treatment (i.e., the timing of concomitant treatment). </p> <p>Similar to the endpoint mortality, the subgroup analysis of the primary study authors suggests that for the seronegative group, the requirement of invasive mechanical ventilation was lower in the casirivimab/imdevimab arm than in the usual care arm (30% compared to 37%; RR 0.83, 95% CI 0.75 to 0.92). In the seropositive and unknown status groups, there was no difference between the treatment arms (seropositive: 19% compared to 17%, RR 1.10, 95% CI 0.97 to 1.24; unknown: 29% compared to 27%; RR 1.05, 95% CI 0.87 to 1.26).  </p> </section> <section id="CD013825-sec-0144"> <p><b>Hospital discharge alive</b></p> <p>In the complete randomised group, casirivimab/imdevimab has probably little to no effect on hospital charge alive by day 28 compared to placebo (697 compared to 690 per 1000; RR 1.01, 95% CI 0.98 to 1.04; 1 RCT, 9785 participants; moderate‐certainty evidence; <a href="./references#CD013825-fig-0053" title="">Analysis 7.3</a>). We downgraded one level due to serious risk of bias, which we rated as high based on the lack of blinding and a yet undefined standard of care, which may have led to differences in concomitant treatment (i.e., the timing of concomitant treatment). </p> <p>The subgroup analysis of the primary study authors suggests that in the seronegative group, more participants were discharged alive by day 28 compared to usual care (64% compared to 58%, RR 1.19, 95% CI 1.08 to 1.30), whereas there was no difference between the arms in the seronegative and unknown group (seropositive: 75% versus 77%, RR 0.94, 95% CI 0.88 to 1.00; unknown: 63% versus 64%, RR 0.96, 95% CI 0.83 to 1.10).  </p> </section> </section> <section id="CD013825-sec-0145"> <h6 class="title">Additional outcomes</h6> <p><a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> did not report results on our additional outcomes admission to ICU, length of ICU stay, viral clearance, and neurological dysfunction. </p> <section id="CD013825-sec-0146"> <p><b>Length of hospital stay</b></p> <p>Length of hospital stay was reported as median duration of hospitalisation. In the complete randomised sample, the median duration was 10 days in the casirivimab/imdevimab group compared to 10 days in the usual care group, it is unclear whether the reported interval was the range or the interquartile range. </p> </section> <section id="CD013825-sec-0147"> <p><b>Thromboembolic events</b></p> <p>Treatment with casirivimab/imdevimab has probably little to no effect on thrombotic events compared with usual care in the complete randomised group; 249 out of 4839 experienced an event in the intervention arm; 248 out of 4946 experienced an event under usual care (RR 1.03; 95% CI 0.86 to 1.22; 1 RCT, 9785 participants; <a href="./references#CD013825-fig-0054" title="">Analysis 7.4</a>).  </p> </section> <section id="CD013825-sec-0148"> <p><b>Renal dysfunction</b></p> <p>Treatment with casirivimab/imdevimab has probably little effect on the requirement of renal replacement therapy for those not on renal replacement therapy at baseline, with 203 out of 4783 in the casirivimab/imdevimab arm experiencing an event compared with 201 out of 4887 in the usual care arm (RR 1.03, 95% CI 0.85 to 1.25; 1 RCT, 9670 participants; <a href="./references#CD013825-fig-0055" title="">Analysis 7.5</a>). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013825-sec-0149" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013825-sec-0149"></div> <section id="CD013825-sec-0150"> <h3 class="title" id="CD013825-sec-0150">Summary of main results</h3> <p>The aim of this review was to assess the effectiveness and safety of SARS‐CoV‐2‐neutralising neutralising monoclonal antibodies (mAbs) for the treatment of COVID‐19. We identified six randomised controlled trials (RCTs) (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>; <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>; <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>; <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>). Three studies were published as preprint only (<a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>; <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>).  <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> or as a journal publication with additional data from two preprints (<a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>).  </p> <p>Four studies included outpatients receiving either bamlanivimab or bamlanivimab in combination with etesevimab (<a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>), a combination of casirivimab and imdevimab (under the trade name REGN‐COV2) (<a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>), regdanvimab (<a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>), or sotrovimab (<a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>). Two studies included hospitalised participants treated with bamlanivimab (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>) or a combination of casirivimab and imdevimab (<a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>).  </p> <p>All six included RCTs are active. However, most of them have stopped enrolment and participants are being followed‐up. One study is continuing observation of the respective arm (<a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>), two have added additional arms with different mAbs or doses (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>,  <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>), and one continues with other treatments not relevant to this review (<a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>). <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, part of a phase 2 to 3 study examining three doses of bamlanivimab and combination therapy with etesevimab, published interim results on 592 randomised participants. Additionally, results from phase 3 of this study were reported for 1035 participants who received bamlanivimab/etesevimab or placebo (<a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>). Regdanvimab at two different doses (0.04 g or 0.08g) compared to placebo was examined in <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>, a two‐part phase 2 to 3 study. Results of a preplanned interim anlysis of the first part of the study, including 327 participants, were reported in a preprint.  <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>, another phase 2 to 3 study, examined sotrovimab compared to placebo and reported results of a preprint interim analysis on 583 participants. Recruitment was stopped on 10 March 2021 for benefit after 1057 participants had been randomised. There were separate data cut‐offs for efficacy and safety. <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> published a final analysis of phase 1/2 on 799 participants who were assigned to casirivimab plus imdevimab (2.4g or 8.0g) or placebo and results from the ongoing phase 3 (<a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>) where 5607 participants were randomised to receive the combination casirivimab plus imdevimab (at three different doses 1.2g, 2.4g, 8.0g) or placebo. Based on results from <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>, the trial was amended in November 2020 and only participants with at least one risk factor for severe COVID‐19 were included and no longer randomised to 8.0g casirivimab and imdevimab. In February 2021, participants were no longer randomised to placebo. <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>, a platform trial, stopped recruitment to the bamlanivimab arm for futility after preplanned interim analysis, including 314 patients. In <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>, another platform trial, 9785 participants were randomised to receive either a combination of casirivimab and imdevimab or usual care. </p> <section id="CD013825-sec-0151"> <h4 class="title">Non‐hospitalised individuals</h4> <p>Evidence suggests that the various doses of bamlanivimab may reduce admissions to hospital or death in outpatients (mild cases according to the previous World Health Organization (WHO) scale) compared to placebo, although the confidence intervals include both benefit and harm. Little to no effect may be seen on the occurrence of adverse events and viral clearance. The occurrence of serious adverse events was too rare to allow a judgment. All evidence should be interpreted with caution due to very serious imprecision; data are from one small study, event numbers are low and confidence intervals are wide.  </p> <p>For the mAb combination bamlanivimab and etesevimab compared to placebo in mild cases, evidence suggests a similar pattern to bamlanivimab. The combination may reduce admissions to hospital, but may have little to no effect on the occurrence of adverse events. We could not assess mortality in this study as there were no deaths, and the occurrence of serious adverse events was too rare to allow a judgment. Other preplanned outcomes for this review were not reported. Similar to the comparison for bamlanivimab alone in mild COVID‐19, data are from one small study only, so evidence should be considered uncertain due to very serious imprecision.  </p> <p>Although a preprint with phase 3 data for the comparison between multiple doses of casirivimab and imdevimab to placebo was available, we base our summary on the part 1/2 preprint only due to several uncertainties regarding the included participants. Casirivimab/imdevimab may reduce hospital admissions, however, the confidence interval includes both benefits and harms. For the outcomes grades 3 to 4 adverse events and serious adverse events, there were too few events to allow a judgment. No other outcomes were reported in part 1/2 of the study. Evidence should be considered uncertain due to very serious imprecision.  </p> <p>Sotrovimab may reduce the number of participants with oxygen requirement, hospitalisations or death, the number of hospital admissions or death, and the occurrence of grades 3 to 4 and serious adverse events compared to placebo, although the confidence intervals include both benefit and harms. Events for the outcomes mortality and invasive mechanical ventilation (IMV) requirement or death were too rare to allow a judgment on the effect. Data for this comparison should be interpreted with caution as they originate from one small study with low number of events and wide confidence intervals. </p> <p>Evidence suggests that regdanvimab at either 40 mg or 80 mg/kg may reduce hospital admissions, and the 80 mg/kg dose may reduce adverse events when compared with placebo, although the confidence interval includes both benefits and harms. In contrast, regdanvimab may increase grade 3 adverse events, however, the confidence intervals include both benefit and harm. It may have little to no effect on viral clearance at day 15. We could not assess mortality, IMV requirement or death, serious adverse events, and admission to: intensive care unit (ICU), as no or few events took place. Due to the small sample size and low number of events, any evidence has to be interpreted with caution. </p> </section> <section id="CD013825-sec-0152"> <h4 class="title">Hospitalised individuals</h4> <p>We are uncertain whether bamlanivimab has an effect on mortality and serious adverse events in hospitalised, moderate‐to‐severe COVID‐19 cases, compared to placebo. It may increase grades 3 to 4 adverse events compared to placebo but seemed to have little to no effect on hospital discharge, non‐invasive ventilation (NIV) or IMV requirement or death, and sustained recovery. The number of events for the outcomes neurological dysfunction, thromboembolic events and renal failure was too low to allow for judgment. Our certainty in the evidence is low due to very serious imprecision. Our certainty in the evidence for NIV or IMV requirement was further downgraded for indirectness due to the short time frame. The study authors reported results for 90‐day mortality and<b> </b>serious adverse events (SAEs) that suggest a difference in effect between participants who were seronegative as compared to seropositive at baseline; for seronegative, the effect may be in favour of bamlanivimab, the opposite tendency was observed in seropositive participants. </p> <p>Evidence for casirivimab/imdevimab suggests that the treatment at a dose of 8.0 g may have little to no effect on all‐cause mortality, clinical progression to IMV or death, hospital discharge alive, thrombotic events, and renal replacement therapy requirement compared with usual care alone in the complete randomised cohort. We have moderate certainty in the evidence due to high risk of bias. In line with the subgroups from ACTIV‐3, when looked at seronegative participants at baseline only, the study authors found an effect, while no effect was found for participants who already seroconverted or with unknown status. </p> </section> <section id="CD013825-sec-0153"> <h4 class="title">Ongoing studies</h4> <p>Thirty‐six RCTs examining 23 different SARS‐CoV‐2‐specific mAbs or mAb combinations are currently ongoing or completed without published results. Of these, all except one are being explored in phase 2 studies onwards. We identified five additional mAbs that have not yet been tested in RCTs as part of our tracking of emerging mAbs. </p> </section> </section> <section id="CD013825-sec-0154"> <h3 class="title" id="CD013825-sec-0154">Overall completeness and applicability of evidence</h3> <section id="CD013825-sec-0155"> <h4 class="title">Completeness of the evidence</h4> <p>Completeness within our included studies varied. <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> reported on all preplanned outcomes, and <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> on all outcomes, but not in all preplanned formats. These outcomes are, unfortunately, not our complete set of preplanned outcomes. <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>; <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>; <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> and <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> reported up to eight preplanned outcomes, but <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> did not fully report these for all doses. <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> reported only three preplanned outcomes. We contacted study authors, but they could not provide us with additional data or did not reply. As some studies were published as interim analyses or preprints, we expect that more data will become available with the final analysis and in full publications. </p> </section> <section id="CD013825-sec-0156"> <h4 class="title">Applicability of the evidence</h4> <p>Overall, the evidence included in this review  represents two distinct populations: individuals with mild disease, and individuals with moderate‐to‐severe disease who are already hospitalised due to COVID‐19. During the course of this review, the WHO progression scale has changed multiple times. Since the decision to use the scale in <a href="#CD013825-fig-0001">Figure 1</a>, it was changed on 25 January 2021 to represent different cut‐offs and categories: mild, moderate, severe and critical disease based on severity of pneumonia instead of hospitalisation (<a href="./references#CD013825-bbs2-0273" title="World Health Organization. COVID-19 Clinical management - living guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 (last accessed 08.07.2021)2021. [WHO/2019-nCoV/clinical/2021.1]">WHO 2021c</a>). We will consider adopting the most recent scale in a future update of this review. </p> <p>Four RCTs examined SARS‐CoV‐2‐specific mAbs in outpatients with mild disease. The various treatment arms in the samples included between 63% to 100% of participants who have at least one risk factor for severe disease, which may be slightly overrepresented when compared to modelling estimates for the general population (<a href="./references#CD013825-bbs2-0187" title="ClarkA , JitM , Warren-GashC , GuthrieB , WangHH , MercerSW , et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Global Health2020;8(8):E1003-17. [DOI: 0.1016/S2214-109X(20)30264-3]">Clark 2020</a>). However, this subgroup would be in more urgent need for the prevention of serious adverse outcomes. This was reflected in the initial emergency use authorisation (EUA) that was provided by the US Food and Drug Administration (FDA) for the combination of casirivimab and imdevimab, bamlanivimab, and bamlanivimab with etesevimab. The EUA for bamlanivimab was revoked on 17 April 2021 per Eli Lilly's request for bamlanivimab alone due to an increase in virus variants that are resistant to bamlanivimab monotherapy (<a href="./references#CD013825-bbs2-0197" title="US Food and Drug Administration. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab. www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab (accessed 27 April 2021).">FDA 2021b</a>). </p> <p>The median time from symptom onset to randomisation ranged from two to six days (median five, range three to six days in <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; four days, range 0 to 29 days in <a href="./references#CD013825-bbs2-0006" title="DouganM , NirulaA , AzizadM , MocherlaB , GottliebRL , ChenP , et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. New England Journal of Medicine2021;-:-. [DOI: 10.1056/NEJMoa2102685]DouganM , NirulaA , GottliebRL , AzizadM , MocherlaB , ChenP , et al. Bamlanivimab + etesevimab for treatment of COVID-19 in high-risk ambulatory patients. Topics in Antiviral Medicine2021;29(1):33, abstract no. 122. ">BLAZE‐1 (phase 3)</a>; three days, rangetwo2 to four days in <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a> and three days, range two to five days in <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>). We are unable to extrapolate the evidence from this time window to a longer period. It remains to be seen whether the time frame in the context of an RCT with predefined eligibility criteria (i.e. symptom onset within seven days of enrolment) can be transferred to a situation of possibly overwhelmed hospitals where space may be scarce for treatments that need intravenous infusions. </p> <p>The platform trial that examined bamlanivimab in hospitalised, moderate‐to‐severe cases in the USA, Denmark and Singapore (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>), had less restrictive eligibility criteria with a maximum of 12 days being allowed between symptom onset and treatment. However, the population that is considered to quote:  "require admission to hospital for acute medical care" may vary depending on context. Despite this possible source of heterogeneity, in general, we would consider evidence from <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> applicable to inpatients (moderate to severe disease). <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>, which examined the combination casirivimab/imdevimab, allowed clinically suspected cases without a positive polymerase chain reaction(PCR) result to enter the study, but the number of non‐confirmed cases was low (&lt; 1% PCR‐negative, ~ 2.3% unknown). The study did not limit inclusion based on time from symptom onset. However, time from symptom onset varied between the serostatus groups (seronegative: 7 days, 4 to 10; seropositive: 10 days, 7 to 13; unknown: 9 days, 6 to 13), underlining the assumption that SARS‐CoV‐2 specific mAbs may be more effective early in the course of the disease. </p> <p>Over time, the virus has developed changes compared to the original strain. Some of these changes have led to increased resistance to viral neutralisation by antibody therapy (<a href="./references#CD013825-bbs2-0197" title="US Food and Drug Administration. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab. www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab (accessed 27 April 2021).">FDA 2021b</a>; <a href="./references#CD013825-bbs2-0223" title="MadhiSA , BaillieV , CutlandCL , VoyseyM , KoenAL , FairlieL , et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. New England Journal of Medicine2021;384:1885-98. [DOI: 10.1056/NEJMoa2102214]">Madhi 2021</a>; <a href="./references#CD013825-bbs2-0278" title="ZhouD , Wanwisa DejnirattisaiW , SupasaP , LiuC , MentzerAJ , GinnHM , et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell2021;184(9):2348-61. [DOI: 10.1016/j.cell.2021.02.037]">Zhou 2021</a>), which led to the retraction of the EUA for bamlanivimab monotherapy (<a href="./references#CD013825-bbs2-0197" title="US Food and Drug Administration. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for monoclonal antibody bamlanivimab. www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab (accessed 27 April 2021).">FDA 2021b</a>). </p> <p><a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> mentioned assessing viral strains at baseline, with only two out of the 613 included participants having detectable variants at baseline. The enrolment into the <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> bamlanivimab arm stopped in October 2020, before the wider spread of variants, and reported. Therefore, results from these early studies probably apply mainly to the wild type variant. It is important to note that the beta, gamma, delta, and epsilon variants, which are currently more widespread, have shown resistance to bamlanivimab using pseudovirus and clinical viral isolate assays (<a href="./references#CD013825-bbs2-0208" title="HoffmannM , AroraP , GroßR , SeidelA , HörnichBF , HahnAS , et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell2021;184(9):2384-93.e12. [DOI: 10.1016/j.cell.2021.03.036]">Hoffmann 2021b</a>; <a href="./references#CD013825-bbs2-0228" title="McCallumM , BassiJ , De MarcoA , ChenA , WallsAC , Di IulioJ , et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science2021;-:eabi7994. [DOI: 10.1126/science.abi7994 Article]">McCallum 2021</a>; <a href="./references#CD013825-bbs2-0243" title="PlanasD , VeyerD , BaidaliukA , StaropoliI , Guivel-BenhassineF , RajahMM , et al. Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals. bioRxiv2021. [DOI: 10.1101/2021.05.26.445838]">Planas 2021</a>; <a href="./references#CD013825-bbs2-0261" title="WangP , NairMS , LiuL , IketaniS , LuoY , GuoY , et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature2021;593:130-5. [DOI: 10.1038/s41586-021-03398-2]">Wang 2021b</a>). Etesevimab has shown diminished activity against the alpha and epsilon variant but remained active against beta and delta (<a href="./references#CD013825-bbs2-0243" title="PlanasD , VeyerD , BaidaliukA , StaropoliI , Guivel-BenhassineF , RajahMM , et al. Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals. bioRxiv2021. [DOI: 10.1101/2021.05.26.445838]">Planas 2021</a>; <a href="./references#CD013825-bbs2-0228" title="McCallumM , BassiJ , De MarcoA , ChenA , WallsAC , Di IulioJ , et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science2021;-:eabi7994. [DOI: 10.1126/science.abi7994 Article]">McCallum 2021</a>). </p> <p>In the study on sotrovimab, virus variants were not assessed in participants. In vitro studies indicate that sotrovimab probably remains active against the alpha, beta, gamma (<a href="./references#CD013825-bbs2-0181" title="CathcartAL , Havenar-DaughtonC , LemppFA , MaD , SchmidM , AgostiniML , et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. [DOI: 10.1101/2021.03.09.434607]">Cathcart 2021</a>), and epsilon (<a href="./references#CD013825-bbs2-0228" title="McCallumM , BassiJ , De MarcoA , ChenA , WallsAC , Di IulioJ , et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science2021;-:eabi7994. [DOI: 10.1126/science.abi7994 Article]">McCallum 2021</a>) variants. The study examining regdanvimab has not assessed the virus strains participants were infected with. In vitro, regdanvimab maintained potency against the gamma variant, but showed reduced binding to the beta and epsilon variants (<a href="./references#CD013825-bbs2-0247" title="Ryu D-K, SongR , KimM , Kim Y-I, KimC , Kim J-I, et al. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochemical and Biophysical Research Communications2021;566:135-40. [PMID: 10.1016/j.bbrc.2021.06.016]">Ryu 2021</a>; <a href="./references#CD013825-bbs2-0228" title="McCallumM , BassiJ , De MarcoA , ChenA , WallsAC , Di IulioJ , et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science2021;-:eabi7994. [DOI: 10.1126/science.abi7994 Article]">McCallum 2021</a>). </p> <p><a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> and <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>/<a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> did not explicitly assess the variants that affected their participants. However, the dominant strain at the time of <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> enrolment was the B1.1.7 (alpha) variant in the UK, which has not shown resistance to casirivimab/imdevimab (<a href="./references#CD013825-bbs2-0261" title="WangP , NairMS , LiuL , IketaniS , LuoY , GuoY , et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature2021;593:130-5. [DOI: 10.1038/s41586-021-03398-2]">Wang 2021b</a>). In general, imdevimab and the combination casirivimab/imdevimab has not shown diminished performance against alpha, beta, gamma, delta and epsilon variants (<a href="./references#CD013825-bbs2-0207" title="HoffmannM , Hofmann-WinklerH , KrügerN , KempfA , NehlmeierI , GraichenL , et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. bioRxiv2021. [DOI: 10.1101/2021.05.04.442663]">Hoffmann 2021a</a>; <a href="./references#CD013825-bbs2-0243" title="PlanasD , VeyerD , BaidaliukA , StaropoliI , Guivel-BenhassineF , RajahMM , et al. Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals. bioRxiv2021. [DOI: 10.1101/2021.05.26.445838]">Planas 2021</a>; <a href="./references#CD013825-bbs2-0190" title="CopinR , BaumA , WlogaE , PascalKE , GiordanoS , FultonBO , et al. In vitro and in vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans. bioRxiv. [DOI: 10.1101/2021.03.10.434834]">Copin 2021</a>; <a href="./references#CD013825-bbs2-0228" title="McCallumM , BassiJ , De MarcoA , ChenA , WallsAC , Di IulioJ , et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science2021;-:eabi7994. [DOI: 10.1126/science.abi7994 Article]">McCallum 2021</a>). Whereas, casirivimab alone was less active against the beta (<a href="./references#CD013825-bbs2-0261" title="WangP , NairMS , LiuL , IketaniS , LuoY , GuoY , et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature2021;593:130-5. [DOI: 10.1038/s41586-021-03398-2]">Wang 2021b</a>) and delta variants (<a href="./references#CD013825-bbs2-0207" title="HoffmannM , Hofmann-WinklerH , KrügerN , KempfA , NehlmeierI , GraichenL , et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. bioRxiv2021. [DOI: 10.1101/2021.05.04.442663]">Hoffmann 2021a</a>). </p> <p>Overall, combination therapies may be more applicable because of the broader spectrum of neutralisation and a smaller possibility of viral escape (<a href="./references#CD013825-bbs2-0190" title="CopinR , BaumA , WlogaE , PascalKE , GiordanoS , FultonBO , et al. In vitro and in vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans. bioRxiv. [DOI: 10.1101/2021.03.10.434834]">Copin 2021</a>). </p> </section> </section> <section id="CD013825-sec-0157"> <h3 class="title" id="CD013825-sec-0157">Quality of the evidence</h3> <p>We judged the risk of bias to be low for two studies (<a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>), to be of some concerns for one study (<a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>), and high for two studies (<a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>; <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a>) for all reported outcomes. In <a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>, we judged risk of bias to be of some concerns for the outcome hospital admission or death and for the other reported outcomes we judged risk of bias to be low. In <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> we judged risk of bias to be high for the outcomes hospital admission or death and adverse events grades 3 to 4, and for the other reported outcomes we judged risk of bias to be low.  We excluded <a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> from analysis due to the unclear participant flow diagram and potentially selected analyses. </p> <p>All data included in the summary of findings tables resulted from analyses according to the intention‐to‐treat principle or modified intention‐to‐treat principle, as prespecified in the respective study protocol (exclusions if randomised by error, withdrawal before any study treatment or not positive on diagnostic reverse transcription polymerase chain reaction (RT‐PCR)). However, we rated the certainty in the evidence as low or very low for each prioritised outcome in all studies except <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>, due to serious imprecision based on low number of events, small sample size, and resulting wide 95% confidence intervals (for details, see summary of findings tables) with evidence per comparison resulting from one study only. We downgraded one outcome, development of severe symptoms (NIV, IMV or extracorporeal membrane oxygenation (ECMO)), because of serious indirectness, as we considered follow‐up at day five as too short. For the results from <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>, we rated down one level due to lack of blinding and the potential influence from participants or staff on additional treatment options, as usual care is constantly changing seen the rapid development of the pandemic. </p> </section> <section id="CD013825-sec-0158"> <h3 class="title" id="CD013825-sec-0158">Potential biases in the review process</h3> <p>The publication of preliminary results in form of press releases and preprints has become widespread during the COVID‐19 pandemic. While we had decided to include and report on preprints, we have not tracked all possible sources of press releases because quality may be low and reports may lack detail regarding participants and outcomes, although some are indexed in Epistemonikos. </p> <p>In addition to regular RCTs, we performed a search for ongoing platform trials, as they may add treatments during the course of the study. We are regularly checking these studies via the registry, any related trial websites we are aware of, and press releases that are indexed in Epistemonikos. Up to now, this has proved useful in identifying new treatment arms with SARS‐CoV‐2‐specific mAbs in <a href="./references#CD013825-bbs2-0137" title="NCT04518410. ACTIV-2: a study for outpatients with COVID-19. clinicaltrials.gov/ct2/show/NCT04518410 (first received 19 August 2020). ">ACTIV‐2</a>, <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>, <a href="./references#CD013825-bbs2-0138" title="EUCTR2020-001860-27. AGILE: seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment. A randomised phase I/II study to determine the safety and effectiveness of multiple drugs for the treatment of COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001860-27/GB (first received 17 April 2020). GriffithsG , FitzgeraldR , JakiT , CorkhillA , MarwoodE , ReynoldsH , et al. AGILE-ACCORD: a randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: a structured summary of a study protocol for a randomised platform trial. Trials2020;21(1):544. [DOI: 10.1186/s13063-020-04473-1]">AGILE</a>, <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>, <a href="./references#CD013825-bbs2-0139" title="AderF , Discovery French Trial Management Team. Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ open2020;10(9):e041437. [DOI: 10.1136/bmjopen-2020-041437]NCT04315948. Trial of treatments for COVID-19 in hospitalised adults (DisCoVeRy). clinicaltrials.gov/ct2/show/NCT04315948 (first received 20 March 2020). ">DISCOVERY</a>, and <a href="./references#CD013825-bbs2-0172" title="NCT04790786. UPMC OPTIMISE-C19 Trial, a COVID-19 Study (OPTIMISE-C19). clinicaltrials.gov/ct2/show/NCT04790786. ">OPTIMISE‐C19</a>. We will run these searches and check for additional treatment arms monthly. Interestingly, in addition to large‐scale platform trials, flexible study designs such as combined phase 1/2/3 trials with preplanned interim analyses, the potential to change the treatment dose during the process, and the batch‐wise recruitment of participants according to new cases have become common, posing a challenge on estimating the arrival of new studies and the decision on when to potentially update this review in the future. </p> <p>Due to the novelty of SARS‐CoV‐2, numerous interventions are currently under development. To maintain the currency of our evidence and to follow the newly developed mAbs that enter clinical studies in humans, we adapted our search strategy each week, based on a monoclonal antibody tracker (<a href="./references#CD013825-bbs2-0185" title="Chinese Antibody Society. chineseantibody.org (accessed 9 November 2020).">Chinese Antibody Society 2020</a>). Recently, this tracker has not identified any new SARS‐CoV‐2‐specific mAbs. There may be two possible underlying reasons for this: 1) no mAbs have entered clinical trial phase, which is unlikely given the rapidly changing COVID‐19‐related treatment landscape, 2) updating the list may have been delayed or stopped. In the latter case, we may have missed studies that are identified only with a drug name that is currently unknown to us. However, we would count on the fact that clinical studies in an advanced phase and their publications would provide more keywords for identification by our search strategy. We, therefore, assume that we have identified and will identify important phase 2, 3, and 4 RCTs in individuals infected with SARS‐CoV‐2. </p> <p>For feasibility reasons, we did an abbreviated search between submission and response to peer review. We included publications on already included studies, but listed one new study under <a href="./references#CD013825-bbs1-0003" title="">Studies awaiting classification</a> for integration into the next version of this review. </p> <p>Before data extraction, we had decided not to pool different monoclonal antibodies/antibody cocktails due to the different epitopes they are targeting, and not to pool different doses of the same mAb as they may produce varying levels of antibody‐dependent enhancement. We acknowledge that combining across doses and substances may have provided insight into the class effect, however, this would limit its utility in clinical decision‐making by combining substances that target different pathways and may be used in different settings due to varying prevalence of variants to which a mAb may have become resistant. </p> <p>In contrast to the protocol, we changed some of our outcomes based on input from the German clinical guideline, and we faced difficulties obtaining a clear definition for outcomes covered by the WHO Progression Scale (<a href="#CD013825-sec-0182">Differences between protocol and review</a>). Of note, most of our predefined outcomes are prone to competing events (i.e. death), therefore we have changed and replaced these where possible, and noted down where not reported. We do not think this has introduced bias, as we chose the outcomes based on clinical interest rather than the effect estimate. </p> </section> <section id="CD013825-sec-0159"> <h3 class="title" id="CD013825-sec-0159">Agreements and disagreements with other studies or reviews</h3> <p>We identified low‐certainty evidence about the effects of bamlanivimab at doses of 0.7 g, 2.8 g, and 7.0 g, the combination of bamlanivimab and etesevimab, the of combination casirivimab and imdevimab, sotrovimab at a dose of 0.5 g, and regdanvimab at 40 mg/kg and 80 mg/kg compared to placebo in non‐hospitalised individuals with asymptomatic or mild disease. Further, we identified low‐ to very low‐certainty evidence that treatment with bamlanivimab in hospitalised individuals with moderate‐to‐severe disease is not effective for the treatment of COVID‐19, when compared to placebo; and moderate‐certainty evidence that casirivimab/imdeviman is not effective to treat COVID‐19 when compared to usual care in the complete allocated cohort of a study. </p> <p>The identified studies published as full texts and preprints are in line with the evidence used in the Australian clinical guideline (<a href="./references#CD013825-bbs2-0234" title="National COVID-19 Clinical Evidence Taskforce. Caring for people with COVID-19: supporting Australia’s healthcare professionals with continually updated, evidence-based clinical guidelines. covid19evidence.net.au/#living-guidelines (accessed 7 December 2020).">National COVID‐19 Clinical Evidence Taskforce 2020</a>). This guideline pooled the two studies that examined bamlanivimab, and did not consider the conference abstract on bamlanivimab/etesevimab. Another difference is that we decided to refrain from meta‐analysing participants with mild versus moderate and severe disease, as working mechanisms are anticipated to differ between early administration and administration later during the course of the disease. The prioritised outcomes differed from this review, the guideline included clinical recovery for regdanvimab and withdrawals due to adverse events for casirivimab/imdevimab in non‐hospitalised participants. </p> <p>A difference in the mechanism between the granting of an emergency use authorization (EUA) and summaries in systematic reviews and recommendations by several national clinical guidance (e.g. Australia, Germany) should be noted. An EUA is possible only in the context of a declared emergency when no viable alternatives are available. It does not constitute the approval of a medical product but facilitates its availability when it is not yet approved or is approved for a different indication. This decision may be based on favourable interim or final analyses of an RCT and may be revoked once the justification of its issuance is no longer in place (<a href="./references#CD013825-bbs2-0198" title="US Food and Drug Administration. Emergency use authorization. www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.">FDA 2021c</a>). In contrast, systematic reviews aim to synthesise all available evidence, usually from peer‐reviewed journals only, thus targeting the inclusion of mature data (although for the current review, mainly interim analyses from preprint or full‐text publications were available). </p> <p>The efficacy and safety of SARS‐CoV‐2‐neutralising mAbs are not yet well‐characterised, with only a few studies having been published (<a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a>; <a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a>; <a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a>; <a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a>; <a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a>; <a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a>). Additional data in the form of full‐text publications are expected to be published soon, and several studies have completed recruitment, therefore new evidence will not be long in coming. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013825-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-FIG-01" target="_blank"><b></b></a></p> </div><img alt="ECMO: extracorporeal membrane oxygenation; FiO2: fraction of inspired oxygen; NIV: non‐invasive ventilation; pO2: partial pressure of oxygen; RNA: ribonucleic acid; SpO2: oxygen saturationaWHO Clinical Progression Scale from The Lancet Infectious diseases: Marshall 2020. Copyright © 2020 Elsevier Ltd. All rights reserved: reproduced with permission.bIf hospitalised for isolation only, record status for ambulatory patient." data-id="CD013825-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p><b>ECMO:</b> extracorporeal membrane oxygenation; <b>FiO<sub>2</sub>:</b> fraction of inspired oxygen; <b>NIV:</b> non‐invasive ventilation; <b>pO<sub>2</sub>:</b> partial pressure of oxygen; <b>RNA:</b> ribonucleic acid; <b>SpO<sub>2</sub>:</b> oxygen saturation </p> <p><sup>a</sup>WHO Clinical Progression Scale from The Lancet Infectious diseases: <a href="./references#CD013825-bbs2-0226" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>. Copyright © 2020 Elsevier Ltd. All rights reserved: reproduced with permission. </p> <p><sup>b</sup>If hospitalised for isolation only, record status for ambulatory patient. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-FIG-02" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD013825-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-FIG-02.jpg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-FIG-02.jpg" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-FIG-02.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-FIG-03" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram RCT search between 18 June and 30 July 2021" data-id="CD013825-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-FIG-03.jpg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-FIG-03.jpg" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>PRISMA flow diagram RCT search between 18 June and 30 July 2021</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-FIG-03.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Mortality by day 30" data-id="CD013825-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Mortality by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 2: Admission to hospital or death" data-id="CD013825-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 2: Admission to hospital or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 3: Viral clearance at day 7" data-id="CD013825-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 3: Viral clearance at day 7 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 4: Viral clearance at day 15" data-id="CD013825-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 4: Viral clearance at day 15 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 5: Adverse events: all grades" data-id="CD013825-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 5: Adverse events: all grades </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 6: Serious adverse events" data-id="CD013825-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 6: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Mortality by day 30" data-id="CD013825-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Mortality by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 2: Admission to hospital or death" data-id="CD013825-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 2: Admission to hospital or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 3: Viral clearance at day 3" data-id="CD013825-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 3: Viral clearance at day 3 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 4: Viral clearance at day 7" data-id="CD013825-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 4: Viral clearance at day 7 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 5: Viral clearance at day 15" data-id="CD013825-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 5: Viral clearance at day 15 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 6: Adverse events: all grades" data-id="CD013825-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 6: Adverse events: all grades </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 7: Serious adverse events" data-id="CD013825-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 7: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Casirivimab/imdevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Admission to hospital or death" data-id="CD013825-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Casirivimab/imdevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Admission to hospital or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Casirivimab/imdevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 2: Adverse events: grade 3 and 4" data-id="CD013825-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Casirivimab/imdevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 2: Adverse events: grade 3 and 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Casirivimab/imdevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 3: Serious adverse events" data-id="CD013825-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Casirivimab/imdevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 3: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Mortality by day 30" data-id="CD013825-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Mortality by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 2: Development of severe symptoms according to WHO scale (≥ 5, incl. death)" data-id="CD013825-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 2: Development of severe symptoms according to WHO scale (≥ 5, incl. death) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 3: Development of severe symptoms according to WHO scale (≥ score 7, IMV, incl. death)" data-id="CD013825-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 3: Development of severe symptoms according to WHO scale (≥ score 7, IMV, incl. death) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 4: Admission to hospital or death" data-id="CD013825-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 4: Admission to hospital or death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 5: Admission to ICU by day 29" data-id="CD013825-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 5: Admission to ICU by day 29 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 6: Adverse events: all grades" data-id="CD013825-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 6: Adverse events: all grades </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 7: Adverse events: grade 3 and 4" data-id="CD013825-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 7: Adverse events: grade 3 and 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 8: Serious adverse events" data-id="CD013825-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 8: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Mortality by day 30" data-id="CD013825-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Mortality by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 2: Development of severe symptoms according to WHO scale (≥ score 7, IMV, incl. death)" data-id="CD013825-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 2: Development of severe symptoms according to WHO scale (≥ score 7, IMV, incl. death) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 3: Admission to hospital or death by day 30" data-id="CD013825-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 3: Admission to hospital or death by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 4: Admission to ICU by day 30" data-id="CD013825-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 4: Admission to ICU by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 5: Viral clearance at day 15" data-id="CD013825-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 5: Viral clearance at day 15 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 6: Adverse events: all grades" data-id="CD013825-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 6: Adverse events: all grades </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 7: Adverse events: grade 3 and 4" data-id="CD013825-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 7: Adverse events: grade 3 and 4 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 8: Serious adverse events" data-id="CD013825-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 8: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 1: Mortality by day 30" data-id="CD013825-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 1: Mortality by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 2: Mortality by day 90" data-id="CD013825-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 2: Mortality by day 90 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 3: Development of severe symptoms: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7)" data-id="CD013825-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 3: Development of severe symptoms: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 4: Development of severe symptoms: clinical status at day 5, intubation (group 6 at pulmonary scale)" data-id="CD013825-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 4: Development of severe symptoms: clinical status at day 5, intubation (group 6 at pulmonary scale) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 5: Hospital discharge up to 26 October 2020" data-id="CD013825-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 5: Hospital discharge up to 26 October 2020 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 6: Hospital discharge: at day 5" data-id="CD013825-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 6: Hospital discharge: at day 5 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 7: Adverse events: grade 3 and 4 by day 30" data-id="CD013825-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 7: Adverse events: grade 3 and 4 by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 8: Serious adverse events by day 30" data-id="CD013825-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 8: Serious adverse events by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 9: Serious adverse events (90 day follow‐up)" data-id="CD013825-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 9: Serious adverse events (90 day follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 10: Sustained recovery (90 day follow‐up)" data-id="CD013825-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 10: Sustained recovery (90 day follow‐up) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 11: Neurological dysfunction by day 30: transient ischemic events" data-id="CD013825-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 11: Neurological dysfunction by day 30: transient ischemic events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 12: Neurological dysfunction by day 30: acute delirium CVA" data-id="CD013825-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 12: Neurological dysfunction by day 30: acute delirium CVA </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 13: Neurological dysfunction by day 30: cerebrovascular event" data-id="CD013825-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 13: Neurological dysfunction by day 30: cerebrovascular event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 14: Thromboembolic events by day 30" data-id="CD013825-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 14: Thromboembolic events by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-006.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 15: Renal dysfunction (or need for dialysis) by day 30" data-id="CD013825-fig-0050" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-006.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6: Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 15: Renal dysfunction (or need for dialysis) by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-006.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 1: Mortality by day 30" data-id="CD013825-fig-0051" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 1: Mortality by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 2: Development of severe symptoms: requirement for IMV or death by day 28 (WHO ≥ 7)" data-id="CD013825-fig-0052" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 2: Development of severe symptoms: requirement for IMV or death by day 28 (WHO ≥ 7) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 3: Hospital discharge alive by day 30" data-id="CD013825-fig-0053" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 3: Hospital discharge alive by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 4: Thromboembolic events by day 30" data-id="CD013825-fig-0054" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 4: Thromboembolic events by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013825-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/urn:x-wiley:14651858:media:CD013825:CD013825-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 5: Renal dysfunction (or need for dialysis) by day 30" data-id="CD013825-fig-0055" src="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_t/tCD013825-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease), Outcome 5: Renal dysfunction (or need for dialysis) by day 30 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/media/CDSR/CD013825/image_n/nCD013825-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013825-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Bamlanivimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>Bamlanivimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> non‐hospitalised individuals with COVID‐19  <b>Setting:</b> outpatient<b> Intervention:</b> bamlanivimab<b> Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b> </b> </p> <p><b>Anticipated absolute effects* (95% CI)</b> </p> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty in the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo<br/> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with SARS‐CoV‐2‐specific mAb<br/> </b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Not estimable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101 bamlanivimab/156 placebo</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No events observed. We are uncertain whether 0.7 g bamlanivimab has any impact on mortality at up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 2.8 g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000 </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Not estimable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107 bamlanivimab/156 placebo</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No events observed. We are uncertain whether 2.8 g bamlanivimab has any impact on mortality at up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 7.0 g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Not estimable</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101 bamlanivimab/156 placebo</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No events observed. We are uncertain whether 7.0 g bamlanivimab has any impact on mortality at up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression/improvement of symptoms</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Admission to hospital by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>58 per 1000<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000 </b> </p> <p>(1 to 77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.17</b> </p> <p>(0.02 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g may decrease hospital admission at day 30.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 2.8 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>58 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>18 per 1000 </b> </p> <p>(4 to 85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.32</b> </p> <p>(0.07 to 1.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g may decrease hospital admission at day 30.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 7.0 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>58 per 1000<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>20 per 1000 </b> </p> <p>(5 to 90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.34 </b> </p> <p>(0.08 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g may decrease hospital admission at day 30.<br/>  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: all grades</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>269 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>267 per 1000 </b> </p> <p><b>(178 to 404)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.99</b> </p> <p>(0.66 to 1.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g may have little to no effect on all‐grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 2.8 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>269 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>242 per 1000</b> </p> <p>(159 to 372)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.90</b> </p> <p>(0.59 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263 </p> <p>(1RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 2.8 g may have little to no effect on all‐grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 7.0 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>269 per 1000<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>218 per 1000 </b> </p> <p>(140 to 342)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.81</b> </p> <p>(0.52 to 1.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 7.0 g may have little to no effect on all‐grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 0.7 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3 per 1000</b> </p> <p>(0 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.51</b> </p> <p>(0.02 to 12.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257 </p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>b</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced serious adverse events to determine whether bamlanivimab 0.7 g made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 2.8 g<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 1000<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3 per 1000</b> </p> <p>(0 to 76)<br/><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.48 </b> </p> <p>(0.02 to 11.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263 </p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced serious adverse events to determine whether bamlanivimab 2.8 g made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab 7.0 g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3 per 1000</b> </p> <p>(0 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.51</b> </p> <p>(0.02 to 12.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>257</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced serious adverse events to determine whether bamlanivimab 7.0 g made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk on the comparison group and the <b>relative effect</b> of the intervention (and its 95% confidence interval). </p> <p> </p> <p><b>CI:</b> confidence interval; <b>mAb:</b> monoclonal antibody; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty: </b>our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision, no events observed, effect not estimable<br/><sup>b</sup>Downgraded two levels for very serious imprecision, because of small sample size, low number of events and/or wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Bamlanivimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013825-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Bamlanivimab/etesevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bamlanivimab/etesevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) <b>Setting</b> : outpatients <b>Intervention</b> : bamlanivimab/etesevimab <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with bamlanivimab/ etesevimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b><br/>(0 to 15) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.05</p> <p>(0.00 to 0.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1035<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab/etesevimab may reduce all‐cause mortality by day 30.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60 ‐ not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Admission to hospital or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>21 per 1000</b><br/>(11 to 41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.30</b><br/>(0.16 to 0.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1035<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab/ etesevimab may decrease the risk hospital admission by day 30.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: all grades</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>116 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>133 per 1000</b><br/>(96 to 184) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.15</b><br/>(0.83 to 1.59) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1035<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab/ etesevimab may have little to no effect on the risk of all grade adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>14 per 1000</b><br/>(4 to 42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.40</b><br/>(0.45 to 4.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1035<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab/ etesevimab may increase the risk of serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_422966277463976837" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_422966277463976837</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels for very serious imprecision due to low number of events and low sample size<br/><sup>b</sup> Downgraded two levels for very serious imprecision, because of small sample size </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Bamlanivimab/etesevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013825-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Casirivimab/imdevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Casirivimab/imdevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population</b> : non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) <b>Setting</b> : outpatients <b>Intervention</b> : casirivimab/imdevimab <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Dose</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants </b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with casirivimab/imdevimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one study which was excluded from analysis reported results on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression: requirement of IMV (WHO 7, 8 or 9), 1.2g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one study which was excluded from analysis reported results on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Admission to hospital or death</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1.2g</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.4g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>9 per 1000</b><br/>(2 to 47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.43</b><br/>(0.08 to 2.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>446<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Casirivimab/imdevimab at 2.4 g or 8.0 g may reduce the occurrence of hospital admissions or death at day 30. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8.0g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>22 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5 per 1000</b><br/>(0 to 39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.21</b><br/>(0.02 to 1.79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>450<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Adverse events: grade 3‐4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1.2g</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one study which was excluded from analysis reported results on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.4g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>15 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12 per 1000</b><br/>(3 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.76</b> </p> <p>(0.17 to 3.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>a </sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>There were too few who experienced am event to determine whether any dose of casirivimab/imdevimab made a difference </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8.0g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>15 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b><br/>(1 to 42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.50</b><br/>(0.09 to 2.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>522<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: all grades</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one study which was excluded from analysis reported results on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1.2g</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only one study which was excluded from analysis reported results on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.4g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>16 per 1000</b><br/>(4 to 54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.68</b><br/>(0.19 to 2.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>520<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>There were too few who experienced am event to determine whether any dose of casirivimab/imdevimab made a difference. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>8.0g</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>23 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>8 per 1000</b><br/>(2 to 38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.34</b><br/>(0.07 to 1.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>522<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels due to very serious imprecision; low sample size and low number of events  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Casirivimab/imdevimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic or mild disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013825-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sotrovimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sotrovimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) <b>Setting</b> : outpatients <b>Intervention</b> : sotrovimab <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcome</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects*</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants** <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with sotrovimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b> </p> <p>(0 to 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.33</b><br/>(0.01 to 8.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced mortality to determine whether sotrovimab made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression: oxygen requirement (≥ 5 WHO scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>65 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>7 per 1000</b> </p> <p>(1 to 29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.11</b><br/>(0.02 to 0.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab may reduce the number of participants with any oxygen requirement.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression: IMV or death (≥ 7 WHO scale)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>10 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1 per 1000</b> </p> <p>(0 to 28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.14</b><br/>(0.01 to 2.76) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced an event to determine whether sotrovimab made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Admission to hospital or death by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>72 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>10 per 1000</b> </p> <p>(3 to 35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.14</b><br/>(0.04 to 0.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab may reduce the occurrence of hospital admissions or death.  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: all grades</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>194 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>169 per 1000</b> </p> <p>(128 to 225)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.87</b><br/>(0.66 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>868</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝</p> <p>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab may have little to no effect on the occurrence of all grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: grades 3 and 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 per 1000</b> </p> <p>(7 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.26</b><br/>(0.12 to 0.60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>868</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab may reduce the occurrence of grade 3‐4 adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>59 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 per 1000</b> </p> <p>(7 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.27</b><br/>(0.12 to 0.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>868</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab may reduce the occurrence of serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/>  </p> <p>**This study included a total of 868 participants. All were 868 participants randmoised were included in the safety set, but only 583 participants were analysed in the efficacy set. </p> <p> <br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty: </b>our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels for very serious imprecision, because of low sample size, very low number of events and very wide confidence interval </p> <p><sup>b</sup> Downgraded two levels for very serious imprecision, because of low sample size and/or low number of events </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sotrovimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013825-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Regdanvimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Regdanvimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population</b> : non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) <b>Setting</b> : outpatient <b>Intervention</b> : regdanvimab <b>Comparison</b>: placebo    </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> </b> (95% CI)<b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI) </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies) </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE) </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with regdanvimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Regdanvimab 40mg/kg</p> <p>CT‐P59 80 mg/kg</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b><br/>(0 to 0)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No events observed. We are uncertain whether CT‐P59 has any impact on mortality at up to day 30. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Clinical progression: development of severe symptoms (≥ 7 WHO scale, IMV)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b><br/>(0 to 0)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No events observed. We are uncertain whether 40 mg/kg regdanvimab has any impact on IMV requirement or death. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0 per 1000</b><br/>(0 to 0)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.00</b><br/>(0.12 to 72.80)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103<br/>(1 study)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There were too few who experienced IMV or death to determine whether CT‐P59, 80 mg/kg made a difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Admission to hospital or death by day 30 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>87 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39 per 1000</b><br/>(12 to 124) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.45</b><br/>(0.14 to 1.42)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204<br/>(1 RCT)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Regdanvimab, 40 mg/kg or 80 mg/kg may decrease hospital admission or death by day 30. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>87 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>49 per 1000</b><br/>(17 to 140) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.56</b><br/>(0.19 to 1.60)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206<br/>(1 RCT)  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events: all grades</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>309 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>297 per 1000</b><br/>(198 to 442) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.96</b><br/>(0.64 to 1.43)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>215<br/>(1 RCT)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regdanvimab 40 mg/kg may have little to no effect on all grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>309 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>244 per 1000</b><br/>(161 to 377) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.79</b><br/>(0.52 to 1.22)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220<br/>(1 RCT)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regdanvimab 80 mg/kg may reduce the occurrence of all grade adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Adverse events: grades 3 and 4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>40 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>48 per 1000</b><br/>(9 to 239)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.62</b><br/>(0.52 to 13.12)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>215<br/>(1 RCT)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Regdanvimab 40 mg/kg or 80 mg/kg may increase the occurrence of grade 3 adverse events.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>80 mg/kg </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 1000 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>36 per 1000</b><br/>(7 to 195)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.00</b><br/>(0.37 to 10.70)  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220<br/>(1 RCT)  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 per 1000</p> <p>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⨁⨁⊖⊖<br/>Low<sup>b</sup>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether regdanvimab, 40 mg/kg or 80 mg/kg has an effect on serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty: </b>our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels for very serious imprecision, because no events were observed, the sample size small and the effect not estimable </p> <p><sup>b</sup> Downgraded two levels for very serious imprecision, because few event(s) were observed and/or  the sample size was small. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Regdanvimab compared to placebo in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013825-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Bamlanivimab compared to placebo in hospitalised individuals with COVID‐19 (moderate to severe disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bamlanivimab compared to placebo in hospitalised individuals with COVID‐19 (moderate to severe disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : hospitalised individuals with COVID‐19 (moderate to severe disease) <b>Setting</b> : inpatient <b>Intervention</b> : bamlanivimab <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty in the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with bamlanivimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>37 per 1000</b><br/>(11 to 128) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.39</b><br/>(0.40 to 4.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether bamlanivimab has an effect on mortality at 28 days.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 90</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>73 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 1000</b> </p> <p>(36 to 168) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HR 1.09</b> </p> <p>(0.49 to 2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab may have little to no effect on mortality by day 90.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7)<br/>assessed with: 7‐point scale, lower better </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>180 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>211 per 1000</b><br/>(135 to 333) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.17</b><br/>(0.75 to 1.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>311<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab may slightly increase the development of severe symptoms (assessed by the need for NIV, IMV, ECMO, or renal replacement therapy) at day 5. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Time to hospital discharge up to 26.10.2020, absolute effects for day 10</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>762 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>752 per 1000</b><br/>(664 to 816) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>HR 0.97</b><br/>(0.76 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab may have little to no impact on hospital discharge until data cut off (26 October 2020). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: grades 3 and 4 by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>179 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>227 per 1000</b><br/>(145 to 354) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.27</b><br/>(0.81 to 1.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab may slightly increase the risk of grade 3 and 4 adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>33 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>31 per 1000</b><br/>(9 to 104) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.93</b><br/>(0.27 to 3.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether bamlanivimab has an effect the occurrence of serious adverse events. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR:</b> hazard Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_422871223304980961" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_422871223304980961</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels for very serious imprecision, because of wide confidence interval, low sample size and/or low number of events, imbalances in baseline characteristics. </p> <p><sup>a</sup> Downgraded one level for serious indirectness, because the time frame of 5 days was short for assessing clinical status. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Bamlanivimab compared to placebo in hospitalised individuals with COVID‐19 (moderate to severe disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013825-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Casirivimab/imdevimab compared to usual care alone in hospitalised individuals with COVID‐19 (moderate to severe disease)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Casirivimab/imdevimab compared to usual care in hospitalised individuals with COVID‐19 (moderate to severe disease)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : hospitalised individuals with COVID‐19 (moderate to severe disease) <b>Setting</b> : inpatient <b>Intervention</b> : casirivimab/imdevimab <b>Comparison</b>: usual care alone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty in the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with usual care alone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p>Risk with c<b>asirivimab/imdevimab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>236 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>221 per 1000</b><br/>(205 to 241) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.94</b><br/>(0.87 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9785<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casirivimab/imdevimab 8.0 g has probably little to no effect on mortality by day 30 in the overall cohort of hospitalised participants. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality by day 60</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical progression: need for IMV or death (WHO ≥ 7)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>248 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>238 per 1000</b><br/>(223 to 258) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.96</b><br/>(0.90 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9198<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casirivimab/imdevimab 8.0 g has probably little to no effect on IMV requirement or death by day 30 in the overall cohort of hospitalised participants. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospital discharge alive by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>690 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>697 per 1000</b><br/>(676 to 718) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b><br/>(0.98 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9785<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>Moderate<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casirivimab/imdevimab 8.0 g has probably little to no effect on discharge from hospital alive by day 30 in the overall cohort of hospitalised participants. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events: grades 3 and 4 by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events by day 30</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We did not identify any study reporting this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious risk of bias, the study was not blinded. Currently, there is no clearly defined standard of care for COVID‐19, therefore, a lack of blinding can have resulted in differential treatments/timings of treatment between arms. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Casirivimab/imdevimab compared to usual care alone in hospitalised individuals with COVID‐19 (moderate to severe disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013825-tbl-0008"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Main study characteristics of included RCTs</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N randomised up to data cut‐off</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Status</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0001" title="LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskySM , et al. A neutralizing monoclonal antibody for hospitalised patients with COVID-19. New England Journal of Medicine2021;384:905-14. [DOI: 10.1056/NEJMoa2033130]LundgrenJD , GrundB , BarkauskasCE , HollandTL , GottliebRL , SandkovskyU , et al . Clinical and virological response to a neutralizing monoclonal antibody for hospitalized patients with COVID-19. medrxiv [Preprint]2021. [DOI: 10.1101/2021.07.19.21260559]">ACTIV‐3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab (7.0 g)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Inpatients, moderate disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Denmark, Singapore, Spain, India, Poland, Switzerland, UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interim analysis, bamlanivimab arm stopped for futility, recruitment ongoing for other arms </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0005" title="ChenP , NirulaA , HellerB , GottliebRL , BosciaJ , MorrisJ , et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. New England Journal of Medicine2020;384:229-37. [DOI: 10.1056/NEJMoa2029849]GottliebRL , NirulaA , ChenP , BosciaJ , HellerB , MorrisJ , et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA2021;325(7):632-44. [DOI: 10.1001/jama.2021.0202]">BLAZE‐1 (phase 2)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bamlanivimab (0.7 g, 2.8 g, 7.0 g)</p> <p>bamlanivimab/etesevimab (2.8 g + 2.8 g)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outpatients, mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Puerto Rico (added after publication of interim results)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recruiting, estimated enrolment 4000 participants</p> <p>Estimated study completion: May 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0014" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail in outpatients with COVID-19. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.09.21257915]WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-19. New England Journal of Medicine2020;384:238-51. [DOI: 10.1056/NEJMoa2035002]">Weinreich (phase 1/2)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casirivimab/imdevimab (REGN10933/ REGN10987; 2.4 g, 8 g)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outpatients, mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Chile, Mexico, Romania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interim analysis, recruiting, estimated enrolment 6420 participants</p> <p>Estimated study completion: August 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0015" title="WeinreichDM , SivapalasingamS , NortonT , AliS , GaoH , BhoreR , et al. REGEN-COV antibody cocktail clinical outcomes study in COVID-19 outpatients. medRxiv [Preprint]. [DOI: 10.1101/2021.05.19.21257469]">Weinreich (phase 3)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casirivimab/imdevimab (REGN10933/ REGN10987; 1200 mg, 2400 mg, )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outpatients, mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Mexico, Chile, Romania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interim analysis, recruiting, estimated enrolment 6420 participants</p> <p>Estimated study completion: August 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0011" title="HorbyPW , MafhamM , PetoL , CampbellM , Pessoa-AmorimG , SpataE , et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv [Preprint]2021. [DOI: 10.1101/2021.06.15.21258542]">RECOVERY</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Casivirimab/imdevimab (4g, 4g)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospitalised patients, moderate or severe disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preprint publication, recruiting, estimated enrolment 40000 participants, estimated study completion: December 2031 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0007" title="GuptaA , Gonzalez-RojasY , JuarezE , Crespo CasalM , MoyaJ , Rodrigues FalciD , et al. Early COVID-19 treatment with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv [Preprint]2021. [DOI: 10.1101/2021.05.27.21257096]">COMET‐ICE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sotrovimab (VIR‐7831; GSK4182136; 500 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outpatients, mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USA, Brazil, Canada, Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>583</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Preprint publication, interim analysis, data collection ongoing;</p> <p>Estimated completion date: July 2021</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD013825-bbs2-0008" title="EomJS , IsonM , Streinu-CercelA , SăndulescuO , PreotescuLL , KimYS , et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection. researchsquare.com/article/rs-296518/v1. [DOI: 10.21203/rs.3.rs-296518/v1]">Eom 2021</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Regdanvimab (CT‐P59; 40 mg/kg, 80 mg/kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Outpatients, mild disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>South Korea, Romania, Spain and USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>recruiting, estimated enrolment: 1020 participants</p> <p>Estimated completion date: September 2021</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Main study characteristics of included RCTs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/full#CD013825-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013825-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Mortality by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Admission to hospital or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Viral clearance at day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Viral clearance at day 15 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse events: all grades <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Bamlanivimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013825-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Mortality by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Admission to hospital or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Viral clearance at day 3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Viral clearance at day 7 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Viral clearance at day 15 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Adverse events: all grades <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bamlanivimab/etesevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013825-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Casirivimab/imdevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Admission to hospital or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Adverse events: grade 3 and 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Casirivimab/imdevimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013825-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Mortality by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Development of severe symptoms according to WHO scale (≥ 5, incl. death) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Development of severe symptoms according to WHO scale (≥ score 7, IMV, incl. death) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Admission to hospital or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Admission to ICU by day 29 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Adverse events: all grades <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Adverse events: grade 3 and 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013825-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Mortality by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Development of severe symptoms according to WHO scale (≥ score 7, IMV, incl. death) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Admission to hospital or death by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Admission to ICU by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Viral clearance at day 15 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Adverse events: all grades <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Adverse events: grade 3 and 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Regdanvimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013825-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Mortality by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Mortality by day 90 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Development of severe symptoms: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Development of severe symptoms: clinical status at day 5, intubation (group 6 at pulmonary scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Hospital discharge up to 26 October 2020 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Hospital discharge: at day 5 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Adverse events: grade 3 and 4 by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Serious adverse events by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 Serious adverse events (90 day follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.10 Sustained recovery (90 day follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.11 Neurological dysfunction by day 30: transient ischemic events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.12 Neurological dysfunction by day 30: acute delirium CVA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.13 Neurological dysfunction by day 30: cerebrovascular event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.14 Thromboembolic events by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.15 Renal dysfunction (or need for dialysis) by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Bamlanivimab in hospitalised individuals with COVID‐19 (moderate and severe disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013825-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Mortality by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Development of severe symptoms: requirement for IMV or death by day 28 (WHO ≥ 7) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Hospital discharge alive by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Thromboembolic events by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Renal dysfunction (or need for dialysis) by day 30 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Casirivimab/imdevimab in hospitalised individuals with COVID‐19 (moderate and severe disease)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#CD013825-tbl-0015">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Mortality by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 0.7g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 257 out of 265 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 2.8g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 263 out of 270 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 7.0g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 257 out of 265 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 Mortality by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Admission to hospital or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 0.7g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 257 out of 265 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was likely appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 2.8g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 263 out of 270 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was likely appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 7.0g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 257 out of 265 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was likely appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Admission to hospital or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Viral clearance at day 7</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 0.7g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data of 5 participants in the treatment arm and of 16 participants in the control arm were missing. The study was double‐blinded and it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 2.8g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data of 8 participants in the treatment arm and of 16 participants in the control arm were missing. The study was double‐blinded and it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 7.0g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data of 5 participants in the treatment arm and of 16 participants in the control arm were missing. The study was double‐blinded and it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Viral clearance at day 7</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Viral clearance at day 15</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 0.7g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data of 13 participants in the treatment arm and of 29 participants in the control arm were missing. The study was double‐blinded and it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 2.8g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data of 12 participants in the treatment arm and of 29 participants in the control arm were missing. The study was double‐blinded and it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 7.0g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data of 10 participants in the treatment arm and of 29 participants in the control arm were missing. The study was double‐blinded and it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Viral clearance at day 15</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Adverse events: all grades</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 0.7g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 257 out of 265 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 2.8g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 263 out of 270 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 7.0g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 257 out of 265 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Adverse events: all grades</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 0.7g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 257 out of 265 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 2.8g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 263 out of 270 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 2, 7.0g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 257 out of 265 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Mortality by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 3)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and an appropriate analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 1035 out of 1049 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 Mortality by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 Admission to hospital or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 3)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and an appropriate analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 1035 out of 1049 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result were analysed in accordance to the protocol.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 Admission to hospital or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Viral clearance at day 3</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 3)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and an appropriate analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants (968 out of 1035 participants randomised). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We used data from Kaplan‐Meier curve to calculate cumulative frequency of viral clearance.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 Viral clearance at day 3</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 Viral clearance at day 7</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 3)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and an appropriate analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants (968 out of 1035 participants randomised). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We used data from Kaplan‐Meier curve to calculate cumulative frequency of viral clearance.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 Viral clearance at day 7</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.5 Viral clearance at day 15</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 3)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and an appropriate analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for nearly all participants (968 out of 1035 participants randomised). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>We used data from Kaplan‐Meier curve to calculate cumulative frequency of viral clearance.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.5 Viral clearance at day 15</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-12"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.6 Adverse events: all grades</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 3)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and an appropriate analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 1035 out of 1049 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.6 Adverse events: all grades</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-12">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-13"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.7 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>BLAZE‐1 (phase 3)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and an appropriate analysis was performed. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 1035 out of 1049 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.7 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-13">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-14"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Admission to hospital or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Weinreich (phase 1/2, 2.4 g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were centrally randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 446 out of 532 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>SAP and protocol not provided for this preprint. There is no indication that the outcome measurement and the results have been selected. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias due to the randomisation process, due to deviations from the intended interventions, missing outcomes, measurement of the outcome. There are some concerns for risk of bias due to selection of reported results. </p> </td> </tr> <tr class="study-data"> <td> <p>Weinreich (phase 1/2, 8.0 g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were centrally randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 450 out of 533 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>SAP and protocol not provided for this preprint. There is no indication that the outcome measurement and the results have been selected. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias due to the randomisation process, due to deviations from the intended interventions, missing outcomes, measurement of the outcome. There are some concerns for risk of bias due to selection of reported results. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.1 Admission to hospital or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-14">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-15"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Adverse events: grade 3 and 4</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Weinreich (phase 1/2, 2.4 g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were centrally randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 520 out of 532 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information whether measurement of the outcome was appropriate, but it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the previous protocol. There is no indication that the outcome measurement and the results have been selected. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias due to the randomisation process, due to deviations from the intended interventions, missing outcomes and due to selection of reported results. However, there are some concerns for risk of bias due to measurement of the outcome. </p> </td> </tr> <tr class="study-data"> <td> <p>Weinreich (phase 1/2, 8.0 g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were centrally randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 522 out of 533 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>There is no information whether measurement of the outcome was appropriate, but it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the previous protocol. There is no indication that the outcome measurement and the results have been selected. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias due to the randomisation process, due to deviations from the intended interventions, missing outcomes and due to selection of reported results. However, there are some concerns for risk of bias due to measurement of the outcome. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.2 Adverse events: grade 3 and 4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-15">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-16"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Weinreich (phase 1/2, 2.4 g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were centrally randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 520 out of 532 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the previous protocol. There is no indication that the outcome measurement and the results have been selected. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Weinreich (phase 1/2, 8.0 g)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were centrally randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 520 out of 532 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the previous protocol. There is no indication that the outcome measurement and the results have been selected. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 3.3 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-16">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-17"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 Mortality by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>COMET‐ICE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 583 out of 583 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial protocol and SAP were not available. We have some concerns regarding selection of the reported results because the trial was stopped preliminary. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias from the randomization process, due to deviations from intended interventions, due to missing outcomes and due to measurement of the outcome. However, there are some concerns for bias due to selection of the reported results. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.1 Mortality by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-17">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-18"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.2 Development of severe symptoms according to WHO scale (≥ 5, incl. death)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>COMET‐ICE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 583 out of 583 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial protocol and SAP were not available. We have some concerns regarding selection of the reported results because the trial was stopped preliminary. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias from the randomization process, due to deviations from intended interventions, due to missing outcomes and due to measurement of the outcome. However, there are some concerns for bias due to selection of the reported results. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.2 Development of severe symptoms according to WHO scale (≥ 5, incl. death)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-18">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-19"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.3 Development of severe symptoms according to WHO scale (≥ score 7, IMV, incl. death)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>COMET‐ICE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 583 out of 583 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial protocol and SAP were not available. We have some concerns regarding selection of the reported results because the trial was stopped preliminary. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias from the randomization process, due to deviations from intended interventions, due to missing outcomes and due to measurement of the outcome. However, there are some concerns for bias due to selection of the reported results. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.3 Development of severe symptoms according to WHO scale (≥ score 7, IMV, incl. death)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-19">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-20"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.4 Admission to hospital or death</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>COMET‐ICE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 583 out of 583 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial protocol and SAP were not available. We have some concerns regarding selection of the reported results because the trial was stopped preliminary. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias from the randomization process, due to deviations from intended interventions, due to missing outcomes and due to measurement of the outcome. However, there are some concerns for bias due to selection of the reported results. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.4 Admission to hospital or death</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-20">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-21"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.5 Admission to ICU by day 29</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>COMET‐ICE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 583 out of 583 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial protocol and SAP were not available. We have some concerns regarding selection of the reported results because the trial was stopped preliminary. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias from the randomization process, due to deviations from intended interventions, due to missing outcomes and due to measurement of the outcome. However, there are some concerns for bias due to selection of the reported results. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.5 Admission to ICU by day 29</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-21">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-22"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.6 Adverse events: all grades</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>COMET‐ICE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 868 out of 868 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial protocol and SAP were not available. We have some concerns regarding selection of the reported results because the trial was stopped preliminary and the time point measured was not entirely clear. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias from the randomization process, due to deviations from intended interventions, due to missing outcomes and due to measurement of the outcome. However, there are some concerns for bias due to selection of the reported results. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.6 Adverse events: all grades</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-22">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-23"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.7 Adverse events: grade 3 and 4</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>COMET‐ICE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 868 out of 868 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial protocol and SAP were not available. We have some concerns regarding selection of the reported results because the trial was stopped preliminary and the time point measured was not entirely clear. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias from the randomization process, due to deviations from intended interventions, due to missing outcomes and due to measurement of the outcome. However, there are some concerns for bias due to selection of the reported results. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.7 Adverse events: grade 3 and 4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-23">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-24"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.8 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>COMET‐ICE</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were probably unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 868 out of 868 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was probably appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The trial protocol and SAP were not available. We have some concerns regarding selection of the reported results because the trial was stopped preliminary and the time point measured was not entirely clear. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias from the randomization process, due to deviations from intended interventions, due to missing outcomes and due to measurement of the outcome. However, there are some concerns for bias due to selection of the reported results. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 4.8 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-24">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-25"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 Mortality by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Eom 2021 (40 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 307 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Eom 2021 (80 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 307 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.1 Mortality by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-25">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-26"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.2 Development of severe symptoms according to WHO scale (≥ score 7, IMV, incl. death)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Eom 2021 (40 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 307 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Eom 2021 (80 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 307 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.2 Development of severe symptoms according to WHO scale (≥ score 7, IMV, incl. death)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-26">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-27"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.3 Admission to hospital or death by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Eom 2021 (40 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 307 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Eom 2021 (80 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 307 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.3 Admission to hospital or death by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-27">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-28"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.4 Admission to ICU by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Eom 2021 (40 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 307 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Eom 2021 (80 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 307 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.4 Admission to ICU by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-28">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-29"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.5 Viral clearance at day 15</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Eom 2021 (40 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 307 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Eom 2021 (80 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 307 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.5 Viral clearance at day 15</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-29">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-30"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.6 Adverse events: all grades</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Eom 2021 (40 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 325 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Eom 2021 (80 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 325 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.6 Adverse events: all grades</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-30">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-31"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.7 Adverse events: grade 3 and 4</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Eom 2021 (40 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 325 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Eom 2021 (80 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 325 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.7 Adverse events: grade 3 and 4</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-31">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-32"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.8 Serious adverse events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Eom 2021 (40 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 325 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> <tr class="study-data"> <td> <p>Eom 2021 (80 mg/kg)</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via an Interactive Web Response System (IWRS) and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the intervention received. Participants with a negative PCR were excluded from analysis in both groups (intervention and placebo group) and one participant in the placebo arm did not receive the allocated intervention. The analysis was probably appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 325 out of 327 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 5.8 Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-32">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-33"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 Mortality by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 314 out of 326 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.1 Mortality by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-33">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-34"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.2 Mortality by day 90</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 168 out of 168 participants with sustained recovery. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.2 Mortality by day 90</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-34">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-35"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.3 Development of severe symptoms: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 311 out of 326 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.3 Development of severe symptoms: need for NIV, IMV, ECMO, or renal replacement therapy at day 5 (group 5, 6 or 7)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-35">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-36"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.4 Development of severe symptoms: clinical status at day 5, intubation (group 6 at pulmonary scale)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 311 out of 326 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.4 Development of severe symptoms: clinical status at day 5, intubation (group 6 at pulmonary scale)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-36">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-37"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.5 Hospital discharge up to 26 October 2020</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 314 out of 326 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.5 Hospital discharge up to 26 October 2020</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-37">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-38"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.6 Hospital discharge: at day 5</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 314 out of 326 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.6 Hospital discharge: at day 5</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-38">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-39"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.7 Adverse events: grade 3 and 4 by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 314 out of 326 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.7 Adverse events: grade 3 and 4 by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-39">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-40"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.8 Serious adverse events by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 314 out of 326 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.8 Serious adverse events by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-40">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-41"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.9 Serious adverse events (90 day follow‐up)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 168 out of 168 participants with sustained recovery. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.9 Serious adverse events (90 day follow‐up)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-41">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-42"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.10 Sustained recovery (90 day follow‐up)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 314 out of 326 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.10 Sustained recovery (90 day follow‐up)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-42">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-43"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.11 Neurological dysfunction by day 30: transient ischemic events</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data of 17 participants in the treatment arm and of 16 participants in the control arm were missing. The study was double‐blinded and it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.11 Neurological dysfunction by day 30: transient ischemic events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-43">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-44"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.12 Neurological dysfunction by day 30: acute delirium CVA</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data of 17 participants in the treatment arm and of 16 participants in the control arm were missing. The study was double‐blinded and it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.12 Neurological dysfunction by day 30: acute delirium CVA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-44">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-45"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.13 Neurological dysfunction by day 30: cerebrovascular event</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data of 17 participants in the treatment arm and of 16 participants in the control arm were missing. The study was double‐blinded and it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.13 Neurological dysfunction by day 30: cerebrovascular event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-45">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-46"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.14 Thromboembolic events by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data of 17 participants in the treatment arm and of 16 participants in the control arm were missing. The study was double‐blinded and it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.14 Thromboembolic events by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-46">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-47"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.15 Renal dysfunction (or need for dialysis) by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>ACTIV‐3</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via mass‐weighted urn randomisation. There are baseline differences, but they are unlikely to suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were unaware of the assigned intervention received and the analysis was appropriate. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data of 17 participants in the treatment arm and of 16 participants in the control arm were missing. The study was double‐blinded and it is not likely that missingness in the outcome depended on its true value. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. The outcome assessors were unaware of the intervention received. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed in accordance with the pre‐specified analysis plan and the outcome was reported as planned in the protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias for all the domains.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 6.15 Renal dysfunction (or need for dialysis) by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-47">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-48"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 Mortality by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>RECOVERY</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via web‐based randomisation and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received and nearly all participants received assigned intervention. The analysis was appropriate. Because of no standard treatment for COVID‐19, control group may have received concomitant treatment more quickly. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 9785 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. It was unclear whether outcome assessors were unaware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed and reported as planned in the protocol and SAP. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias due to the randomisation process, due to missing outcomes, due to measurement of the outcome and due to selection of reported results. However, there is high risk of bias due to deviations from the intended interventions. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.1 Mortality by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-48">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-49"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.2 Development of severe symptoms: requirement for IMV or death by day 28 (WHO ≥ 7)</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>RECOVERY</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via web‐based randomisation and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received and nearly all participants received assigned intervention. The analysis was appropriate. Because of no standard treatment for COVID‐19, control group may have received concomitant treatment more quickly. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 9198 out of 9785 participants randomised. 587 participants were on mechanical ventilation at randomisation and therefore excluded. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. It was unclear whether outcome assessors were unaware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed and reported as planned in the protocol and SAP. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias due to the randomisation process, due to missing outcomes, due to measurement of the outcome and due to selection of reported results. However, there is high risk of bias due to deviations from the intended interventions. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.2 Development of severe symptoms: requirement for IMV or death by day 28 (WHO ≥ 7)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-49">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-50"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.3 Hospital discharge alive by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>RECOVERY</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via web‐based randomisation and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received and nearly all participants received assigned intervention. The analysis was appropriate. Because of no standard treatment for COVID‐19, control group may have received concomitant treatment more quickly. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 9785 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. It was unclear whether outcome assessors were unaware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was pre‐specified and there is no indication for selective reporting.</p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias due to the randomisation process, due to missing outcomes, due to measurement of the outcome and due to selection of reported results. However, there is high risk of bias due to deviations from the intended interventions. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.3 Hospital discharge alive by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-50">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-51"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.4 Thromboembolic events by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>RECOVERY</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via web‐based randomisation and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received and nearly all participants received assigned intervention. The analysis was appropriate. Because of no standard treatment for COVID‐19, control group may have received concomitant treatment more quickly. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for all 9785 participants randomised.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. It was unclear whether outcome assessors were unaware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed and reported as planned in the protocol and SAP. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias due to the randomisation process, due to missing outcomes, due to measurement of the outcome and due to selection of reported results. However, there is high risk of bias due to deviations from the intended interventions. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.4 Thromboembolic events by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-51">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-52"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.5 Renal dysfunction (or need for dialysis) by day 30</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>RECOVERY</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col4" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-high col12" colspan="2"><img alt="High risk of bias" src="/cochrane-theme/images/high.png" title="High risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Participants were randomised via web‐based randomisation and the allocation sequence was concealed. There are no baseline differences that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received and nearly all participants received assigned intervention. The analysis was appropriate. Because of no standard treatment for COVID‐19, control group may have received concomitant treatment more quickly. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data for this outcome was available for 9670 out of 9785 participants randomised. Participants on renal replacement therapy at randomisation were therefore excluded. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The measurement of the outcome was appropriate and it is unlikely that it differed between intervention groups. It was unclear whether outcome assessors were unaware of the intervention received, but it is unlikely that knowledge of intervention received could have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The data that produced this result was analysed and reported as planned in the protocol and SAP. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>For this outcome, there is a low risk of bias due to the randomisation process, due to missing outcomes, due to measurement of the outcome and due to selection of reported results. However, there is high risk of bias due to deviations from the intended interventions. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 7.5 Renal dysfunction (or need for dialysis) by day 30</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013825.pub2/references#riskOfBias2Table-52">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013825.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD013825-note-0016">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD013825-note-0049">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013825-note-0040">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013825-note-0043">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD013825-note-0037">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD013825-note-0028">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013825-note-0034">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013825-note-0046">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD013825-note-0025">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD013825-note-0031">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013825-note-0019">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013825-note-0022">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013825\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013825\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013825\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013825\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013825\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013825.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013825.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013825.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013825.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013825.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716893705"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013825.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716893709"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013825.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918daa842f131be3',t:'MTc0MDcxNjg5NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 